Details of Disease

General Information of Disease (ID: DISQ0M8R)

• Disease Name: Hepatitis C virus infection
• Synonyms: chronic hepatitis C; viral hepatitis C; Hepatitis C virus hepatitis; hepatitis C infection; NANBH; non-A, non-B Hepatitis; Hepatitis C virus caused hepatitis; hepatitis Nona nonB; hepatitis type C
• Disease Class: 1E50-1E51: Hepatitis virus infection
• Definition: A viral infection caused by the hepatitis C virus.
• Disease Hierarchy:
  DISXXX35: Hepatitis
  DISVT5Q7: Viral hepatitis
  DISEM33Q: Infectious disease
  DISQ0M8R: Hepatitis C virus infection
• ICD Code:
  ICD-11: ICD-11: 1E51.1
  ICD-10: ICD-10: B18.2
• Disease Identifiers:
  MONDO ID: MONDO_0005231
  MESH ID: D006526
  UMLS CUI: C0019196
  MedGen ID: 42425
  SNOMED CT ID: 50711007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BOCEPREVIR	DMBSHMF	Approved	Small molecular drug	[1]
Daclatasvir	DMSFK9V	Approved	Small molecular drug	[2]
Glecaprevir; pibrentasvir	DMF6Z5T	Approved	Combination drug	[3]
Merimepodib	DM0HS92	Approved	Small molecular drug	[4]
Peginterferon alfa-2b	DMAP58Y	Approved	NA	[5]
PSI-7977	DMLSUWZ	Approved	Small molecular drug	[6]
Ribavirin	DMEYLH9	Approved	Small molecular drug	[7]
Telaprevir	DMMRV29	Approved	Small molecular drug	[8]

This Disease is Treated as An Indication in 114 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-267	DMNQ869	Phase 3	Small molecular drug	[9]
Albinterferon alfa-2b	DMK0QW6	Phase 3	NA	[10]
Alisporivir	DM83EBP	Phase 3	Protein/peptide drug	[11]
BI 201335	DM3MXT8	Phase 3	Small molecular drug	[12]
Civacir	DMKUQU3	Phase 3	NA	[13]
Hepatitis C immune globulin	DM4LYFJ	Phase 3	NA	[14]
IMO-2125	DM735FA	Phase 3	NA	[15]
Interferon alpha 2a	DMOTH6V	Phase 3	NA	[16]
LCQ908	DMFLJHQ	Phase 3	Small molecular drug	[17]
MK-8742	DMK301H	Phase 3	NA	[18]
SD-101	DMAMTGI	Phase 3	Oligonucleotide	[19]
Viramidine	DMJFNR9	Phase 3	Small molecular drug	[20]
IR208	DM30Z38	Phase 2/3	NA	[21]
ANA773	DMSC8YW	Phase 2a	NA	[22]
177Lu-DOTATATE	DMT8GVU	Phase 2	NA	[23]
ABT-384	DM7XW5Y	Phase 2	Small molecular drug	[24]
ABT-450	DMFW860	Phase 2	NA	[25]
ACH-0137171	DMG746H	Phase 2	NA	[26]
ACH-1625	DMIVUFL	Phase 2	Small molecular drug	[27]
ACH-3102	DM0RPY5	Phase 2	NA	[28]
AP33	DMNVHTY	Phase 2	NA	[29]
BI 207127	DMMSGAT	Phase 2	Small molecular drug	[12]
BMS 650032	DMQI43G	Phase 2	Small molecular drug	[30]
BMS 791325	DMKH4PI	Phase 2	Small molecular drug	[30]
BMS-824393	DM95F96	Phase 2	NA	[31]
CB-5300	DMA86N0	Phase 2	NA	[32]
CF102	DMP56WJ	Phase 2	Small molecular drug	[33]
CIGB-230	DM8NZOW	Phase 2	NA	[34]
CpG-10101	DM6MUCX	Phase 2	NA	[35]
Danoprevir	DM20MDU	Phase 2	Small molecular drug	[36]
Filibuvir	DMNSYXB	Phase 2	Small molecular drug	[37]
GI-5005	DMMCEV0	Phase 2	NA	[38]
GS-4774	DMUG132	Phase 2	NA	[39]
GS-5885	DMSL3DX	Phase 2	Small molecular drug	[40]
GS-9256	DMCZH5B	Phase 2	Small molecular drug	[41]
GS-9857	DMYU6P5	Phase 2	Small molecular drug	[42]
GSK2336805	DMI2YU1	Phase 2	NA	[43]
HDV-interferon	DMAX632	Phase 2	NA	[44]
Hepatitis C vaccine	DM1VUDL	Phase 2	NA	[39]
Human interferon alpha oral	DMKQ3MC	Phase 2	NA	[45]
IFN-alpha	DM4H8EZ	Phase 2	NA	[46]
Interferon	DMYTKF5	Phase 2	NA	[47]
Interferon alpha-2b	DMVACTU	Phase 2	NA	[48]
INX-189	DMSTJ6Q	Phase 2	Small molecular drug	[49]
Isatoribine	DMHOJ8W	Phase 2	Small molecular drug	[50]
ITCA-638	DMDZWPL	Phase 2	NA	[51]
KPE-02001003	DM9DB5L	Phase 2	NA	[52]
MBL-HCV1	DMJVU7Y	Phase 2	NA	[53]
Miravirsen	DMWJMFZ	Phase 2	Small molecular drug	[54]
Mitoquinone	DMKPZ0Q	Phase 2	Small molecular drug	[55]
MK-5172	DMSPWX6	Phase 2	Small molecular drug	[56]
PF-4136309	DM2JZC8	Phase 2	Small molecular drug	[57]
PF-4878691	DM24I0N	Phase 2	NA	[58]
PPI-668	DM4EHVB	Phase 2	NA	[59]
Q-301	DMLRBXM	Phase 2	NA	[60]
R-IFN-1a	DMO9QB8	Phase 2	NA	[61]
RG-101	DM2UGT7	Phase 2	NA	[62]
SCY-635	DM1C9NQ	Phase 2	Small molecular drug	[63]
Setrobuvir	DMTNDM2	Phase 2	Small molecular drug	[22]
Tegobuvir	DM6YI5T	Phase 2	Small molecular drug	[41]
TG-2349	DMZ571Y	Phase 2	NA	[64]
Vaniprevir	DMCF5E0	Phase 2	Small molecular drug	[56]
VX-135	DMZ3FE8	Phase 2	NA	[65]
VX-222	DMO3U4W	Phase 2	Small molecular drug	[66]
VX-759	DMJUSM8	Phase 2	Small molecular drug	[66]
ANZ-521	DM65512	Phase 1/2	NA	[67]
AZD-2836	DMT2FAP	Phase 1/2	NA	[68]
BZF961	DMSN820	Phase 1/2	NA	[69]
ChronVac-C hepatitis C DNA vaccine	DMRSI1O	Phase 1/2	Vaccine	[70]
IDX-184	DM7U458	Phase 1/2	Small molecular drug	[71]
IDX-719	DMCRVM5	Phase 1/2	NA	[72]
Interferon alpha	DMPYYQP	Phase 1/2	NA	[73]
NAHE-001	DMU6MJ1	Phase 1/2	NA	[51]
PerCvax	DMD6IAT	Phase 1/2	NA	[74]
TT-034	DM22IOE	Phase 1/2	Small molecular drug	[75]
A-837093	DMX0JLI	Phase 1	Small molecular drug	[76]
ABT-072	DMG4H9Y	Phase 1	NA	[77]
ABT-333	DM7TOWX	Phase 1	Small molecular drug	[77]
ACH-2684	DMW6X0O	Phase 1	Small molecular drug	[78]
AV4025	DME630T	Phase 1	NA	[79]
AZD-7295	DM84WXZ	Phase 1	Small molecular drug	[80]
Balapiravir	DMAJPOX	Phase 1	Small molecular drug	[81]
Belerofon	DM9R0VA	Phase 1	NA	[82]
BIT225	DMGAR9Y	Phase 1	Small molecular drug	[83]
BMS-824383	DMPQ5XC	Phase 1	NA	[30]
CC-31244	DMAYHT4	Phase 1	Small molecular drug	[84]
Clemizole	DM4UAPD	Phase 1	Small molecular drug	[85]
EDP-239	DMXW07J	Phase 1	NA	[86]
GS-6620	DMRDNPC	Phase 1	Small molecular drug	[87]
GSK-625433	DM7CIN4	Phase 1	Small molecular drug	[88]
HCV vaccine	DMMLMC1	Phase 1	NA	[89]
HCVax	DMWNFJP	Phase 1	Vaccine	[90]
IDX-189	DMYG3PZ	Phase 1	NA	[91]
IN0-8000	DM5QJN4	Phase 1	NA	[92]
INO-8000	DMV5OT7	Phase 1	NA	[39]
JNJ-47910382	DM1ERXJ	Phase 1	NA	[93]
MB-110	DMPE0KD	Phase 1	Small molecular drug	[94]
MBX-700	DMTXIZ1	Phase 1	NA	[95]
MK-3281	DMG0Q27	Phase 1	Small molecular drug	[56]
MK-6325	DMV8BI4	Phase 1	Small molecular drug	[96]
PHX-1766	DMERJ6V	Phase 1	NA	[97]
PPI-383	DMEOJUN	Phase 1	NA	[98]
PPI-461	DMTOXLG	Phase 1	NA	[99]
PSI-938	DM5ZR4Q	Phase 1	Small molecular drug	[6]
RG-7348	DMFDKS7	Phase 1	NA	[100]
RO-5303253	DM177J3	Phase 1	NA	[101]
RO-5428029	DM27J2O	Phase 1	NA	[102]
Samatasvir	DMAWDZZ	Phase 1	Small molecular drug	[103]
TMC-647055	DMYEALO	Phase 1	Small molecular drug	[104]
TMC649128	DMAOV7M	Phase 1	NA	[105]
VBY-376	DMU263R	Phase 1	NA	[106]
VX-500	DM8UTPJ	Phase 1	NA	[66]
VX-916	DMAJ2T4	Phase 1	NA	[66]
XTL-6865	DML3K9N	Phase 1	NA	[107]

This Disease is Treated as An Indication in 39 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
HCV-796	DMPQSE4	Discontinued in Phase 2	Small molecular drug	[76]
Heptazyme	DM7W1QR	Discontinued in Phase 2	NA	[108]
IDX375	DMRPBJW	Discontinued in Phase 2	NA	[109]
INNO-101	DM87U7Z	Discontinued in Phase 2	NA	[110]
ISIS 14803	DMGZV7U	Discontinued in Phase 2	Antisense drug	[111]
JTK-003	DMB0V5Y	Discontinued in Phase 2	NA	[112]
Omega interferon	DMX6GFR	Discontinued in Phase 2	NA	[113]
PYN-17	DMYESCR	Discontinued in Phase 2	NA	[114]
R7128	DM9BI3Y	Discontinued in Phase 2	Small molecular drug	[115]
RS-130830	DMOTANY	Discontinued in Phase 2	Small molecular drug	[116]
VP-50406	DMR2AXN	Discontinued in Phase 2	NA	[117]
GNI-103	DMY5B1B	Discontinued in Phase 1/2	NA	[118]
GS-9132	DMXB4T9	Discontinued in Phase 1/2	Small molecular drug	[119]
HCV/MF59	DMMT5O1	Discontinued in Phase 1/2	Small molecular drug	[120]
IDX-320	DMAYLS3	Discontinued in Phase 1/2	Small molecular drug	[121]
R-803	DMRQPOD	Discontinued in Phase 1/2	Small molecular drug	[122]
ACH-2928	DMSPW3N	Discontinued in Phase 1	NA	[123]
AG-021541	DM1TYM4	Discontinued in Phase 1	Small molecular drug	[76]
BLX-883	DMR7WYX	Discontinued in Phase 1	NA	[124]
HCV-371	DMI17F3	Discontinued in Phase 1	Small molecular drug	[125]
JTK-109	DMUNYR7	Discontinued in Phase 1	Small molecular drug	[126]
JTK-652	DMZFEY1	Discontinued in Phase 1	NA	[127]
JTK-853	DM64FX9	Discontinued in Phase 1	Small molecular drug	[128]
R-1479	DM9C6LN	Discontinued in Phase 1	Small molecular drug	[129]
R-1518	DM2J5AO	Discontinued in Phase 1	NA	[130]
RG-7432	DMSUV3B	Discontinued in Phase 1	NA	[131]
XTL-2125	DM3Y6M7	Discontinued in Phase 1	NA	[76]
ANA-246	DMUEABR	Terminated	NA	[134]
APC-6336	DMBA4DK	Terminated	Small molecular drug	[135]
BMS-605339	DMY7ZRA	Terminated	NA	[136]
CBH-11	DMIML1Y	Terminated	NA	[137]
ED-001	DMB56MU	Terminated	NA	[138]
GNI-104	DMHXRN8	Terminated	Antibody	[139]
GSK-2485852	DMOALVR	Terminated	NA	[140]
Hepatitis C virus E2 protein vaccines	DMOWNQ6	Terminated	NA	[141]
HuMax-HepC	DMFVB7Z	Terminated	Antibody	[142]
PRO-206	DM14A00	Terminated	NA	[143]
PSI-6130	DMWUOA8	Terminated	Small molecular drug	[144]
PSI-661	DM579WS	Terminated	NA	[145]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IDX136	DMRIMZL	Preclinical	NA	[132]
NA-808	DMDE7OR	Preclinical	NA	[133]

This Disease is Treated as An Indication in 51 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1,5-Benzodiazepines series	DMNVAE7	Investigative	NA	[146]
4SC-301	DMV336G	Investigative	NA	[146]
A-058	DMHSPRE	Investigative	NA	[146]
ACH-1095	DM17TPF	Investigative	NA	[146]
ALS-2158	DMXX5XJ	Investigative	NA	[146]
ALS-2160	DM29LFW	Investigative	NA	[146]
Anti-HCV agent	DMSLX1T	Investigative	NA	[146]
Anti-HCV peptides	DMZ0JP5	Investigative	NA	[146]
AVL-181	DMRQIQ3	Investigative	NA	[146]
BCX-5191	DMMQS6W	Investigative	NA	[146]
BMS-633	DMBZS0A	Investigative	NA	[146]
BMS-766	DMNMRJ1	Investigative	NA	[146]
C-Immune	DMJP1EX	Investigative	NA	[146]
C-Rx	DMEQ0JU	Investigative	NA	[146]
C-Vaxin	DM0USNM	Investigative	NA	[146]
CB-183872	DMU7734	Investigative	NA	[146]
EBP-1597	DMO3JOM	Investigative	NA	[146]
EPB-415	DMBLSX3	Investigative	NA	[147]
EPB-500	DMKBUPH	Investigative	NA	[146]
EPB-600	DMK7C30	Investigative	NA	[146]
EQ-317	DMMZIKN	Investigative	NA	[146]
EQ-318	DM828E1	Investigative	NA	[146]
Fusopin	DMAL64H	Investigative	NA	[146]
Glycoferon	DMLI5Y9	Investigative	NA	[146]
GX-137	DMTH9PQ	Investigative	NA	[146]
HAp-IFN	DM9K6H5	Investigative	NA	[148]
HCV-specific STAR fusions	DMH6JOO	Investigative	NA	[146]
HepaVaxx C	DM2G6Q4	Investigative	NA	[146]
HS-HCV	DMHL8O7	Investigative	NA	[146]
ID-12	DMAFO38	Investigative	NA	[146]
IPH-1201	DMMI6N1	Investigative	NA	[146]
ISG15-LNP01	DMQ8Y1B	Investigative	NA	[146]
ITX-4520	DM63MP0	Investigative	NA	[146]
ITX-7650	DM4VSRB	Investigative	NA	[146]
KIN-100	DM6A9F3	Investigative	NA	[146]
KPE-00001113	DMG749U	Investigative	NA	[146]
LG-912	DM4GE7L	Investigative	NA	[146]
Long-acting polysialic acid-interferon alpha 2b conjugate	DMMBGKF	Investigative	NA	[146]
Mu5B3	DM11N9Y	Investigative	NA	[146]
OBP-AI1	DMLIUWO	Investigative	NA	[146]
PPI-1301	DMJGUTD	Investigative	NA	[146]
PSI 7851	DM5ZU1V	Investigative	Small molecular drug	[149]
PSI-879	DM0SXSW	Investigative	NA	[146]
PTC-725	DM471WY	Investigative	NA	[146]
RM-4864	DMD1YFN	Investigative	NA	[146]
SCH-10363	DM1YJP1	Investigative	NA	[146]
SCY-524	DMM4F9L	Investigative	NA	[146]
SP-30	DMJZC0D	Investigative	NA	[146]
TBI-301	DM7OSJ5	Investigative	NA	[146]
VBY-106	DM0RGF4	Investigative	NA	[146]
ZN-1014	DMWIMZL	Investigative	NA	[146]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 354 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS13	TTUREBK	Limited	Altered Expression	[152]
APCS	TTB7VAT	Limited	Biomarker	[153]
APOBEC3G	TTP96KH	Limited	Biomarker	[154]
APOC3	TTXOZQ1	Limited	Altered Expression	[155]
APOH	TT2OUI9	Limited	Biomarker	[156]
ARG1	TT7ZQEV	Limited	Genetic Variation	[157]
CCL3	TT8I4WB	Limited	Genetic Variation	[158]
CCR3	TTD3XFU	Limited	Genetic Variation	[159]
CD14	TT6I7DC	Limited	Biomarker	[160]
CDK5R1	TTBYM6V	Limited	Biomarker	[161]
CES1	TTMF541	Limited	Altered Expression	[162]
CHUK	TT1F8OQ	Limited	Altered Expression	[163]
CR1	TTEA8OW	Limited	Biomarker	[164]
CYP1A2	TTS1DTU	Limited	Biomarker	[165]
EIF2AK3	TT79U1M	Limited	Altered Expression	[166]
EIF4EBP1	TTKGEBL	Limited	Altered Expression	[167]
FAP	TTGPQ0F	Limited	Altered Expression	[168]
FPR2	TTOJ1NF	Limited	Biomarker	[169]
FTH1	TT975ZT	Limited	Biomarker	[170]
IFNGR2	TT13TL0	Limited	Genetic Variation	[171]
IL37	TTQTX98	Limited	Biomarker	[172]
IRAK1	TTXAJWN	Limited	Biomarker	[173]
ITGA2	TTSJ542	Limited	Biomarker	[174]
ITGAE	TTH0Z37	Limited	Altered Expression	[175]
KLRC1	TTC4IMS	Limited	Biomarker	[176]
KRT19	TT3JF9E	Limited	Biomarker	[177]
LBP	TTVQJLY	Limited	Biomarker	[178]
LIPE	TTLUQ8E	Limited	Genetic Variation	[179]
LPL	TTOF3WZ	Limited	Biomarker	[180]
MAGEA3	TTWSKHD	Limited	Altered Expression	[181]
MBTPS1	TTNSM2I	Limited	Biomarker	[182]
MCM7	TT1RM3F	Limited	Altered Expression	[183]
NCL	TTK1V5Q	Limited	Biomarker	[184]
NME1	TTDY8JH	Limited	Biomarker	[185]
NR1H3	TTECBXN	Limited	Biomarker	[186]
PKN2	TTTHO0M	Limited	Genetic Variation	[187]
PPP2CA	TTHTKNY	Limited	Altered Expression	[188]
PSMB8	TTEAD9J	Limited	Biomarker	[189]
RTN4	TT7GXMU	Limited	Genetic Variation	[190]
RXRA	TT6PEUO	Limited	Altered Expression	[191]
SAA1	TTY0DN9	Limited	Altered Expression	[192]
SEMA4D	TT5UT28	Limited	Biomarker	[193]
SERPINB3	TT6QLPX	Limited	Altered Expression	[194]
SLC40A1	TT6Y1PG	Limited	Altered Expression	[195]
SREBF2	TTRQ4AP	Limited	Altered Expression	[196]
ST14	TTPRO7W	Limited	Genetic Variation	[197]
TACSTD2	TTP2HE5	Limited	Biomarker	[198]
TIGIT	TTWNL74	Limited	Altered Expression	[199]
TLR7	TTRJ1K4	Limited	Biomarker	[200]
TNFRSF10A	TT5WLRX	Limited	Biomarker	[201]
TNFSF13B	TTWMIDN	Limited	Genetic Variation	[202]
TNFSF4	TTBW580	Limited	Biomarker	[203]
TSLP	TTHMW3T	Limited	Altered Expression	[204]
ULK1	TT4D7MJ	Limited	Biomarker	[205]
ASRGL1	TT4WT91	moderate	Genetic Variation	[206]
DCLK1	TTOHTCY	moderate	Altered Expression	[207]
DDX58	TTVB0O3	moderate	Altered Expression	[208]
FCGR1A	TTZK4I3	moderate	Altered Expression	[209]
GCG	TT6Y4PN	moderate	Biomarker	[210]
IRF1	TT4TU3L	moderate	Genetic Variation	[211]
KIR2DS1	TTVWAGF	moderate	Biomarker	[212]
KIR3DL2	TTQH3N0	moderate	Biomarker	[212]
LOXL2	TTFSUHX	moderate	Biomarker	[213]
NDUFA13	TTRU1NG	moderate	Biomarker	[214]
SCARB1	TTRE324	moderate	Biomarker	[215]
SCD	TT6RIOV	moderate	Biomarker	[216]
SMAD6	TTON5JB	moderate	Biomarker	[217]
SRD5A2	TTT02K8	moderate	Altered Expression	[218]
TBX21	TTNF9PH	moderate	Genetic Variation	[219]
TPT1	TT3PTB6	moderate	Biomarker	[220]
AAK1	TT0Z32T	Strong	Biomarker	[221]
ABCB11	TTUXCAF	Strong	Biomarker	[222]
ABCB4	TTJUXV6	Strong	Genetic Variation	[223]
ACAT1	TTK3C21	Strong	Altered Expression	[162]
ACKR1	TTKY2NS	Strong	Genetic Variation	[224]
ACTG1	TTGAZF9	Strong	Altered Expression	[225]
ADH1A	TT5AHZ0	Strong	Altered Expression	[226]
ADIPOQ	TTXKA7D	Strong	Altered Expression	[227]
AHCY	TTE2KUJ	Strong	Genetic Variation	[228]
AIF1	TT12MEP	Strong	Genetic Variation	[229]
ALAS1	TTG1FXO	Strong	Altered Expression	[230]
AOC3	TT7HC21	Strong	Biomarker	[231]
APOA2	TTGQA9W	Strong	Genetic Variation	[232]
APOB	TTN1IE2	Strong	Biomarker	[154]
ARF1	TT70KXY	Strong	Biomarker	[233]
ATG7	TTLVB9Z	Strong	Biomarker	[234]
ATP4A	TTF1QVM	Strong	Biomarker	[235]
BACH1	TT2ME4S	Strong	Biomarker	[236]
BCL6	TTC9YX5	Strong	Biomarker	[237]
BLVRA	TTJBPN3	Strong	Altered Expression	[238]
BMP6	TT07RIB	Strong	Biomarker	[239]
BMPR2	TTGKF90	Strong	Biomarker	[240]
BRD7	TT07ZS1	Strong	Altered Expression	[241]
BTLA	TTER58P	Strong	Biomarker	[242]
C1QBP	TTWTD7F	Strong	Genetic Variation	[243]
CASP1	TTCQIBE	Strong	Biomarker	[244]
CASP7	TTM7Y45	Strong	Altered Expression	[245]
CBLB	TTHRAIJ	Strong	Biomarker	[246]
CCL17	TTMPHAE	Strong	Altered Expression	[247]
CCNA2	TTAMQ62	Strong	Biomarker	[248]
CCR1	TTC24WT	Strong	Genetic Variation	[249]
CCR6	TTFDB30	Strong	Biomarker	[250]
CD163	TTTZ9DE	Strong	Genetic Variation	[251]
CD19	TTW640A	Strong	Altered Expression	[252]
CD209	TTBXIM9	Strong	Biomarker	[253]
CD274	TT8ZLTI	Strong	Altered Expression	[254]
CD28	TTQ13FT	Strong	Biomarker	[255]
CD300A	TTI2YFK	Strong	Genetic Variation	[256]
CD33	TTJVYO3	Strong	Biomarker	[257]
CD5	TTEGYK1	Strong	Biomarker	[258]
CD55	TT5Z9WY	Strong	Biomarker	[259]
CD58	TT5KSBY	Strong	Biomarker	[260]
CD69	TTPQE9F	Strong	Altered Expression	[175]
CDA	TTQ12RK	Strong	Biomarker	[154]
CDK11B	TT5Q79O	Strong	Biomarker	[261]
CDKN1A	TT9GUW0	Strong	Biomarker	[262]
CDKN2C	TTBRUGA	Strong	Altered Expression	[263]
CEBPB	TTUI35N	Strong	Biomarker	[264]
CEL	TTTRNQW	Strong	Genetic Variation	[265]
CHIT1	TTDYX6T	Strong	Altered Expression	[266]
CLDN4	TTMTS9H	Strong	Biomarker	[267]
CLEC4C	TT7YT06	Strong	Biomarker	[268]
CPE	TTXPWO6	Strong	Biomarker	[269]
CPS1	TT42M75	Strong	Biomarker	[270]
CRHR2	TTIY658	Strong	Genetic Variation	[271]
CRTC2	TTFWETR	Strong	Biomarker	[272]
CRY1	TT5MLZR	Strong	Altered Expression	[273]
CRY2	TTAO58M	Strong	Altered Expression	[273]
CRYZ	TTP6UO8	Strong	Biomarker	[274]
CSK	TTX6F0Q	Strong	Altered Expression	[275]
CSNK1A1	TTFQEMX	Strong	Genetic Variation	[276]
CSNK1D	TTH30UI	Strong	Biomarker	[277]
CSNK1G2	TT0UZJ9	Strong	Biomarker	[277]
CSNK1G3	TT34L5N	Strong	Biomarker	[277]
CTSS	TTUMQVO	Strong	Biomarker	[278]
CXCL11	TTWG0RE	Strong	Genetic Variation	[279]
CXCL9	TTWE5PB	Strong	Altered Expression	[280]
CXCR3	TT1UCIJ	Strong	Biomarker	[281]
CYP24A1	TT82UI1	Strong	Genetic Variation	[282]
CYP2A6	TTAQ6ZW	Strong	Biomarker	[283]
CYP2B6	TTMH124	Strong	Genetic Variation	[284]
CYP2C19	TTZ58XG	Strong	Altered Expression	[285]
CYP2C9	TTR40YJ	Strong	Biomarker	[286]
CYP2D6	TTVG215	Strong	Biomarker	[286]
CYP2E1	TTWVHQ5	Strong	Altered Expression	[287]
CYP3A4	TTWP7HQ	Strong	Biomarker	[288]
CYP3A5	TTHS0OK	Strong	Biomarker	[289]
DAPK3	TTERVQN	Strong	Biomarker	[290]
DFFA	TTYVQ9C	Strong	Altered Expression	[291]
DGAT1	TT0GV3R	Strong	Biomarker	[292]
DGAT2	TTRHEQ4	Strong	Altered Expression	[293]
DHCR24	TTTK0NH	Strong	Biomarker	[294]
DNASE1	TTYWGOJ	Strong	Biomarker	[295]
DPP4	TTDIGC1	Strong	Altered Expression	[168]
ELAVL1	TTPC9D0	Strong	Altered Expression	[296]
ENPP2	TTSCIM2	Strong	Biomarker	[297]
EPHA3	TTHS2LR	Strong	Altered Expression	[298]
ERAP1	TT60XFL	Strong	Genetic Variation	[299]
F2	TT6L509	Strong	Biomarker	[300]
FABP1	TTIV96N	Strong	Biomarker	[301]
FABP2	TTS4YLO	Strong	Biomarker	[301]
FASN	TT7AOUD	Strong	Biomarker	[302]
FCAR	TTGUJAO	Strong	Biomarker	[303]
FCGR2B	TT5RWKQ	Strong	Altered Expression	[304]
FCGR3A	TTIFOC0	Strong	Altered Expression	[305]
FKBP5	TT0J5KQ	Strong	Genetic Variation	[306]
FOXP3	TT1X3QF	Strong	Biomarker	[307]
FPR1	TT5Y4EM	Strong	Genetic Variation	[308]
G3BP1	TTG0R8Z	Strong	Biomarker	[309]
G6PC	TTBQMJ8	Strong	Biomarker	[272]
GADD45B	TTMDW9L	Strong	Altered Expression	[310]
GAK	TT0AGBL	Strong	Biomarker	[221]
GAP43	TTSGLN5	Strong	Biomarker	[311]
GGT1	TTZVT7O	Strong	Biomarker	[312]
GOT1	TTU507L	Strong	Altered Expression	[313]
GP6	TTTJUVZ	Strong	Genetic Variation	[314]
GPC3	TTJTSX4	Strong	Genetic Variation	[315]
GPR55	TTNET8J	Strong	Altered Expression	[316]
GPX1	TTYAHBP	Strong	Genetic Variation	[317]
GRB2	TTEYRJ9	Strong	Biomarker	[318]
GSTO1	TTWO3SH	Strong	Genetic Variation	[319]
GUCY1B1	TTLBYH1	Strong	Altered Expression	[320]
GUSB	TTHS7CM	Strong	Genetic Variation	[321]
GZMB	TTKEPHX	Strong	Biomarker	[322]
HDAC8	TTT6LFV	Strong	Altered Expression	[323]
HHAT	TT1VNCG	Strong	Biomarker	[182]
HK2	TTK02H8	Strong	Biomarker	[324]
HLA-DQA1	TTU2I3J	Strong	Altered Expression	[325]
HLA-G	TTLKFB3	Strong	Biomarker	[326]
HMBS	TTT0HW3	Strong	Altered Expression	[327]
HMGCS1	TTQF4TK	Strong	Altered Expression	[244]
HMGCS2	TTS0EZJ	Strong	Altered Expression	[244]
HMOX2	TTWZRL4	Strong	Biomarker	[238]
HNF1A	TT01M3K	Strong	Altered Expression	[328]
HNF4A	TT2F3CD	Strong	Altered Expression	[329]
HSD17B13	TTDJYZR	Strong	Genetic Variation	[330]
HSPA8	TTMQL3K	Strong	Biomarker	[328]
HSPB8	TTY0OJN	Strong	Altered Expression	[331]
HTR6	TTJS8PY	Strong	Biomarker	[332]
HTT	TTIWZ0O	Strong	Genetic Variation	[333]
ID2	TTW8A5N	Strong	Biomarker	[334]
IDO1	TTZJYKH	Strong	Biomarker	[335]
IFNAR1	TTSYFMA	Strong	Altered Expression	[336]
IFNAR2	TTMQB37	Strong	Altered Expression	[337]
IL10RB	TTJTRMK	Strong	Genetic Variation	[338]
IL12A	TTRTK6Y	Strong	Genetic Variation	[339]
IL15	TTJFA35	Strong	Biomarker	[340]
IL15RA	TTGN89I	Strong	Altered Expression	[341]
IL17D	TTC5LTG	Strong	Biomarker	[342]
IL19	TT87RWS	Strong	Biomarker	[343]
IL1R2	TT51DEV	Strong	Altered Expression	[344]
IL1RL2	TTUS18T	Strong	Biomarker	[345]
IL1RN	TT6GSR3	Strong	Genetic Variation	[346]
IL20	TTNZMY2	Strong	Biomarker	[343]
IL21	TT9QEJ6	Strong	Genetic Variation	[347]
IL22	TTLDX4N	Strong	Biomarker	[348]
IL23A	TTC1GLB	Strong	Biomarker	[349]
IL7	TT8FRMO	Strong	Biomarker	[348]
IL7R	TTAWI51	Strong	Altered Expression	[350]
IMPDH2	TTTB4UP	Strong	Biomarker	[351]
IRF3	TTYR7OH	Strong	Biomarker	[352]
IRS1	TTAJSQ0	Strong	Biomarker	[353]
ITGAL	TT48WR6	Strong	Biomarker	[354]
ITPR3	TTH1769	Strong	Biomarker	[355]
JAK1	TT6DM01	Strong	Altered Expression	[356]
JUN	TTS7IR5	Strong	Altered Expression	[357]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[358]
KIR2DL2	TTU0P73	Strong	Biomarker	[359]
KIR2DS2	TTV3CFI	Strong	Altered Expression	[360]
KLRG1	TT299E6	Strong	Biomarker	[361]
KLRK1	TTLRN4A	Strong	Biomarker	[362]
LAG3	TTNVXAW	Strong	Biomarker	[363]
LAIR1	TTSI7A8	Strong	Altered Expression	[364]
LAMP1	TTC214J	Strong	Biomarker	[365]
LANCL1	TTZW8NS	Strong	Biomarker	[366]
LAPTM4B	TTEJQT0	Strong	Biomarker	[367]
LARP1	TTSN1YP	Strong	Biomarker	[368]
LCK	TT860QF	Strong	Biomarker	[369]
LIPA	TTS8T1M	Strong	Altered Expression	[370]
LOX	TTQHNAM	Strong	Biomarker	[371]
LTF	TTSZDQU	Strong	Biomarker	[372]
LY75	TTG180Q	Strong	Genetic Variation	[373]
LY9	TTZCL1U	Strong	Biomarker	[374]
MAGEA4	TT9EQUY	Strong	Biomarker	[375]
MAP3K11	TTETX6Q	Strong	Biomarker	[376]
MAPKAP1	TTWDKCL	Strong	Biomarker	[377]
MAPKAPK3	TTFS4VU	Strong	Genetic Variation	[378]
MAPKAPK5	TT3UJ7Z	Strong	Altered Expression	[379]
MBP	TT2RY5P	Strong	Biomarker	[380]
MCM6	TTQGKSD	Strong	Biomarker	[381]
MFGE8	TT1GLAJ	Strong	Biomarker	[382]
MS4A1	TTUE541	Strong	Altered Expression	[325]
MTTP	TTUS1RD	Strong	Genetic Variation	[383]
NAAA	TTMN4HY	Strong	Biomarker	[384]
NCAM1	TTVXPHT	Strong	Altered Expression	[385]
NCR1	TTQNRJM	Strong	Genetic Variation	[386]
NEK2	TT3VZ24	Strong	Biomarker	[387]
NLRX1	TTKT026	Strong	Biomarker	[388]
NOTCH4	TTXDIK2	Strong	Genetic Variation	[389]
NOX4	TTQRBSJ	Strong	Altered Expression	[390]
NPC1L1	TTPD1CN	Strong	Genetic Variation	[391]
NR0B2	TT25A9Q	Strong	Biomarker	[392]
NRP2	TTRXUVC	Strong	Genetic Variation	[393]
NTSR1	TTTUMEP	Strong	Biomarker	[394]
NUAK2	TTHVOTQ	Strong	Biomarker	[395]
OPRM1	TTKWM86	Strong	Biomarker	[396]
OXTR	TTSCIUP	Strong	Genetic Variation	[157]
P2RX4	TT1NLOA	Strong	Biomarker	[397]
PAK2	TT279WO	Strong	Biomarker	[261]
PDCD1LG2	TTW14O3	Strong	Biomarker	[398]
PDZK1	TTDTBLM	Strong	Biomarker	[399]
PF4	TTSG7Q5	Strong	Altered Expression	[400]
PHGDH	TT8DRCK	Strong	Biomarker	[169]
PI4KA	TTCUS9F	Strong	Biomarker	[401]
PI4KB	TTNPL3B	Strong	Biomarker	[402]
PIM2	TT69J2Z	Strong	Biomarker	[403]
PLIN1	TTIV27N	Strong	Biomarker	[404]
PMEL	TT8MK59	Strong	Altered Expression	[405]
PPARA	TTJ584C	Strong	Biomarker	[406]
PPIA	TTL2ADK	Strong	Biomarker	[407]
PPIB	TT6ZFQ4	Strong	Biomarker	[408]
PPM1A	TTLA7IX	Strong	Altered Expression	[409]
PREP	TTNGKET	Strong	Biomarker	[410]
PROC	TTZUXYS	Strong	Altered Expression	[411]
PRSS1	TT2WR1T	Strong	Biomarker	[412]
PSMD10	TT2H4LN	Strong	Genetic Variation	[319]
PTBP1	TTWMX0U	Strong	Biomarker	[413]
PTPN7	TT2C1DT	Strong	Altered Expression	[414]
PTPRC	TTUS45N	Strong	Biomarker	[415]
RAB7A	TTF6WAQ	Strong	Biomarker	[416]
RACK1	TTJ10AL	Strong	Biomarker	[417]
RECK	TTRZBW7	Strong	Genetic Variation	[418]
RNF7	TTODWGT	Strong	Genetic Variation	[419]
RORA	TT1TYN7	Strong	Altered Expression	[273]
RORC	TTGV6LY	Strong	Genetic Variation	[420]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[421]
RRM2	TT1S4LJ	Strong	Altered Expression	[422]
S100A9	TT0TMQG	Strong	Altered Expression	[423]
SDC1	TTYDSVG	Strong	Biomarker	[424]
SDC2	TT5H2F0	Strong	Biomarker	[425]
SETD7	TTJ0FSU	Strong	Biomarker	[426]
SIGMAR1	TT5TPI6	Strong	Biomarker	[427]
SLC10A1	TTWZRY5	Strong	Genetic Variation	[428]
SLC12A3	TTP362L	Strong	Genetic Variation	[429]
SLC22A1	TTM5Q4V	Strong	Biomarker	[430]
SLC25A1	TTTD730	Strong	Genetic Variation	[431]
SLC27A4	TT20AYF	Strong	Biomarker	[169]
SLC28A2	TTVP9IQ	Strong	Biomarker	[432]
SLC29A1	TTLXAKE	Strong	Genetic Variation	[433]
SLC30A8	TTXIGT7	Strong	Genetic Variation	[434]
SLC3A2	TT5CZSM	Strong	Biomarker	[435]
SLC6A12	TTQBMPI	Strong	Altered Expression	[436]
SLCO1A2	TTUGD21	Strong	Genetic Variation	[437]
SLCO2B1	TTDL3UZ	Strong	Genetic Variation	[222]
SMAD1	TT9GR53	Strong	Altered Expression	[438]
SMAD7	TT0J32Z	Strong	Biomarker	[439]
SMYD3	TTKLJYX	Strong	Biomarker	[440]
SQSTM1	TTOT2RY	Strong	Altered Expression	[358]
SRC	TT6PKBN	Strong	Biomarker	[441]
SREBF1	TTER0UB	Strong	Altered Expression	[442]
STAT1	TTN7R6K	Strong	Biomarker	[443]
TAP1	TT7JZI8	Strong	Altered Expression	[444]
TDP1	TT64IHJ	Strong	Biomarker	[445]
TERF2	TT5XSLT	Strong	Altered Expression	[446]
TGFBR1	TTP4520	Strong	Biomarker	[447]
THPO	TTCG5PE	Strong	Biomarker	[448]
TICAM1	TT2GQT6	Strong	Biomarker	[449]
TLR2	TTY7ZHS	Strong	Genetic Variation	[450]
TLR3	TTD24Y0	Strong	Biomarker	[451]
TLR6	TTWRI8V	Strong	Biomarker	[452]
TLR8	TT8CWFK	Strong	Genetic Variation	[453]
TLR9	TTSHG0T	Strong	Altered Expression	[454]
TM6SF2	TTE1OHM	Strong	Genetic Variation	[455]
TMSB4X	TTMVAIU	Strong	Altered Expression	[456]
TNFRSF21	TT8UA0T	Strong	Altered Expression	[457]
TNFRSF25	TTDV6BQ	Strong	Biomarker	[458]
TNK2	TTIET93	Strong	Biomarker	[459]
TOP1	TTGTQHC	Strong	Biomarker	[460]
TPX2	TT0PHL4	Strong	Altered Expression	[405]
TRAF6	TTCDR6M	Strong	Biomarker	[461]
TREM1	TTHZQP0	Strong	Altered Expression	[462]
TRIM27	TTTO3QN	Strong	Biomarker	[352]
TRPC5	TT32NQ1	Strong	Biomarker	[463]
UBC	TTBP3XA	Strong	Altered Expression	[464]
UBE3A	TTUZX6V	Strong	Biomarker	[465]
WAS	TTE8T73	Strong	Biomarker	[466]
WRN	TT2H5WQ	Strong	Altered Expression	[467]
XRCC5	TTCB9KW	Strong	Biomarker	[468]
ZAP70	TTUMHT8	Strong	Biomarker	[469]
CTLA4	TTI2S1D	Definitive	Genetic Variation	[470]
GAPDH	TTUGSWA	Definitive	Biomarker	[260]
MERTK	TTO7LKR	Definitive	Genetic Variation	[211]
PIK3CB	TT9H4P3	Definitive	Biomarker	[471]
RNASEL	TT7V0K4	Definitive	Altered Expression	[405]

This Disease Is Related to 13 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A3	DTN1FMD	Limited	Biomarker	[472]
ABCC6	DT582KR	Strong	Biomarker	[473]
ABCD1	DTKM9DZ	Strong	Biomarker	[474]
ATP12A	DT5NLZA	Strong	Biomarker	[235]
SLC25A20	DTQOUM4	Strong	Genetic Variation	[475]
SLC27A2	DTXK9WA	Strong	Altered Expression	[320]
SLC28A3	DT4YL5R	Strong	Biomarker	[476]
SLC29A2	DTW78DQ	Strong	Genetic Variation	[477]
SLC2A2	DTUJPOL	Strong	Biomarker	[328]
SLC35A2	DT0567K	Strong	Genetic Variation	[478]
SLC4A1	DTB0Q3P	Strong	Genetic Variation	[479]
SLC7A9	DTP7AEQ	Strong	Genetic Variation	[480]
SLCO6A1	DTIFXNS	Strong	Biomarker	[481]

This Disease Is Related to 20 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1B10	DEP6GT1	Limited	Altered Expression	[482]
DHCR7	DEL7GFA	Limited	Genetic Variation	[483]
HINT1	DEWJATF	Limited	Biomarker	[484]
TPMT	DEFQ8VO	Limited	Genetic Variation	[485]
NAT10	DEZV4AP	moderate	Genetic Variation	[206]
UGT1A7	DEZO4N3	moderate	Genetic Variation	[486]
ABO	DESIA7R	Strong	Biomarker	[487]
ADH4	DEOCWU3	Strong	Biomarker	[226]
CES2	DETHCPD	Strong	Altered Expression	[488]
CYP27A1	DEBS639	Strong	Genetic Variation	[489]
CYP2C18	DEZMWRE	Strong	Altered Expression	[285]
CYP4F3	DEFCMPI	Strong	Altered Expression	[285]
EPHX1	DELB4KP	Strong	Genetic Variation	[490]
MT2A	DEFKGT7	Strong	Biomarker	[491]
PCYT1A	DEQYXD4	Strong	Altered Expression	[492]
PER1	DE9HF0I	Strong	Altered Expression	[273]
SMOX	DEOH5V3	Strong	Altered Expression	[493]
SULT2A1	DE0P6LK	Strong	Biomarker	[469]
THOP1	DE95LJC	Strong	Altered Expression	[494]
UBASH3B	DE10BJ5	Strong	Biomarker	[495]

This Disease Is Related to 592 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AGA	OTNWT1WB	Limited	Biomarker	[496]
ARF4	OT3GMDHA	Limited	Biomarker	[497]
ARHGAP24	OTCQCEZS	Limited	Biomarker	[263]
ARHGEF7	OT9BPJCL	Limited	Biomarker	[498]
ATF2	OTNIZPEA	Limited	Biomarker	[499]
ATG14	OTPZDKI0	Limited	Biomarker	[417]
ATG16L1	OTEOYC5D	Limited	Biomarker	[500]
B3GAT1	OTXFP98E	Limited	Biomarker	[501]
CALM2	OTNYA92F	Limited	Biomarker	[502]
CAMKMT	OTLJBRUW	Limited	Biomarker	[502]
CBFA2T2	OTNOIB23	Limited	Biomarker	[498]
CCL14	OT8QETQU	Limited	Genetic Variation	[249]
CCL8	OTCTWYN8	Limited	Altered Expression	[503]
CCNG1	OT17IA9L	Limited	Altered Expression	[504]
CD82	OTH8MC64	Limited	Biomarker	[505]
CHCHD2	OTL5PA3Y	Limited	Biomarker	[506]
CISH	OT8T5NYL	Limited	Biomarker	[507]
CKB	OTUCKOTT	Limited	Altered Expression	[508]
CLIP1	OTTGAEJE	Limited	Biomarker	[509]
CLIP2	OTSCIQIY	Limited	Biomarker	[509]
CREB3	OT9617UO	Limited	Altered Expression	[510]
CREM	OTJIJ5AL	Limited	Biomarker	[511]
CYP2D7	OTYJTL3S	Limited	Genetic Variation	[512]
DCAF1	OT3ZDVOE	Limited	Biomarker	[513]
DCTN3	OTQOSUES	Limited	Biomarker	[514]
DDB1	OTTR2L3Z	Limited	Biomarker	[513]
DDX56	OTGURA53	Limited	Genetic Variation	[515]
DHX58	OT19BYB1	Limited	Biomarker	[516]
DYNC1H1	OTD1KRKO	Limited	Biomarker	[514]
EFNA4	OTITKZQH	Limited	Biomarker	[517]
EIF2A	OTWXELQP	Limited	Biomarker	[518]
EIF4G1	OT2CF1E6	Limited	Biomarker	[518]
EIF5B	OTZTT22W	Limited	Biomarker	[519]
ETFA	OTXX61VZ	Limited	Biomarker	[520]
EXT1	OTRPALJK	Limited	Biomarker	[521]
FBN2	OT3KYJQL	Limited	Biomarker	[522]
FLNB	OTPCOYL6	Limited	Genetic Variation	[523]
FOXA2	OTJOCVOY	Limited	Biomarker	[524]
GC	OTWS63BY	Limited	Genetic Variation	[525]
GPR158	OTYOC1RQ	Limited	Genetic Variation	[526]
GPX2	OTXI2NTI	Limited	Biomarker	[527]
HERC5	OTZ5PR39	Limited	Biomarker	[528]
HFM1	OTHV3EFE	Limited	Genetic Variation	[529]
HJV	OT4235J2	Limited	Altered Expression	[530]
HLA-DOB	OTKADDUB	Limited	Genetic Variation	[531]
HPCAL1	OTOBBFRD	Limited	Altered Expression	[532]
IFNA6	OTX5EQ87	Limited	Biomarker	[533]
IGF2BP1	OT9G360P	Limited	Biomarker	[534]
IL10RA	OTOX3D1D	Limited	Genetic Variation	[535]
ILF3	OTKMZ5K5	Limited	Biomarker	[536]
IRF9	OTK4MYQJ	Limited	Biomarker	[537]
ITGA2B	OT4Y17PY	Limited	Genetic Variation	[174]
ITGAX	OTOGIMHE	Limited	Altered Expression	[325]
JUNB	OTG2JXV5	Limited	Altered Expression	[538]
JUND	OTNKACJD	Limited	Altered Expression	[538]
KIDINS220	OTLBH2MA	Limited	Genetic Variation	[539]
KIR2DL5B	OTSV0JL9	Limited	Altered Expression	[360]
KLF6	OTQY9S7F	Limited	Biomarker	[540]
KLRB1	OTQ2959Y	Limited	Biomarker	[541]
KLRD1	OTMYLOV4	Limited	Biomarker	[153]
KRIT1	OT58AP1I	Limited	Biomarker	[502]
KRT7	OTLT3JFN	Limited	Biomarker	[542]
LBR	OT1HG3HG	Limited	Biomarker	[543]
LIG4	OT40DNXU	Limited	Biomarker	[544]
MARCHF1	OTI2EYO6	Limited	Genetic Variation	[545]
MCM2	OTGGORIQ	Limited	Altered Expression	[183]
MICB	OTS2DVDW	Limited	Genetic Variation	[480]
MNAT1	OTXLOYCB	Limited	Biomarker	[546]
MTG1	OTC9U1LI	Limited	Biomarker	[547]
MX1	OT6X8G5T	Limited	Genetic Variation	[548]
NANOG	OTUEY1FM	Limited	Biomarker	[549]
NCR3	OT20M764	Limited	Biomarker	[550]
NEIL2	OTV6JEON	Limited	Genetic Variation	[551]
NHS	OTKE8QAT	Limited	Biomarker	[552]
NPC1	OTRIPICX	Limited	Biomarker	[553]
NT5C1A	OTS7UF36	Limited	Biomarker	[554]
NTPCR	OTTRT6Z9	Limited	Biomarker	[555]
NXF1	OTEFHXG6	Limited	Genetic Variation	[523]
OASL	OTZ05YRP	Limited	Altered Expression	[556]
PCBD1	OTDSRUD5	Limited	Biomarker	[557]
PHB2	OTCAX3AW	Limited	Biomarker	[514]
PIAS1	OTZVAHZI	Limited	Biomarker	[558]
PIK3R2	OTZSUQK5	Limited	Biomarker	[498]
PMPCA	OT5X1G9Q	Limited	Biomarker	[559]
PPP1R12C	OT9Q86JO	Limited	Biomarker	[498]
PPP1R13B	OTC88VQO	Limited	Biomarker	[498]
RACGAP1	OTQE8IEH	Limited	Biomarker	[248]
RMDN1	OTE1NB6U	Limited	Biomarker	[560]
RMDN2	OTK5WSFI	Limited	Biomarker	[560]
RMDN3	OTKO7AUM	Limited	Biomarker	[560]
RNH1	OT6EC79B	Limited	Biomarker	[561]
RTN1	OTCX1SMK	Limited	Biomarker	[562]
SARDH	OTQ49Q27	Limited	Biomarker	[563]
SELENOP	OT02B8IR	Limited	Altered Expression	[208]
SET	OTGYYQJO	Limited	Biomarker	[564]
SHBG	OTPWU5IW	Limited	Biomarker	[565]
SPINT1	OT1CLR5L	Limited	Genetic Variation	[197]
SRL	OT7IEBWZ	Limited	Biomarker	[563]
STAT4	OTAK3VFR	Limited	Genetic Variation	[566]
SUMO1	OTJFD4P5	Limited	Biomarker	[567]
SYBU	OT3FQV7N	Limited	Biomarker	[560]
TFF3	OTJJDRTU	Limited	Altered Expression	[568]
TGFBRAP1	OT80QNR5	Limited	Altered Expression	[532]
TJP1	OTBDCUPK	Limited	Biomarker	[569]
TP73	OT0LUO47	Limited	Biomarker	[263]
TRIM22	OTJBLG5R	Limited	Biomarker	[570]
ALPP	OTZU4G9W	moderate	Genetic Variation	[206]
ATRNL1	OTY5JUX2	moderate	Genetic Variation	[206]
CCL27	OTUZYC61	moderate	Genetic Variation	[206]
DCC	OT2C1SHW	moderate	Biomarker	[571]
MIP	OTEBLU3E	moderate	Genetic Variation	[572]
NRDC	OTWBBCXO	moderate	Biomarker	[573]
PDLIM3	OTVXQC81	moderate	Genetic Variation	[206]
SLPI	OTUNFUU8	moderate	Genetic Variation	[206]
SMG1	OTTS3SXE	moderate	Biomarker	[297]
TFR2	OTMYCCEO	moderate	Genetic Variation	[574]
ACACA	OT5CQPZY	Strong	Biomarker	[575]
ACAT2	OTZ092ZJ	Strong	Altered Expression	[162]
ACD	OTC54EPO	Strong	Biomarker	[576]
ACSL3	OT3MWER1	Strong	Biomarker	[577]
ACTA1	OTOVGLPG	Strong	Biomarker	[578]
ADI1	OT8IOD03	Strong	Biomarker	[579]
AFM	OTPOR8IO	Strong	Biomarker	[580]
AGFG1	OTI8ZKC4	Strong	Biomarker	[581]
AGL	OTWBM7WY	Strong	Biomarker	[582]
AGO1	OTD3R434	Strong	Biomarker	[583]
AGO2	OT4JY32Q	Strong	Biomarker	[584]
AIMP1	OTTA5C3U	Strong	Biomarker	[481]
ALDH7A1	OTV57BZD	Strong	Biomarker	[585]
ALG10	OTM1ATVR	Strong	Altered Expression	[320]
AMPD1	OTU17BCI	Strong	Biomarker	[586]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[495]
AP1S3	OTPCMV24	Strong	Biomarker	[587]
AP2M1	OTQCOSFN	Strong	Biomarker	[588]
APCDD1	OTV9AD0L	Strong	Biomarker	[589]
APOBEC3B	OTHLNI51	Strong	Biomarker	[154]
APOC1	OTA58CED	Strong	Biomarker	[590]
APOC2	OTLINYIQ	Strong	Altered Expression	[155]
APOC4	OTE8ZUXY	Strong	Altered Expression	[591]
APOL3	OT95SQHR	Strong	Altered Expression	[327]
APOM	OTI3FQQC	Strong	Biomarker	[592]
ARF5	OTZO9S3U	Strong	Biomarker	[497]
ARHGAP26	OTNGQU7A	Strong	Genetic Variation	[190]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[593]
ARHGEF9	OTB1FLIW	Strong	Biomarker	[594]
ARID2	OTIRJXWM	Strong	Genetic Variation	[595]
ARMH1	OTTJC0D6	Strong	Biomarker	[366]
ASCC2	OT3B204T	Strong	Altered Expression	[405]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[596]
ATG5	OT4T5SMS	Strong	Biomarker	[597]
ATP2C1	OTQN51T3	Strong	Altered Expression	[598]
ATP6V1G2	OTM1DSKL	Strong	Genetic Variation	[480]
AZIN1	OTX5W77I	Strong	Biomarker	[599]
BCAP31	OTKSACR4	Strong	Genetic Variation	[319]
BCCIP	OTFFKG79	Strong	Biomarker	[220]
BCL2L12	OTS6IFZY	Strong	Biomarker	[600]
BCL9	OTRBIPR4	Strong	Biomarker	[403]
BMP3	OTCTI0UW	Strong	Biomarker	[403]
BMPER	OTBYON4H	Strong	Biomarker	[601]
BMS1	OTEGQ8ZO	Strong	Biomarker	[575]
BOC	OTXBCY9W	Strong	Genetic Variation	[602]
BTG3	OT9ANHVT	Strong	Biomarker	[603]
BTN1A1	OTSQWC36	Strong	Genetic Variation	[604]
BTN3A2	OT3DIBU3	Strong	Genetic Variation	[604]
BTN3A3	OTKMSJRA	Strong	Genetic Variation	[604]
CABIN1	OT4G5CIK	Strong	Altered Expression	[554]
CAPN5	OTQ8QM7K	Strong	Biomarker	[246]
CARD16	OT4NUHWB	Strong	Biomarker	[233]
CARD8	OTXXZYWU	Strong	Biomarker	[605]
CAV3	OTWSFDB4	Strong	Genetic Variation	[157]
CAVIN1	OTFO915U	Strong	Biomarker	[606]
CAVIN2	OTFHHDRU	Strong	Altered Expression	[606]
CAVIN3	OTOLBK79	Strong	Altered Expression	[606]
CCL3L1	OTQXCYB1	Strong	Biomarker	[607]
CD1C	OT4XINUJ	Strong	Biomarker	[608]
CD1D	OT3ROU4J	Strong	Biomarker	[609]
CD200R1	OT65Q9M6	Strong	Altered Expression	[364]
CD226	OT4UG0KB	Strong	Biomarker	[610]
CD244	OTSMR85N	Strong	Biomarker	[153]
CD2AP	OTC76KQM	Strong	Biomarker	[353]
CD300LF	OTQWJGSR	Strong	Genetic Variation	[256]
CD63	OT2UGZA9	Strong	Biomarker	[611]
CD68	OTOYEY3J	Strong	Altered Expression	[462]
CD8A	OTDWQJXK	Strong	Genetic Variation	[243]
CD8B	OTMZ1T7J	Strong	Altered Expression	[325]
CD99	OTPUZ5DE	Strong	Biomarker	[612]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[366]
CDK2AP2	OTR99SJ8	Strong	Altered Expression	[423]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[613]
CDSN	OTQW4HV6	Strong	Biomarker	[614]
CELF1	OT6JQ5RS	Strong	Genetic Variation	[615]
CH25H	OT9S2BSW	Strong	Altered Expression	[286]
CHI3L1	OT2Z7VJH	Strong	Genetic Variation	[616]
CINP	OTZ31XOT	Strong	Biomarker	[617]
CIRBP	OTXWTPBL	Strong	Biomarker	[618]
CLCN5	OT9YXZSO	Strong	Biomarker	[619]
CLDN7	OTNE0XHQ	Strong	Biomarker	[620]
CLEC4M	OT2WUIIP	Strong	Biomarker	[621]
CLTC	OTBFASMA	Strong	Genetic Variation	[479]
CMC2	OTRYIO1J	Strong	Genetic Variation	[622]
CNBP	OTTGM9NK	Strong	Biomarker	[623]
CNOT1	OTTEU05F	Strong	Biomarker	[624]
COP1	OT6J2K12	Strong	Biomarker	[233]
COX8A	OTU0NR39	Strong	Genetic Variation	[625]
CPQ	OTTNZNLD	Strong	Altered Expression	[626]
CPT1A	OTI862QH	Strong	Altered Expression	[302]
CPT2	OTIN6G20	Strong	Altered Expression	[302]
CRABP1	OTISDG5X	Strong	Biomarker	[627]
CRABP2	OTY01V9G	Strong	Biomarker	[627]
CREB3L3	OTDMU3GP	Strong	Biomarker	[628]
CRISP3	OTBSWMPL	Strong	Biomarker	[629]
CRLF3	OTT9TMXN	Strong	Biomarker	[537]
CRLS1	OT7XNL0K	Strong	Biomarker	[421]
CRYGD	OTW29JC4	Strong	Biomarker	[630]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[631]
CUX1	OTU1LCNJ	Strong	Altered Expression	[405]
CYBA	OT16N9ZO	Strong	Genetic Variation	[632]
CYP2A7	OTRJ3P2Z	Strong	Biomarker	[633]
DCDC2	OTSUFH1H	Strong	Biomarker	[634]
DCTN4	OTM7C943	Strong	Altered Expression	[358]
DDOST	OT39PDMS	Strong	Biomarker	[635]
DDX18	OTKB9C3S	Strong	Genetic Variation	[455]
DDX19A	OTBTDR44	Strong	Genetic Variation	[636]
DDX39A	OT0Z6E1K	Strong	Genetic Variation	[480]
DDX39B	OTEVCFVU	Strong	Genetic Variation	[480]
DDX3X	OTDO4TRX	Strong	Altered Expression	[637]
DDX41	OT6KEIHP	Strong	Biomarker	[638]
DDX46	OTB2X9TO	Strong	Genetic Variation	[636]
DDX6	OTKWXVDY	Strong	Biomarker	[515]
DEPDC5	OTE70JLY	Strong	Genetic Variation	[639]
DHX16	OTW8KZAU	Strong	Genetic Variation	[636]
DHX9	OT5AAOQI	Strong	Biomarker	[534]
DIAPH2	OTBEYFEZ	Strong	Biomarker	[640]
DNAJC3	OT7ROIJF	Strong	Biomarker	[261]
DNAJC5B	OTHDMM7O	Strong	Biomarker	[331]
DNALI1	OTTB3L8N	Strong	Genetic Variation	[319]
DUSP11	OTU6C41M	Strong	Biomarker	[619]
DUSP6	OT4H6RKW	Strong	Altered Expression	[641]
DYM	OTQ670WI	Strong	Biomarker	[642]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[366]
EDEM1	OTWHN69S	Strong	Biomarker	[643]
EDEM3	OT4GJX9R	Strong	Biomarker	[643]
EFL1	OTMEXJZA	Strong	Biomarker	[644]
EIF2D	OTE109AY	Strong	Biomarker	[518]
EIF3A	OTFABY9G	Strong	Biomarker	[645]
EIF6	OTEXMUED	Strong	Altered Expression	[646]
ELF1	OTV5LKIA	Strong	Biomarker	[644]
EMB	OT67E3Q1	Strong	Genetic Variation	[647]
ENAM	OTK8PU0T	Strong	Biomarker	[648]
ERC1	OTYBGGNO	Strong	Biomarker	[649]
ERLIN1	OTUOOODY	Strong	Biomarker	[650]
ERVW-1	OTWV8DXJ	Strong	Genetic Variation	[651]
FAM107B	OT5RG4J0	Strong	Genetic Variation	[652]
FAM72A	OTBZYSR3	Strong	Biomarker	[653]
FAM72B	OT6AOG64	Strong	Biomarker	[653]
FARP2	OTNRQIMK	Strong	Biomarker	[654]
FBP1	OTQBANEP	Strong	Biomarker	[220]
FBXL2	OT5EZ7PD	Strong	Biomarker	[355]
FCGR2C	OTNLMNYB	Strong	Altered Expression	[304]
FCGR3B	OTSLSPZG	Strong	Altered Expression	[305]
FCN2	OTTHJBKZ	Strong	Biomarker	[655]
FCRL4	OT3DVTRV	Strong	Biomarker	[656]
FEV	OTYEC4IR	Strong	Biomarker	[657]
FKBP8	OT8RPSOC	Strong	Biomarker	[658]
FLVCR1	OT9XCFOC	Strong	Altered Expression	[230]
FUBP1	OT77SC9N	Strong	Biomarker	[220]
FUNDC2	OTY3TQM5	Strong	Biomarker	[659]
FUT1	OTODG57A	Strong	Altered Expression	[660]
FUT8	OTJJCVG1	Strong	Biomarker	[661]
GABARAP	OTAQUX6E	Strong	Biomarker	[662]
GALNT8	OT05BKVP	Strong	Genetic Variation	[663]
GBF1	OTY1KEHY	Strong	Genetic Variation	[664]
GBP1	OTUM7RPJ	Strong	Altered Expression	[665]
GCHFR	OTEOT8GI	Strong	Altered Expression	[366]
GCKR	OTSIWXGG	Strong	Altered Expression	[320]
GDE1	OTU6FSBF	Strong	Biomarker	[439]
GFER	OTVK43OK	Strong	Altered Expression	[666]
GFRA1	OT3WBVYB	Strong	Biomarker	[667]
GGPS1	OTVEHG28	Strong	Altered Expression	[668]
GLT8D2	OT4VS9YY	Strong	Genetic Variation	[419]
GLTP	OTM78ZFI	Strong	Biomarker	[669]
GNB3	OTA6HYBA	Strong	Genetic Variation	[670]
GOLM1	OTOZSV6O	Strong	Biomarker	[671]
GOLPH3	OTDLGYM3	Strong	Biomarker	[461]
GOSR1	OTX8TMVU	Strong	Genetic Variation	[319]
GOT2	OT6XBWN0	Strong	Altered Expression	[313]
GP2	OTB6TMGY	Strong	Genetic Variation	[672]
GPR161	OT80FYA3	Strong	Biomarker	[673]
GSTK1	OTDNGWAF	Strong	Biomarker	[481]
GTF2A1L	OTDQHVAI	Strong	Biomarker	[580]
GTF2H1	OTCRXC6B	Strong	Altered Expression	[358]
GZMH	OTG3259L	Strong	Altered Expression	[674]
H1-5	OTAN7RD9	Strong	Biomarker	[675]
HABP2	OTAUIPW0	Strong	Genetic Variation	[676]
HADHA	OTO557N2	Strong	Biomarker	[558]
HARS1	OTHOEOTS	Strong	Biomarker	[677]
HAVCR2	OTOL603T	Strong	Biomarker	[678]
HBP1	OTDPGGDV	Strong	Altered Expression	[679]
HCP5	OTV0YRI8	Strong	Genetic Variation	[680]
HDDC2	OTSO0JP4	Strong	Genetic Variation	[681]
HGS	OTCYYCAC	Strong	Biomarker	[677]
HILPDA	OTEID3ZM	Strong	Biomarker	[682]
HLA-DPA1	OT7OG7Y2	Strong	Biomarker	[683]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[684]
HLA-DQA2	OT1DH0N9	Strong	Genetic Variation	[685]
HLA-DRB3	OT5PM9N7	Strong	Biomarker	[686]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[687]
HLA-E	OTX1CTFB	Strong	Biomarker	[688]
HLA-F	OT76CM19	Strong	Biomarker	[689]
HLF	OTTRK9XN	Strong	Altered Expression	[372]
HM13	OTGEO1LP	Strong	Biomarker	[690]
HNRNPC	OT47AK4C	Strong	Biomarker	[534]
HNRNPD	OT5UO1FA	Strong	Altered Expression	[691]
HNRNPDL	OTB3BFCV	Strong	Biomarker	[534]
HNRNPK	OTNPRM8U	Strong	Biomarker	[692]
HNRNPL	OT0DJX74	Strong	Biomarker	[534]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[174]
HSF4	OT1UX9SK	Strong	Biomarker	[693]
ICAM3	OTTZ5A5D	Strong	Genetic Variation	[694]
IER3	OTZJI5FZ	Strong	Biomarker	[695]
IFI44	OTOKSZVA	Strong	Biomarker	[696]
IFI6	OTWOOAM4	Strong	Biomarker	[697]
IFIT1	OTXOQDSG	Strong	Biomarker	[698]
IFIT5	OTYTSO77	Strong	Biomarker	[261]
IFITM1	OTECO1G8	Strong	Altered Expression	[699]
IFNA4	OTII5O0G	Strong	Biomarker	[700]
IFNE	OTXO5MHZ	Strong	Genetic Variation	[701]
IFNGR1	OTCTQBWW	Strong	Biomarker	[702]
IFNLR1	OTWWWK45	Strong	Altered Expression	[703]
IFT122	OTSK3OAD	Strong	Biomarker	[704]
IGFBP4	OT2HZRBD	Strong	Genetic Variation	[393]
IGSF6	OT5TUH02	Strong	Biomarker	[705]
IGSF8	OTU22IKI	Strong	Biomarker	[706]
IL18BP	OTW0LRYZ	Strong	Biomarker	[707]
IL1RAPL2	OTP7IOJO	Strong	Altered Expression	[344]
IL27	OTIS3OF8	Strong	Biomarker	[342]
IL36RN	OT5CO95A	Strong	Biomarker	[345]
ILF2	OTWWVM9X	Strong	Biomarker	[536]
IMMT	OTBDSLE7	Strong	Biomarker	[708]
IMPACT	OTQ923OB	Strong	Biomarker	[709]
ING2	OT6H0EWF	Strong	Genetic Variation	[243]
INPPL1	OTCDAVBQ	Strong	Altered Expression	[710]
INSRR	OT3F75WA	Strong	Biomarker	[711]
IRAK2	OT6Y1QZN	Strong	Genetic Variation	[712]
IRF2	OTAZRUW3	Strong	Altered Expression	[341]
IRF5	OT8SIIAP	Strong	Biomarker	[713]
IRF7	OTC1A2PQ	Strong	Altered Expression	[714]
IRGM	OTKD3O5Z	Strong	Biomarker	[715]
ITPRIP	OT9YEJXS	Strong	Biomarker	[716]
IVNS1ABP	OTYHL4I7	Strong	Genetic Variation	[717]
JPT1	OT6CRZEU	Strong	Biomarker	[718]
KAT8	OT5LPQTR	Strong	Altered Expression	[320]
KIAA1549L	OT80HUVY	Strong	Genetic Variation	[157]
KIF1B	OTI1XQTO	Strong	Genetic Variation	[719]
KIR2DL5A	OT09FZE1	Strong	Genetic Variation	[720]
KIR2DS3	OT3PSLDL	Strong	Biomarker	[721]
KIR2DS4	OT00N6UJ	Strong	Biomarker	[722]
KIR3DS1	OTJWIO4T	Strong	Biomarker	[723]
KLHL1	OTAX6SAD	Strong	Altered Expression	[724]
KLK10	OTD573EL	Strong	Posttranslational Modification	[725]
KLRC2	OTT4N86S	Strong	Altered Expression	[212]
KPNA1	OTEMVAJ6	Strong	Biomarker	[726]
KRT14	OTUVZ1DW	Strong	Genetic Variation	[727]
KRT18	OTVLQFIP	Strong	Biomarker	[728]
KRT20	OT4RB40L	Strong	Altered Expression	[325]
LAMP3	OTN0XL3W	Strong	Altered Expression	[328]
LAMTOR2	OTHEDISB	Strong	Altered Expression	[423]
LDLRAP1	OT6QTX7R	Strong	Genetic Variation	[729]
LGALS3BP	OT9AGQKH	Strong	Altered Expression	[730]
LGALS4	OTKQCG0H	Strong	Genetic Variation	[731]
LGALS9	OT7MF91K	Strong	Biomarker	[732]
LIX1	OT1CPNCC	Strong	Biomarker	[733]
LMO1	OTB59SKB	Strong	Biomarker	[734]
LPCAT1	OTCV7AGV	Strong	Altered Expression	[735]
LSAMP	OTYXVQX2	Strong	Altered Expression	[328]
LTBP2	OTS88GSD	Strong	Altered Expression	[736]
LUM	OTSRC874	Strong	Altered Expression	[737]
MAP1LC3A	OTPMGIU4	Strong	Biomarker	[738]
MAP1LC3B	OTUYHB84	Strong	Altered Expression	[739]
MARCHF2	OTADQ0OA	Strong	Biomarker	[740]
MASP1	OTWWCNZP	Strong	Altered Expression	[412]
MATK	OTVOJJLJ	Strong	Biomarker	[741]
MCF2L	OTEURA8N	Strong	Biomarker	[635]
MCM3	OTOOHQPM	Strong	Biomarker	[742]
MED19	OTT9RT5N	Strong	Altered Expression	[743]
MED9	OT59OKEJ	Strong	Biomarker	[682]
MFAP1	OTZN4FT3	Strong	Altered Expression	[744]
MICA	OTPEIEAR	Strong	Genetic Variation	[745]
MIXL1	OT584VOQ	Strong	Genetic Variation	[746]
MPG	OTAHW80B	Strong	Genetic Variation	[747]
MPIG6B	OTVNKQWA	Strong	Biomarker	[748]
MR1	OTZU3XX7	Strong	Genetic Variation	[745]
MRPL28	OT4LUTZU	Strong	Biomarker	[749]
MRPS18B	OT1K9PFX	Strong	Altered Expression	[750]
MT1B	OTUA4FFH	Strong	Genetic Variation	[383]
MXD1	OTS5CTHX	Strong	Biomarker	[586]
MYO18A	OT2YPT7O	Strong	Posttranslational Modification	[751]
NAP1L1	OTI7WBZV	Strong	Biomarker	[752]
NCAM2	OT8LBJN8	Strong	Genetic Variation	[190]
NCKIPSD	OT24UORN	Strong	Genetic Variation	[753]
NCOA7	OT2CNBOG	Strong	Biomarker	[754]
NDC80	OTS7D306	Strong	Biomarker	[248]
NEIL1	OTHBU5DJ	Strong	Biomarker	[755]
NELFE	OTL4E94L	Strong	Altered Expression	[756]
NEURL3	OTA3ALQO	Strong	Biomarker	[757]
NFKBIB	OTY1ZJXH	Strong	Altered Expression	[758]
NFKBIE	OTLAYEL9	Strong	Genetic Variation	[759]
NFKBIL1	OTYFTPS0	Strong	Genetic Variation	[480]
NR1D2	OT9CVF41	Strong	Biomarker	[760]
NSUN2	OTZCNM33	Strong	Biomarker	[682]
NUMB	OTMB586Q	Strong	Posttranslational Modification	[761]
NUP62	OTMN63DH	Strong	Altered Expression	[358]
NXT1	OT0VO6AY	Strong	Biomarker	[749]
OAS1	OT8ZLOCY	Strong	Altered Expression	[665]
OAS2	OT64CCTM	Strong	Altered Expression	[762]
OAS3	OT6E5FYS	Strong	Biomarker	[405]
ODR4	OTGC56W3	Strong	Biomarker	[734]
OGT	OT1Z1ZXE	Strong	Altered Expression	[763]
OPTN	OT2UXWH9	Strong	Biomarker	[764]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[765]
OSBP2	OTDGLB4J	Strong	Altered Expression	[766]
PACSIN2	OTC2R00C	Strong	Altered Expression	[767]
PAK3	OT80M3BV	Strong	Biomarker	[473]
PCBP2	OTXCN9CG	Strong	Biomarker	[388]
PCK2	OTJ8LX4N	Strong	Altered Expression	[768]
PCLAF	OTMVIOUU	Strong	Altered Expression	[769]
PDIA3	OTHPQ0Q3	Strong	Biomarker	[261]
PDIK1L	OTISF4KG	Strong	Altered Expression	[770]
PEA15	OTKCKTSX	Strong	Biomarker	[546]
PELI1	OTMLBCLC	Strong	Biomarker	[771]
PER2	OTU2B1DJ	Strong	Genetic Variation	[772]
PER3	OTVKYVJA	Strong	Altered Expression	[273]
PGLYRP2	OTF8319A	Strong	Biomarker	[773]
PIAS2	OTJLSC3V	Strong	Altered Expression	[774]
PIAS3	OT3TWH9R	Strong	Altered Expression	[775]
PIK3C2B	OTY2PROB	Strong	Biomarker	[776]
PIK3C3	OTLUM9L7	Strong	Biomarker	[777]
PINK1	OT50NR57	Strong	Biomarker	[778]
PITPNM1	OTIUYAG5	Strong	Biomarker	[779]
PITX1	OTA0UN4C	Strong	Altered Expression	[780]
PKIB	OT7C8GFN	Strong	Genetic Variation	[190]
PLA1A	OT2IXYNX	Strong	Biomarker	[781]
PLAAT4	OTI66SAJ	Strong	Altered Expression	[208]
PLIN2	OTRXJ9UN	Strong	Altered Expression	[782]
PLIN3	OT9ZA7MR	Strong	Altered Expression	[783]
PLIN5	OTV8G50L	Strong	Altered Expression	[784]
PLXNB1	OTCA7JIT	Strong	Biomarker	[785]
POLDIP3	OTTB5SV7	Strong	Biomarker	[405]
POLE3	OTOELRF6	Strong	Biomarker	[653]
POLRMT	OT5Q8ZUJ	Strong	Biomarker	[786]
POTEF	OTV3WXYE	Strong	Genetic Variation	[787]
POU2F1	OTK7ELJ0	Strong	Biomarker	[430]
PPIG	OTZ8BTTM	Strong	Biomarker	[788]
PPIL1	OTS5S837	Strong	Biomarker	[789]
PPP1R15A	OTYG179K	Strong	Altered Expression	[790]
PRB2	OTAD4JZ0	Strong	Altered Expression	[791]
PRDM6	OTKY12D9	Strong	Biomarker	[771]
PRF1	OTFVXD7H	Strong	Altered Expression	[792]
PRH1	OTQZ6HX0	Strong	Biomarker	[793]
PRIM2	OTGT0KTF	Strong	Biomarker	[261]
PRSS3	OTN3S5YB	Strong	Biomarker	[794]
PSMD3	OT585WY8	Strong	Biomarker	[261]
PSMD7	OT7PZZ4K	Strong	Biomarker	[366]
PSME3	OTSTC4YY	Strong	Altered Expression	[795]
PTBP2	OTF4S7NE	Strong	Biomarker	[413]
PTF1A	OT7SWA57	Strong	Biomarker	[537]
PTGES3	OTPPQWI0	Strong	Biomarker	[161]
PXN	OTVMMUOF	Strong	Biomarker	[796]
QPRT	OT6SKKLL	Strong	Biomarker	[797]
RAB18	OTNMAQLS	Strong	Biomarker	[798]
RAB1A	OTKPHRD0	Strong	Biomarker	[799]
RAB1B	OTAFCUAS	Strong	Biomarker	[800]
RAB29	OTDZT6LP	Strong	Biomarker	[801]
RAB32	OTTR4H7S	Strong	Altered Expression	[802]
RAB40B	OTCA9ZF5	Strong	Posttranslational Modification	[803]
RAB5A	OTFR2KM4	Strong	Biomarker	[804]
RAB6A	OTLS86J5	Strong	Biomarker	[804]
RAB7B	OT60A0E9	Strong	Biomarker	[416]
RABEPK	OTCZSREH	Strong	Biomarker	[366]
RAD21	OTQS84ZF	Strong	Biomarker	[642]
RAD23B	OT0PGOG3	Strong	Biomarker	[261]
RAD51AP1	OTXM7UTD	Strong	Biomarker	[805]
RAPGEF5	OT53VS75	Strong	Biomarker	[806]
RASGRF2	OT67DAGF	Strong	Biomarker	[807]
RBL1	OTDEBFYC	Strong	Altered Expression	[791]
RBM24	OTQI1AR1	Strong	Biomarker	[808]
RBM39	OTCMPTF9	Strong	Genetic Variation	[809]
RERE	OT3G4GBZ	Strong	Genetic Variation	[810]
RETN	OTW5Z1NH	Strong	Biomarker	[210]
RHEB	OTFLTSEC	Strong	Altered Expression	[811]
RILP	OTT6K1GE	Strong	Altered Expression	[416]
RIOK3	OTZYZVIX	Strong	Biomarker	[618]
RNASE1	OTKZ7CO9	Strong	Biomarker	[812]
RNASE4	OTA5SZLC	Strong	Biomarker	[799]
RNF139	OT0PR1X5	Strong	Altered Expression	[813]
ROBO3	OTPVG40S	Strong	Altered Expression	[208]
RPL17	OTTYMPS6	Strong	Biomarker	[814]
RPP14	OT4OYFSK	Strong	Altered Expression	[423]
RPS27A	OTIIGGZ2	Strong	Altered Expression	[464]
RPS4X	OTIH80EK	Strong	Altered Expression	[815]
RPS6	OTT4D1LN	Strong	Biomarker	[816]
RPTOR	OT4TQZ9F	Strong	Biomarker	[377]
RRAS	OTBBF28C	Strong	Biomarker	[161]
RSAD2	OTCA9WCM	Strong	Biomarker	[817]
RTEL1	OTI3PJCT	Strong	Genetic Variation	[818]
RTN3	OTGZ51QF	Strong	Biomarker	[819]
SAG	OTDNS3ZQ	Strong	Biomarker	[820]
SART3	OTC1AM7S	Strong	Altered Expression	[405]
SCAF1	OT16TM3N	Strong	Genetic Variation	[600]
SDC3	OT1P0LJM	Strong	Biomarker	[425]
SDC4	OTKUVUGZ	Strong	Biomarker	[425]
SDHC	OTC8G2MX	Strong	Biomarker	[821]
SDK2	OTTBK3MH	Strong	Genetic Variation	[157]
SEC14L2	OTJST64D	Strong	Biomarker	[822]
SEC24C	OTMTJBQ1	Strong	Biomarker	[823]
SEL1L	OTC0FB7T	Strong	Biomarker	[643]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[824]
SERPINB4	OT88LHZ8	Strong	Genetic Variation	[825]
SF3B6	OTPRKS6S	Strong	Altered Expression	[423]
SFRP2	OT8GZ0CA	Strong	Genetic Variation	[826]
SH2D1A	OTLU49I5	Strong	Biomarker	[153]
SHC2	OTTWMRNQ	Strong	Biomarker	[827]
SIDT1	OTJM5S74	Strong	Genetic Variation	[828]
SIGLEC1	OTNWSQA9	Strong	Altered Expression	[829]
SIX6	OTD1RD9D	Strong	Biomarker	[830]
SLC12A9	OTR7VRAK	Strong	Biomarker	[262]
SMARCA2	OTSGJ8SV	Strong	Altered Expression	[207]
SMIM1	OTWSFC2F	Strong	Biomarker	[831]
SMIM10L2B	OT04IG2N	Strong	Genetic Variation	[832]
SMOC1	OTJG2JQY	Strong	Biomarker	[833]
SMOC2	OTK1EQ49	Strong	Biomarker	[773]
SND1	OTT734JN	Strong	Altered Expression	[405]
SNF8	OTRQA2AI	Strong	Biomarker	[834]
SNRPD1	OTWKZV4E	Strong	Biomarker	[835]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[697]
SOS1	OTTCWXC3	Strong	Biomarker	[836]
SPATA16	OT9GJBI3	Strong	Genetic Variation	[190]
SPATA2	OTOA45GL	Strong	Biomarker	[814]
SPECC1	OTPEML48	Strong	Biomarker	[562]
SPINT2	OTQV7BKQ	Strong	Biomarker	[837]
SPRR2A	OT62ZU6B	Strong	Biomarker	[838]
SPSB2	OT7ZVT8R	Strong	Biomarker	[839]
SRSF4	OTLI7CU1	Strong	Genetic Variation	[321]
SRSF5	OTC5WP98	Strong	Biomarker	[677]
SSB	OTCCTPBR	Strong	Biomarker	[840]
ST13	OTNML6UP	Strong	Biomarker	[537]
STAT2	OTO9G2RZ	Strong	Biomarker	[443]
STAT5A	OTBSJGN3	Strong	Altered Expression	[841]
STAT5B	OTZVPEBT	Strong	Altered Expression	[841]
STAU1	OTTR5311	Strong	Biomarker	[842]
STING1	OTDAP4G0	Strong	Biomarker	[843]
STON1	OT2HPUAI	Strong	Biomarker	[580]
STX2	OTO2IDDR	Strong	Altered Expression	[660]
STX4	OTQ7YUX1	Strong	Biomarker	[844]
STX7	OTHW3GEI	Strong	Biomarker	[845]
SUB1	OTK71JYU	Strong	Altered Expression	[423]
SURF4	OTCSXJ9C	Strong	Biomarker	[846]
SUV39H2	OTU0F4LL	Strong	Biomarker	[847]
SYCE1L	OTXU44F3	Strong	Altered Expression	[724]
TAF8	OTWWGCHV	Strong	Genetic Variation	[848]
TAP2	OTWSYFI7	Strong	Genetic Variation	[531]
TAPBP	OTL81AVZ	Strong	Genetic Variation	[531]
TAT	OT2CJ91O	Strong	Biomarker	[849]
TBC1D20	OTDL1T6E	Strong	Biomarker	[799]
TBP	OT6C0S52	Strong	Biomarker	[850]
TBPL2	OTDEC1KO	Strong	Altered Expression	[851]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[593]
TIMP4	OT8A68SW	Strong	Altered Expression	[852]
TMED10	OTUXSHH7	Strong	Biomarker	[161]
TMED5	OT70W1J8	Strong	Genetic Variation	[319]
TMEM132A	OTNUI7O1	Strong	Biomarker	[558]
TNFAIP6	OT1SLUZH	Strong	Biomarker	[491]
TNFAIP8L2	OTII0RM0	Strong	Biomarker	[853]
TNPO1	OT7W2CM8	Strong	Biomarker	[377]
TNRC6A	OT493IOM	Strong	Biomarker	[854]
TNRC6C	OTBR07PM	Strong	Biomarker	[854]
TOMM34	OTH6MITE	Strong	Biomarker	[855]
TOMM40	OTZDQ29F	Strong	Genetic Variation	[856]
TOP3A	OT3CKUI9	Strong	Biomarker	[460]
TOX	OTE8BL5Z	Strong	Biomarker	[857]
TPR	OTUBBA4W	Strong	Biomarker	[858]
TRAF2	OT1MEZZN	Strong	Biomarker	[859]
TRAT1	OTMPUNPD	Strong	Altered Expression	[860]
TRIB3	OTG5OS7X	Strong	Altered Expression	[861]
TRIM14	OTLQKUG0	Strong	Biomarker	[862]
TRIM56	OTFGU8E3	Strong	Altered Expression	[863]
TRIM69	OTTEGTRD	Strong	Biomarker	[449]
TRIO	OT71X1AK	Strong	Biomarker	[864]
ASPM	OTKXQMNA	Definitive	Biomarker	[865]
DCX	OTISR7K3	Definitive	Biomarker	[207]
NCAN	OT8OO6ZE	Definitive	Genetic Variation	[866]
SARNP	OTE0OVK5	Definitive	Biomarker	[867]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7876).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders. Hepatology. 2009 Dec;50(6):1719-26.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7462).
• [6] 2011 Pipeline of Pharmasset.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7871).
• [9] ClinicalTrials.gov (NCT01773070) A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study. U.S. National Institutes of Health.
• [10] Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
• [11] ClinicalTrials.gov (NCT01500772) Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
• [12] 2011 Pipeline of Boehringer Ingelheim Pharma.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of Biotest Pharmaceuticals.
• [15] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [16] Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000 Aug;18(16):2972-80.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7830).
• [18] ClinicalTrials.gov (NCT02204475) Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066). U.S. National Institutes ofHealth.
• [19] ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.
• [20] A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-na ve patients with chronic hepatitis C: ViSER1 results. Hepatology. 2009 Sep;50(3):717-26.
• [21] ClinicalTrials.gov (NCT02057159) A Study of NeuroVax a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis. U.S. National Institutes of Health.
• [22] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [23] ClinicalTrials.gov (NCT01860742) Randomized Phase III of PRRT Versus Interferon. U.S. National Institutes of Health.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7357).
• [25] Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
• [26] ClinicalTrials.gov (NCT00401947) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ACH-0137171 in Subjects With Chronic Hepatitis C Infection. U.S. National Institutes of Health.
• [27] Clinical pipeline report, company report or official report of Achillion (2011).
• [28] ClinicalTrials.gov (NCT01849562) Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects. U.S. National Institutes of Health.
• [29] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [30] 2011 Pipeline of Bristol-Myers Squibb.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031680)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027325)
• [33] 2011 Pipeline of Can-Fite BioPharm.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041950)
• [35] ClinicalTrials.gov (NCT00277238) CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects. U.S.National Institutes of Health.
• [36] 2011 Pipeline of InterMune.
• [37] Clinical pipeline report, company report or official report of Pfizer (2011).
• [38] ClinicalTrials.gov (NCT00606086) Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection. U.S. National Institutes of Health.
• [39] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [40] ClinicalTrials.gov (NCT01435226) GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection. U.S. National Institutesof Health.
• [41] Clinical pipeline report, company report or official report of Gilead (2011).
• [42] ClinicalTrials.gov (NCT02202980) Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection. U.S. National Institutes of Health.
• [43] ClinicalTrials.gov (NCT01439373) Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects. U.S. National Institutes of Health.
• [44] ClinicalTrials.gov (NCT00703872) HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients. U.S. National Institutes of Health.
• [45] Clinical pipeline report, company report or official report of Amarillo Biosciences.
• [46] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017807)
• [47] Clinical pipeline report, company report or official report of Amarillo biosciences.
• [48] Clinical pipeline report, company report or official report of Hanall biopharma.
• [49] ClinicalTrials.gov (NCT01425970) Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin. U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT00480831) A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g). U.S. National Institutes of Health.
• [51] Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
• [52] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020136)
• [53] Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-54.
• [54] 2011 Pipeline of Santaris Pharma.
• [55] ClinicalTrials.gov (NCT00433108) Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C. U.S. National Institutes of Health.
• [56] Clinical pipeline report, company report or official report of Merck (2011).
• [57] ClinicalTrials.gov (NCT01226797) Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes. U.S. National Institutes of Health.
• [58] ClinicalTrials.gov (NCT00810758) Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691. U.S. National Institutes of Health.
• [59] ClinicalTrials.gov (NCT01859962) Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C. U.S. National Institutes of Health.
• [60] ClinicalTrials.gov (NCT02426359) Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients. U.S. National Institutes of Health.
• [61] A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer. 1997;75(3):423-6.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040120)
• [63] SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72.
• [64] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034971)
• [65] ClinicalTrials.gov (NCT01726946) A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C. U.S. National Institutes of Health.
• [66] 2011 Pipeline of Vertex.
• [67] ClinicalTrials.gov (NCT00800007) Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus. U.S. National Institutes of Health.
• [68] ClinicalTrials.gov (NCT00522808) A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers. U.S. National Institutes of Health.
• [69] ClinicalTrials.gov (NCT01825980) Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients. U.S. NationalInstitutes of Health.
• [70] ClinicalTrials.gov (NCT00563173) Phase I/IIa Dose Ranging CHRONVAC-C Study in Chronic HCV Patients. U.S. National Institutes of Health.
• [71] ClinicalTrials.gov (NCT00807001) Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naive Subjects. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT01508156) Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001). U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT01433133) Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients. U.S. National Institutes of Health.
• [74] Clinical pipeline report, company report or official report of Okairos.
• [75] ClinicalTrials.gov (NCT01899092) Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C. U.S. National Institutes of Health.
• [76] Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
• [77] Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
• [78] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034265)
• [79] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039148)
• [80] ClinicalTrials.gov (NCT00906256) Clinical Pharmacology Study of AZD7295 in Healthy Subjects. U.S. National Institutes of Health.
• [81] ClinicalTrials.gov (NCT01096576) A Study of Balapiravir in Patients With Dengue Virus Infection. U.S. National Institutes of Health.
• [82] Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug. Nautilus Biotech. MAY 14, 2007.
• [83] 2011 Pipeline of Biotron.
• [84] ClinicalTrials.gov (NCT02760758) A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects. U.S. National Institutes of Health.
• [85] The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74.
• [86] ClinicalTrials.gov (NCT01856426) Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT01316237) A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health.
• [88] ClinicalTrials.gov (NCT00439959) Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults. U.S. National Institutes of Health.
• [89] ClinicalTrials.gov (NCT00500747) Chiron Corp HCV E1/E2 Vaccine. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT04318379) Therapeutic Hepatitis C Virus Vaccine. U.S. National Institutes of Health.
• [91] Clinical pipeline report, company report or official report of Idenix (2011).
• [92] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [93] ClinicalTrials.gov (NCT01482611) A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382. U.S. National Institutesof Health.
• [94] ClinicalTrials.gov (NCT02617615) A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients. U.S. National Institutes of Health.
• [95] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037271)
• [96] ClinicalTrials.gov (NCT01329913) Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003). U.S. National Institutes of Health.
• [97] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029167)
• [98] ClinicalTrials.gov (NCT01928147) A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients. U.S. National Institutes of Health.
• [99] 2011 Pipeline of Presidio.
• [100] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031996)
• [101] ClinicalTrials.gov (NCT01181024) A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1. U.S. National Institutes of Health.
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034330)
• [103] ClinicalTrials.gov (NCT01813552) To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006). U.S. National Institutes of Health.
• [104] ClinicalTrials.gov (NCT01202825) TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single OralDoses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients. U.S. National Institutes of Health.
• [105] Clinical pipeline report, company report or official report of Medivir (2011).
• [106] ClinicalTrials.gov (NCT00557583) Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults. U.S. National Institutes of Health.
• [107] ClinicalTrials.gov (NCT00300807) Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health.
• [108] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011335)
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031314)
• [110] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012104)
• [111] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009426)
• [112] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017555)
• [113] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005492)
• [114] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026937)
• [115] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025214)
• [116] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010620)
• [117] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011886)
• [118] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016469)
• [119] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022995)
• [120] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021992)
• [121] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031987)
• [122] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011431)
• [123] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032623)
• [124] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021901)
• [125] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018541)
• [126] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018157)
• [127] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027431)
• [128] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032147)
• [129] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018944)
• [130] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018979)
• [131] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033302)
• [132] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042373)
• [133] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023649)
• [134] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029954)
• [135] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010742)
• [136] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030836)
• [137] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015702)
• [138] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018937)
• [139] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027514)
• [140] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024593)
• [141] Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.J Virol. 2000 Aug;74(15):6885-92.
• [142] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019390)
• [143] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023059)
• [144] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024904)
• [145] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027653)
• [146] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [147] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2625).
• [148] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032074)
• [149] Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem.2010 Nov 5;285(45):34337-47.
• [150] FDA Approved Drug Products from FDA Official Website. 2015. Application Number: (ANDA) 207931.
• [151] Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther. 2012;17(3):411-23.
• [152] Active Hepatitis C Leading to Refractory Thrombotic Thrombocytopenic Purpura - A Dubious Association and The Challenges Faced in Management.Cureus. 2019 Jul 16;11(7):e5147. doi: 10.7759/cureus.5147.
• [153] Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells.PLoS Pathog. 2011 May;7(5):e1002045. doi: 10.1371/journal.ppat.1002045. Epub 2011 May 19.
• [154] APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity.Antiviral Res. 2019 May;165:23-33. doi: 10.1016/j.antiviral.2019.03.005. Epub 2019 Mar 9.
• [155] Amphipathic -helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles.PLoS Pathog. 2014 Dec 11;10(12):e1004534. doi: 10.1371/journal.ppat.1004534. eCollection 2014 Dec.
• [156] Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.Liver Int. 2015 Jul;35(7):1833-44. doi: 10.1111/liv.12759. Epub 2015 Jan 23.
• [157] A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.Hepatology. 2016 Nov;64(5):1462-1472. doi: 10.1002/hep.28695. Epub 2016 Jul 29.
• [158] The association of CCL3 and CCL4 polymorphisms with HCV clearance in Chinese Han population.Gene. 2018 Jul 30;665:35-40. doi: 10.1016/j.gene.2018.04.079. Epub 2018 Apr 27.
• [159] Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients.Clin Exp Immunol. 2004 May;136(2):328-33. doi: 10.1111/j.1365-2249.2004.02444.x.
• [160] Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.AIDS. 2018 Jun 1;32(9):1095-1105. doi: 10.1097/QAD.0000000000001787.
• [161] Processing of hepatitis C virus core protein is regulated by its C-terminal sequence.J Med Virol. 2003 Mar;69(3):357-66. doi: 10.1002/jmv.10297.
• [162] Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production.J Gen Virol. 2014 Sep;95(Pt 9):1900-1910. doi: 10.1099/vir.0.065300-0. Epub 2014 May 24.
• [163] Host cell kinases and the hepatitis C virus life cycle.Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1657-62. doi: 10.1016/j.bbapap.2015.04.011. Epub 2015 Apr 18.
• [164] Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.Hepatology. 2018 Dec;68(6):2118-2129. doi: 10.1002/hep.30087. Epub 2018 Nov 1.
• [165] CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study.Dig Liver Dis. 2017 Apr;49(4):434-439. doi: 10.1016/j.dld.2016.12.002. Epub 2016 Dec 16.
• [166] Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture.Sci Rep. 2017 Aug 23;7(1):9223. doi: 10.1038/s41598-017-10087-6.
• [167] Hepatitis C virus core protein targets 4E-BP1 expression and phosphorylation and potentiates Myc-induced liver carcinogenesis in transgenic mice.Oncotarget. 2017 Apr 20;8(34):56228-56242. doi: 10.18632/oncotarget.17280. eCollection 2017 Aug 22.
• [168] Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.PLoS One. 2018 Dec 3;13(12):e0208225. doi: 10.1371/journal.pone.0208225. eCollection 2018.
• [169] Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.PLoS One. 2013 Aug 5;8(8):e70809. doi: 10.1371/journal.pone.0070809. Print 2013.
• [170] Multiplex diagnosis of viral infectious diseases (AIDS, hepatitis C, and hepatitis A) based on point of care lateral flow assay using engineered proteinticles.Biosens Bioelectron. 2015 Jul 15;69:213-25. doi: 10.1016/j.bios.2015.02.033. Epub 2015 Feb 25.
• [171] Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection.Gut. 2010 Aug;59(8):1120-6. doi: 10.1136/gut.2009.202267. Epub 2010 Jun 29.
• [172] The potential role of interleukin-37 in infectious diseases.Int Rev Immunol. 2020;39(1):3-10. doi: 10.1080/08830185.2019.1677644. Epub 2019 Oct 21.
• [173] Up-regulation of circulating miRNA146a correlates with viral load via IRAK1 and TRAF6 in hepatitis C virus-infected patients.Virus Res. 2017 Jun 15;238:24-28. doi: 10.1016/j.virusres.2017.05.026. Epub 2017 Jun 3.
• [174] Association of human platelet antigens polymorphisms with susceptibility to hepatitis C virus infection in Chinese population.Int J Immunogenet. 2017 Dec;44(6):337-342. doi: 10.1111/iji.12341. Epub 2017 Sep 20.
• [175] Human intrahepatic CD69?CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity.Sci Rep. 2017 Jul 21;7(1):6172. doi: 10.1038/s41598-017-06352-3.
• [176] NKG2A is a NK cell exhaustion checkpoint for HCV persistence.Nat Commun. 2019 Apr 3;10(1):1507. doi: 10.1038/s41467-019-09212-y.
• [177] Immunohistochemical and electron microscopic morphometric image analysis of hepatocellular carcinoma in association of HCV infection.Ultrastruct Pathol. 2018 Mar-Apr;42(2):97-107. doi: 10.1080/01913123.2017.1422065. Epub 2018 Feb 9.
• [178] High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.PLoS One. 2017 Jan 20;12(1):e0170028. doi: 10.1371/journal.pone.0170028. eCollection 2017.
• [179] Transforming Growth Factor Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.J Virol. 2019 Aug 28;93(18):e00811-19. doi: 10.1128/JVI.00811-19. Print 2019 Sep 15.
• [180] Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation.Cell Microbiol. 2017 Apr;19(4). doi: 10.1111/cmi.12673. Epub 2016 Nov 25.
• [181] Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.World J Gastroenterol. 2014 Dec 28;20(48):18240-8. doi: 10.3748/wjg.v20.i48.18240.
• [182] SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection.Antiviral Res. 2015 Mar;115:94-104. doi: 10.1016/j.antiviral.2014.12.017. Epub 2015 Jan 5.
• [183] Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation.Liver Transpl. 2009 Mar;15(3):306-12. doi: 10.1002/lt.21680.
• [184] Binding of cellular nucleolin with the viral core RNA G-quadruplex structure suppresses HCV replication.Nucleic Acids Res. 2019 Jan 10;47(1):56-68. doi: 10.1093/nar/gky1177.
• [185] Hepatitis C virus core protein interacts with cellular metastasis suppressor Nm23-H1 and promotes cell migration and invasion.Arch Virol. 2019 May;164(5):1271-1285. doi: 10.1007/s00705-019-04151-x. Epub 2019 Mar 11.
• [186] Liver X receptor -mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication.Lab Invest. 2012 Aug;92(8):1191-202. doi: 10.1038/labinvest.2012.88. Epub 2012 May 28.
• [187] HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.Sci Rep. 2018 Aug 20;8(1):12469. doi: 10.1038/s41598-018-30460-3.
• [188] Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.Carcinogenesis. 2014 Jan;35(1):114-22. doi: 10.1093/carcin/bgt258. Epub 2013 Jul 29.
• [189] Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study.BMC Infect Dis. 2014 Dec 21;14:716. doi: 10.1186/s12879-014-0716-8.
• [190] Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.J Interferon Cytokine Res. 2019 Oct;39(10):642-649. doi: 10.1089/jir.2019.0013. Epub 2019 Jul 1.
• [191] lncRNA HULC facilitates efficient loading of HCV-core protein onto lipid droplets and subsequent virus-particle release.Cell Microbiol. 2019 Oct;21(10):e13086. doi: 10.1111/cmi.13086. Epub 2019 Jul 22.
• [192] Genomic variants link to hepatitis C racial disparities.Oncotarget. 2017 Aug 1;8(35):59455-59475. doi: 10.18632/oncotarget.19755. eCollection 2017 Aug 29.
• [193] Interferon--induced CD100 on nave CD8(+) T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction.J Int Med Res. 2017 Feb;45(1):89-100. doi: 10.1177/0300060516676136. Epub 2017 Jan 12.
• [194] SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection.Exp Biol Med (Maywood). 2012 Jul;237(7):793-802. doi: 10.1258/ebm.2012.012024. Epub 2012 Jul 24.
• [195] Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation.Dig Liver Dis. 2009 Jul;41(7):e17-20. doi: 10.1016/j.dld.2008.01.020. Epub 2008 Mar 11.
• [196] TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.Gastroenterology. 2018 Dec;155(6):1923-1935.e8. doi: 10.1053/j.gastro.2018.08.027. Epub 2018 Aug 23.
• [197] Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients.Hepatology. 2005 May;41(5):995-1003. doi: 10.1002/hep.20664.
• [198] The role of tacstd-2 level in hepatitis C patients (controlled clinical research).Libyan J Med. 2019 Dec;14(1):1622363. doi: 10.1080/19932820.2019.1622363.
• [199] HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules.Sci Rep. 2019 Jul 23;9(1):10624. doi: 10.1038/s41598-019-47024-8.
• [200] Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.Microb Pathog. 2019 Jun;131:65-74. doi: 10.1016/j.micpath.2019.03.032. Epub 2019 Mar 26.
• [201] Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection.Viral Immunol. 2015 May;28(4):222-8. doi: 10.1089/vim.2014.0111. Epub 2015 Mar 23.
• [202] Association of BAFF -871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients.Mol Diagn Ther. 2015 Apr;19(2):99-106. doi: 10.1007/s40291-015-0134-7.
• [203] Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.J Hepatol. 2018 Mar;68(3):421-430. doi: 10.1016/j.jhep.2017.10.021. Epub 2017 Nov 1.
• [204] Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution.Arthritis Res Ther. 2015 Mar 15;17(1):62. doi: 10.1186/s13075-015-0581-x.
• [205] mTORC1 restricts hepatitis C virus RNA replication through ULK1-mediated suppression of miR-122 and facilitates post-replication events.J Gen Virol. 2020 Jan;101(1):86-95. doi: 10.1099/jgv.0.001356.
• [206] Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon- and ribavirin.Gene. 2017 Sep 30;630:28-34. doi: 10.1016/j.gene.2017.08.005. Epub 2017 Aug 4.
• [207] Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.Oncotarget. 2015 Aug 21;6(24):20327-44. doi: 10.18632/oncotarget.3972.
• [208] Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity.Cell Host Microbe. 2019 Apr 10;25(4):588-601.e7. doi: 10.1016/j.chom.2019.02.015.
• [209] Impact of T cell activation, HIV replication and hepatitis C virus infection on neutrophil CD64 expression.Cytometry B Clin Cytom. 2017 Nov;92(6):492-497. doi: 10.1002/cyto.b.21385. Epub 2016 Jul 4.
• [210] Circulating Resistin Is Associated with Plasma Glucagon-Like Peptide-1 in Cirrhotic Patients with Hepatitis C Virus Genotype-4 Infection.Endocr Res. 2020 Feb;45(1):17-23. doi: 10.1080/07435800.2019.1627551. Epub 2019 Jun 10.
• [211] Genetic prevention of hepatitis C virus-induced liver fibrosis by allele-specific downregulation of MERTK.Hepatol Res. 2017 Jul;47(8):826-830. doi: 10.1111/hepr.12810. Epub 2016 Sep 29.
• [212] The Clinical Features of Patients with Chronic Hepatitis C Virus Infections Are Associated with Killer Cell Immunoglobulin-Like Receptor Genes and Their Expression on the Surface of Natural Killer Cells.Front Immunol. 2018 Jan 5;8:1912. doi: 10.3389/fimmu.2017.01912. eCollection 2017.
• [213] Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.Biomed Res Int. 2017;2017:2067479. doi: 10.1155/2017/2067479. Epub 2017 Apr 5.
• [214] GRIM-19 Restricts HCV Replication by Attenuating Intracellular Lipid Accumulation.Front Microbiol. 2017 Apr 11;8:576. doi: 10.3389/fmicb.2017.00576. eCollection 2017.
• [215] Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1.Infect Genet Evol. 2018 Aug;62:296-303. doi: 10.1016/j.meegid.2018.04.038. Epub 2018 Apr 30.
• [216] Stearoyl-CoA desaturase-1 is required for flavivirus RNA replication.Antiviral Res. 2019 May;165:42-46. doi: 10.1016/j.antiviral.2019.03.002. Epub 2019 Mar 7.
• [217] Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.Gastroenterology. 2017 Jan;152(1):257-270.e7. doi: 10.1053/j.gastro.2016.09.033. Epub 2016 Sep 30.
• [218] Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.J Hepatol. 2003 Oct;39(4):564-70. doi: 10.1016/s0168-8278(03)00355-6.
• [219] Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C.Arch Virol. 2018 May;163(5):1253-1262. doi: 10.1007/s00705-018-3750-9. Epub 2018 Feb 5.
• [220] FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.J Virol. 2015 Aug;89(15):7905-21. doi: 10.1128/JVI.00729-15. Epub 2015 May 20.
• [221] Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release.mBio. 2018 Mar 13;9(2):e02233-17. doi: 10.1128/mBio.02233-17.
• [222] Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage.Clin Pharmacol Ther. 2020 May;107(5):1138-1148. doi: 10.1002/cpt.1717. Epub 2019 Dec 17.
• [223] LPAC syndrome associated with deletion of the full exon 4 in a ABCB4 genetic mutation in a patient with hepatitis C.Rev Esp Enferm Dig. 2014 Dec;106(8):544-7.
• [224] Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C Virus.Balkan Med J. 2017 Aug 4;34(4):308-312. doi: 10.4274/balkanmedj.2016.0766. Epub 2017 Apr 6.
• [225] Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.Vaccine. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16.
• [226] Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C.Arch Med Sci. 2018 Mar;14(2):281-287. doi: 10.5114/aoms.2016.60406. Epub 2016 Jun 7.
• [227] Adiponectin levels and insulin resistance among patients with chronic hepatitis C.Acta Trop. 2018 Feb;178:258-263. doi: 10.1016/j.actatropica.2017.12.004. Epub 2017 Dec 5.
• [228] TNFalpha-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase.Development. 2009 Mar;136(5):865-75. doi: 10.1242/dev.027565.
• [229] Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults.J Neurovirol. 2016 Oct;22(5):650-660. doi: 10.1007/s13365-016-0441-8. Epub 2016 Apr 20.
• [230] Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.PLoS One. 2018 Jun 1;13(6):e0198345. doi: 10.1371/journal.pone.0198345. eCollection 2018.
• [231] Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection.J Clin Med. 2019 Jan 17;8(1):103. doi: 10.3390/jcm8010103.
• [232] Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.Med Microbiol Immunol. 2016 Apr;205(2):111-7. doi: 10.1007/s00430-015-0431-0. Epub 2015 Aug 14.
• [233] Hepatitis C virus replication and Golgi function in brefeldin a-resistant hepatoma-derived cells.PLoS One. 2013 Sep 18;8(9):e74491. doi: 10.1371/journal.pone.0074491. eCollection 2013.
• [234] Regulation of Apolipoprotein E Trafficking by Hepatitis C Virus-Induced Autophagy.J Virol. 2018 Jun 29;92(14):e00211-18. doi: 10.1128/JVI.00211-18. Print 2018 Jul 15.
• [235] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.Am J Gastroenterol. 2016 Jun;111(6):845-51. doi: 10.1038/ajg.2016.108. Epub 2016 Apr 5.
• [236] MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of haem oxygenase-1 expression.J Viral Hepat. 2019 Jun;26(6):655-665. doi: 10.1111/jvh.13072. Epub 2019 Mar 13.
• [237] Circulating CXCR3(+) Tfh cells positively correlate with neutralizing antibody responses in HCV-infected patients.Sci Rep. 2019 Jul 12;9(1):10090. doi: 10.1038/s41598-019-46533-w.
• [238] Expression of Biliverdin Reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patients.PLoS One. 2013;8(3):e57555. doi: 10.1371/journal.pone.0057555. Epub 2013 Mar 11.
• [239] Antiviral activity of bone morphogenetic proteins and activins.Nat Microbiol. 2019 Feb;4(2):339-351. doi: 10.1038/s41564-018-0301-9. Epub 2018 Dec 3.
• [240] Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.World J Gastroenterol. 2015 Mar 21;21(11):3291-9. doi: 10.3748/wjg.v21.i11.3291.
• [241] Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.Cancer Lett. 2016 Feb 1;371(1):107-16. doi: 10.1016/j.canlet.2015.11.027. Epub 2015 Nov 24.
• [242] CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides.Cell Immunol. 2017 Mar;313:1-9. doi: 10.1016/j.cellimm.2016.12.002. Epub 2016 Dec 16.
• [243] Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.Sci Rep. 2019 Apr 5;9(1):5722. doi: 10.1038/s41598-019-42114-z.
• [244] The Hepatitis C Virus-induced NLRP3 Inflammasome Activates the Sterol Regulatory Element-binding Protein (SREBP) and Regulates Lipid Metabolism.J Biol Chem. 2016 Feb 12;291(7):3254-67. doi: 10.1074/jbc.M115.694059. Epub 2015 Dec 23.
• [245] HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes.PLoS One. 2017 Jan 5;12(1):e0166853. doi: 10.1371/journal.pone.0166853. eCollection 2017.
• [246] Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB.PLoS Pathog. 2018 Jul 19;14(7):e1007111. doi: 10.1371/journal.ppat.1007111. eCollection 2018 Jul.
• [247] Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.J Hepatol. 2011 Mar;54(3):422-31. doi: 10.1016/j.jhep.2010.07.014. Epub 2010 Sep 26.
• [248] Identification and functional analysis of a core gene module associated with hepatitis C virus-induced human hepatocellular carcinoma progression.Oncol Lett. 2018 May;15(5):6815-6824. doi: 10.3892/ol.2018.8221. Epub 2018 Mar 9.
• [249] Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance.J Hum Genet. 2018 Jul;63(7):831-839. doi: 10.1038/s10038-018-0452-9. Epub 2018 Apr 27.
• [250] CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer.Exp Cell Res. 2018 Nov 15;372(2):168-177. doi: 10.1016/j.yexcr.2018.09.023. Epub 2018 Oct 2.
• [251] Significance of Markers of Monocyte Activation (CD163 and sCD14) and Inflammation (IL-6) in Patients Admitted for Alcohol Use Disorder Treatment.Alcohol Clin Exp Res. 2020 Jan;44(1):152-158. doi: 10.1111/acer.14228. Epub 2019 Dec 3.
• [252] Enhanced RIG-I expression is mediated by interferon regulatory factor-2 in peripheral blood B cells from hepatitis C virus-infected patients.Biochem Biophys Res Commun. 2010 Jan 22;391(4):1623-8. doi: 10.1016/j.bbrc.2009.12.092. Epub 2009 Dec 23.
• [253] DC-SIGN Polymorphisms Associate with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.J Infect Dis. 2018 Jan 17;217(3):353-357. doi: 10.1093/infdis/jix587.
• [254] Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection.Oncol Lett. 2019 Aug;18(2):1458-1466. doi: 10.3892/ol.2019.10448. Epub 2019 Jun 7.
• [255] Identification of IL-10-secreting CD8(+)CD28(-)PD-1(+) regulatory T cells associated with chronic hepatitis C virus infection.Immunol Lett. 2018 Oct;202:16-22. doi: 10.1016/j.imlet.2018.07.008. Epub 2018 Jul 25.
• [256] Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome.Mol Immunol. 2008 May;45(9):2429-36. doi: 10.1016/j.molimm.2008.01.002. Epub 2008 Mar 4.
• [257] Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN- Production by Altering Cellular Metabolism via Arginase-1.J Immunol. 2016 Mar 1;196(5):2283-92. doi: 10.4049/jimmunol.1501881. Epub 2016 Jan 29.
• [258] Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.PLoS One. 2013 Apr 23;8(4):e62159. doi: 10.1371/journal.pone.0062159. Print 2013.
• [259] Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.J Virol. 2013 Jul;87(14):7902-10. doi: 10.1128/JVI.00917-13. Epub 2013 May 8.
• [260] Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma.World J Gastroenterol. 2008 Oct 21;14(39):6072-7. doi: 10.3748/wjg.14.6072.
• [261] Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation.J Virol. 2018 Nov 27;92(24):e00737-18. doi: 10.1128/JVI.00737-18. Print 2018 Dec 15.
• [262] Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.PLoS One. 2017 Jul 7;12(7):e0181299. doi: 10.1371/journal.pone.0181299. eCollection 2017.
• [263] Physical and functional interaction between HCV core protein and the different p73 isoforms.Oncogene. 2003 May 1;22(17):2573-80. doi: 10.1038/sj.onc.1206333.
• [264] Direct, interferon-independent activation of the CXCL10 promoter by NF-B and interferon regulatory factor 3 during hepatitis C virus infection.J Virol. 2014 Feb;88(3):1582-90. doi: 10.1128/JVI.02007-13. Epub 2013 Nov 20.
• [265] Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.Clin Infect Dis. 2020 Sep 12;71(6):1502-1510. doi: 10.1093/cid/ciz985.
• [266] Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection.Aliment Pharmacol Ther. 2018 Aug;48(3):270-280. doi: 10.1111/apt.14802. Epub 2018 Jun 4.
• [267] Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.Ann N Y Acad Sci. 2017 Jun;1397(1):5-16. doi: 10.1111/nyas.13337. Epub 2017 Apr 17.
• [268] HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells.Blood. 2012 Nov 29;120(23):4544-51. doi: 10.1182/blood-2012-02-413286. Epub 2012 Oct 10.
• [269] Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.Dig Dis Sci. 1997 Aug;42(8):1703-7. doi: 10.1023/a:1018813532098.
• [270] Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection.APMIS. 2019 Feb;127(2):93-105. doi: 10.1111/apm.12917.
• [271] An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.Hum Genet. 2010 Jan;127(1):75-81. doi: 10.1007/s00439-009-0750-6. Epub 2009 Oct 8.
• [272] Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.Int J Mol Sci. 2019 Sep 14;20(18):4569. doi: 10.3390/ijms20184569.
• [273] Mutual antagonism between circadian protein period 2 and hepatitis C virus replication in hepatocytes.PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013.
• [274] NFE2L2 is associated with NQO1 expression and low stage of hepatic fibrosis in patients with chronic hepatitis C.Adv Clin Exp Med. 2019 Sep;28(9):1237-1241. doi: 10.17219/acem/105852.
• [275] Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening.J Biol Chem. 2008 Jan 4;283(1):29-36. doi: 10.1074/jbc.M703988200. Epub 2007 Oct 19.
• [276] The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation.J Virol. 2006 Nov;80(22):11305-12. doi: 10.1128/JVI.01465-06. Epub 2006 Aug 30.
• [277] Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I- in infectious virus production.J Virol. 2014 Jul;88(13):7541-55. doi: 10.1128/JVI.03170-13. Epub 2014 Apr 23.
• [278] Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface.J Virol. 2012 Sep;86(18):9919-28. doi: 10.1128/JVI.00388-12. Epub 2012 Jul 3.
• [279] Single nucleotide polymorphisms of CXCL9-11 chemokines are associated with liver fibrosis in HIV/HCV-coinfected patients.J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):386-95. doi: 10.1097/QAI.0000000000000491.
• [280] High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.Liver Int. 2016 Mar;36(3):344-52. doi: 10.1111/liv.12932. Epub 2015 Sep 6.
• [281] Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection.J Infect Dis. 2019 Apr 16;219(9):1430-1438. doi: 10.1093/infdis/jiy679.
• [282] CYP24A1 genetic variants in the vitamin D metabolic pathway are involved in the outcomes of hepatitis C virus infection among high-risk Chinese population.Int J Infect Dis. 2019 Jul;84:80-88. doi: 10.1016/j.ijid.2019.04.032. Epub 2019 May 7.
• [283] Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.Anticancer Drugs. 2013 Jul;24(6):617-22. doi: 10.1097/CAD.0b013e3283614fef.
• [284] Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.Clin Infect Dis. 2018 Jun 1;66(12):1953-1956. doi: 10.1093/cid/cix1051.
• [285] Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.Int J Oncol. 2005 Sep;27(3):661-7.
• [286] Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation.Hepatology. 2015 Sep;62(3):702-14. doi: 10.1002/hep.27913. Epub 2015 Jul 28.
• [287] Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.PLoS One. 2014 Mar 18;9(3):e92112. doi: 10.1371/journal.pone.0092112. eCollection 2014.
• [288] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.World J Gastroenterol. 2019 May 14;25(18):2229-2239. doi: 10.3748/wjg.v25.i18.2229.
• [289] Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro.Xenobiotica. 2019 Aug;49(8):935-944. doi: 10.1080/00498254.2018.1524947. Epub 2018 Nov 8.
• [290] Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.PLoS One. 2018 Mar 29;13(3):e0194799. doi: 10.1371/journal.pone.0194799. eCollection 2018.
• [291] Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase.Virology. 2003 Dec 5;317(1):24-35. doi: 10.1016/j.virol.2003.08.028.
• [292] Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.Molecules. 2018 Aug 20;23(8):2083. doi: 10.3390/molecules23082083.
• [293] Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro.J Viral Hepat. 2014 Jan;21(1):19-24. doi: 10.1111/jvh.12209. Epub 2013 Nov 4.
• [294] Oxidative Stress and Immune Responses During Hepatitis C Virus Infection in Tupaia belangeri.Sci Rep. 2017 Aug 29;7(1):9848. doi: 10.1038/s41598-017-10329-7.
• [295] Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen.J Med Virol. 2000 Feb;60(2):144-51.
• [296] Interaction of miR-125b-5p with Human antigen R mRNA: Mechanism of controlling HCV replication.Virus Res. 2018 Oct 15;258:1-8. doi: 10.1016/j.virusres.2018.09.006. Epub 2018 Sep 22.
• [297] Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.J Hepatol. 2017 May;66(5):919-929. doi: 10.1016/j.jhep.2017.01.009. Epub 2017 Jan 23.
• [298] The p7 viroporin of the hepatitis C virus contributes to liver inflammation by stimulating production of Interleukin-1.Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):712-720. doi: 10.1016/j.bbadis.2016.12.006. Epub 2016 Dec 13.
• [299] ERAP1 allotypes shape the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection.J Hepatol. 2019 Jun;70(6):1072-1081. doi: 10.1016/j.jhep.2019.01.034. Epub 2019 Feb 13.
• [300] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study.Infect Drug Resist. 2019 Jan 22;12:273-279. doi: 10.2147/IDR.S181638. eCollection 2019.
• [301] Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus.J Infect Dis. 2018 Mar 28;217(8):1289-1297. doi: 10.1093/infdis/jix688.
• [302] Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism.Pathol Res Pract. 2018 Oct;214(10):1700-1706. doi: 10.1016/j.prp.2018.08.013. Epub 2018 Aug 19.
• [303] Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.Immunogenetics. 2006 Dec;58(12):937-46. doi: 10.1007/s00251-006-0159-5. Epub 2006 Oct 11.
• [304] Liver sinusoidal endothelial cells (LSECs) modifications in patients with chronic hepatitis C.Sci Rep. 2019 Jun 19;9(1):8760. doi: 10.1038/s41598-019-45114-1.
• [305] Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.J Hepatol. 2017 Jun;66(6):1130-1137. doi: 10.1016/j.jhep.2017.01.032. Epub 2017 Feb 10.
• [306] Increased cortical expression of FK506 binding protein-51 in HIV-associated neurocognitive disorders.J Neurovirol. 2012 Aug;18(4):313-22. doi: 10.1007/s13365-011-0076-8. Epub 2012 Jan 11.
• [307] Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy.Exp Ther Med. 2019 Nov;18(5):3991-4001. doi: 10.3892/etm.2019.8024. Epub 2019 Sep 18.
• [308] IL28B polymorphisms are associated with severity ofliver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.J Infect. 2013 Feb;66(2):170-8. doi: 10.1016/j.jinf.2012.10.025. Epub 2012 Oct 26.
• [309] Subproteomic study of hepatitis C virus replicon reveals Ras-GTPase-activating protein binding protein 1 as potential HCV RC component.Biochem Biophys Res Commun. 2006 Nov 10;350(1):174-8. doi: 10.1016/j.bbrc.2006.09.027. Epub 2006 Sep 18.
• [310] Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.Cancer Res. 2010 Jun 15;70(12):4901-11. doi: 10.1158/0008-5472.CAN-09-4554. Epub 2010 Jun 8.
• [311] Expression of alternate reading frame protein (F1) of hepatitis C virus in Escherichia coli and detection of antibodies for F1 in Indian patients.Infect Genet Evol. 2008 May;8(3):374-7. doi: 10.1016/j.meegid.2007.12.008. Epub 2008 Jan 5.
• [312] Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.Liver Int. 2020 Mar;40(3):539-548. doi: 10.1111/liv.14186. Epub 2019 Jul 25.
• [313] HCV-RNA and anti-HCV IgM in Egyptian subjects bearing IgG anti-HCV antibodies.Jpn J Infect Dis. 1999 Jun;52(3):113-6.
• [314] Hepatitis C virus interacts with human platelet glycoprotein VI.J Gen Virol. 2006 Aug;87(Pt 8):2243-2251. doi: 10.1099/vir.0.81826-0.
• [315] rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians.Sci Rep. 2019 May 3;9(1):6868. doi: 10.1038/s41598-019-43376-3.
• [316] Lnc-ITM2C-1 and GPR55 Are Proviral Host Factors for Hepatitis C Virus.Viruses. 2019 Jun 13;11(6):549. doi: 10.3390/v11060549.
• [317] Association of Catalase and Glutathione Peroxidase 1 Polymorphisms with Chronic Hepatitis C Outcome.Ann Hum Genet. 2016 May;80(3):145-53. doi: 10.1111/ahg.12152. Epub 2016 Mar 18.
• [318] Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.J Virol. 2002 Sep;76(18):9207-17. doi: 10.1128/jvi.76.18.9207-9217.2002.
• [319] Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?.BMC Infect Dis. 2014;14 Suppl 5(Suppl 5):S5. doi: 10.1186/1471-2334-14-S5-S5. Epub 2014 Sep 5.
• [320] A genetic screen identifies interferon- effector genes required to suppress hepatitis C virus replication.Gastroenterology. 2013 Jun;144(7):1438-49, 1449.e1-9. doi: 10.1053/j.gastro.2013.02.026. Epub 2013 Feb 24.
• [321] Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver.J Viral Hepat. 2011 Jan;18(1):53-60. doi: 10.1111/j.1365-2893.2010.01283.x.
• [322] Hepatitis C Virus Infection: HostVirus Interaction and Mechanisms of Viral Persistence.Cells. 2019 Apr 25;8(4):376. doi: 10.3390/cells8040376.
• [323] Structural isomers of cinnamic hydroxamic acids block HCV replication via different mechanisms.Eur J Med Chem. 2019 Dec 1;183:111723. doi: 10.1016/j.ejmech.2019.111723. Epub 2019 Sep 20.
• [324] Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.J Med Virol. 2016 Sep;88(9):1552-9. doi: 10.1002/jmv.24498. Epub 2016 Mar 8.
• [325] Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers.Arch Virol. 2018 Apr;163(4):855-865. doi: 10.1007/s00705-017-3675-8. Epub 2017 Dec 16.
• [326] HLA-G and anti-HCV in patients on the waiting list for kidney transplantation.Adv Med Sci. 2018 Sep;63(2):317-322. doi: 10.1016/j.advms.2018.04.004. Epub 2018 Jul 13.
• [327] Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis.Hepatol Int. 2016 Nov;10(6):937-946. doi: 10.1007/s12072-016-9733-6. Epub 2016 May 18.
• [328] Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1 via Chaperone-Mediated Autophagy.J Virol. 2018 Jun 13;92(13):e00639-18. doi: 10.1128/JVI.00639-18. Print 2018 Jul 1.
• [329] Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression.Cancers (Basel). 2019 Sep 20;11(10):1407. doi: 10.3390/cancers11101407.
• [330] A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.
• [331] Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.PLoS One. 2017 Nov 28;12(11):e0188467. doi: 10.1371/journal.pone.0188467. eCollection 2017.
• [332] Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.J Virol. 2018 Apr 27;92(10):e01982-17. doi: 10.1128/JVI.01982-17. Print 2018 May 15.
• [333] Infection with GB virus C, hepatitis C and B viruses in 1,044 cases autopsied at the Medical Examiner's Office in Tokyo.J Med Virol. 1998 Jun;55(2):123-8.
• [334] Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile.Int J Oncol. 2006 Dec;29(6):1445-51.
• [335] Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.J Innate Immun. 2015;7(5):530-44. doi: 10.1159/000375161. Epub 2015 Mar 19.
• [336] Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling.Nat Med. 2016 Dec;22(12):1475-1481. doi: 10.1038/nm.4211. Epub 2016 Nov 14.
• [337] TNF- Induced by Hepatitis C Virus via TLR7 and TLR8 in Hepatocytes Supports Interferon Signaling via an Autocrine Mechanism.PLoS Pathog. 2015 May 29;11(5):e1004937. doi: 10.1371/journal.ppat.1004937. eCollection 2015 May.
• [338] Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population.Infect Genet Evol. 2014 Jan;21:8-14. doi: 10.1016/j.meegid.2013.10.009. Epub 2013 Oct 19.
• [339] IL12 Gene Polymorphism in Association with Hepatocellular Carcinoma in HCV-infected Egyptian Patients.Immunol Invest. 2017 Feb;46(2):123-133. doi: 10.1080/08820139.2016.1229789. Epub 2016 Nov 7.
• [340] IL-15 and IFN- signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.Cytokine. 2019 Dec;124:154439. doi: 10.1016/j.cyto.2018.06.006. Epub 2018 Jun 19.
• [341] Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes.Gut. 2014 Apr;63(4):665-73. doi: 10.1136/gutjnl-2012-304377. Epub 2013 Jun 20.
• [342] Impact of IL-27p28 (rs153109) and TNF- (rs1800629) Genetic Polymorphisms on the Progression of HCV Infection in Egyptian Patients.Immunol Invest. 2019 Apr;48(3):255-267. doi: 10.1080/08820139.2018.1510958. Epub 2018 Sep 11.
• [343] Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance.Genes Immun. 2005 Jun;6(4):347-57. doi: 10.1038/sj.gene.6364188.
• [344] Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders.Oncol Rep. 2006 May;15(5):1305-8.
• [345] Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56(bright) NK cells.J Hepatol. 2017 Dec;67(6):1148-1156. doi: 10.1016/j.jhep.2017.07.028. Epub 2017 Aug 11.
• [346] Association of IL-1, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients.IUBMB Life. 2018 Nov;70(11):1156-1163. doi: 10.1002/iub.1929. Epub 2018 Sep 25.
• [347] The association between interleukin-21 (rs2055979G/T) gene polymorphism and the risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus.J Cell Biochem. 2019 Oct;120(10):18524-18532. doi: 10.1002/jcb.29174. Epub 2019 Jun 25.
• [348] Interleukin-7 Regulates T Follicular Helper Cell Function in Patients with Chronic Hepatitis C.Viral Immunol. 2018 Jul/Aug;31(6):417-425. doi: 10.1089/vim.2018.0010. Epub 2018 Apr 19.
• [349] Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.Int J Mol Sci. 2016 Jul 15;17(7):1070. doi: 10.3390/ijms17071070.
• [350] Interleukin-7 augments CD8(+) T cells function and promotes viral clearance in chronic hepatitis C virus infection.Cytokine. 2018 Feb;102:26-33. doi: 10.1016/j.cyto.2017.12.014. Epub 2017 Dec 21.
• [351] Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.Med Microbiol Immunol. 2017 Oct;206(5):379-382. doi: 10.1007/s00430-017-0516-z. Epub 2017 Aug 16.
• [352] TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response.Inflammation. 2019 Aug;42(4):1317-1325. doi: 10.1007/s10753-019-00992-5.
• [353] CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.Hepatology. 2018 Nov;68(5):1710-1725. doi: 10.1002/hep.30073.
• [354] The hepatitis C envelope 2 protein inhibits LFA-1-transduced protein kinase C signaling for T-lymphocyte migration.Gastroenterology. 2006 Feb;130(2):482-92. doi: 10.1053/j.gastro.2005.10.047.
• [355] NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus.Cell Rep. 2018 Oct 23;25(4):833-840.e3. doi: 10.1016/j.celrep.2018.09.088.
• [356] Interferon alpha antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus.Cytokine. 2016 Apr;80:48-55. doi: 10.1016/j.cyto.2015.08.264. Epub 2016 Mar 3.
• [357] Inhibition of miR-148a-3p resists hepatocellular carcinoma progress of hepatitis C virus infection through suppressing c-Jun and MAPK pathway.J Cell Mol Med. 2019 Feb;23(2):1415-1426. doi: 10.1111/jcmm.14045. Epub 2018 Dec 18.
• [358] Hepatitis C virus core or NS3/4A protein expression preconditions hepatocytes against oxidative stress and endoplasmic reticulum stress.Redox Rep. 2019 Dec;24(1):17-26. doi: 10.1080/13510002.2019.1596431.
• [359] Stable Frequencies of HLA-C(*)03:04/Peptide-Binding KIR2DL2/3(+) Natural Killer Cells Following Vaccination.Front Immunol. 2018 Oct 17;9:2361. doi: 10.3389/fimmu.2018.02361. eCollection 2018.
• [360] Human liver-derived CXCR6(+) NK cells are predominantly educated through NKG2A and show reduced cytokine production.J Leukoc Biol. 2019 Jun;105(6):1331-1340. doi: 10.1002/JLB.1MA1118-428R. Epub 2019 Feb 19.
• [361] KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.J Immunol. 2014 Jan 15;192(2):649-57. doi: 10.4049/jimmunol.1302069. Epub 2013 Dec 13.
• [362] HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication.Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):233-240. doi: 10.1016/j.hbpd.2018.03.010. Epub 2018 Mar 26.
• [363] Elevated LAG-3 on CD4(+) T cells negatively correlates with neutralizing antibody response during HCV infection.Immunol Lett. 2019 Aug;212:46-52. doi: 10.1016/j.imlet.2019.06.003. Epub 2019 Jun 16.
• [364] Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.Gastroenterology. 2011 Oct;141(4):1422-31, 1431.e1-6. doi: 10.1053/j.gastro.2011.07.004. Epub 2011 Jul 18.
• [365] Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.J Virol. 2017 Apr 28;91(10):e02129-16. doi: 10.1128/JVI.02129-16. Print 2017 May 15.
• [366] Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals.J Immunol. 1999 May 1;162(9):5584-91.
• [367] Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.Int J Biol Markers. 2018 Aug;33(3):283-292. doi: 10.1177/1724600818773631. Epub 2018 Jun 8.
• [368] LARP1 binding to hepatitis C virus particles is correlated with intracellular retention of viral infectivity.Virus Res. 2019 Oct 2;271:197679. doi: 10.1016/j.virusres.2019.197679. Epub 2019 Aug 6.
• [369] Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt.J Virol. 2004 Jun;78(12):6409-19. doi: 10.1128/JVI.78.12.6409-6419.2004.
• [370] A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2017 May 25;18(6):1134. doi: 10.3390/ijms18061134.
• [371] Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol. 2005 Sep;43(3):499-507. doi: 10.1016/j.jhep.2005.02.052.
• [372] The intracellular inhibition of HCV replication represents a novel mechanism of action by the innate immune Lactoferrin protein.Antiviral Res. 2014 Nov;111:13-22. doi: 10.1016/j.antiviral.2014.08.012. Epub 2014 Sep 1.
• [373] Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.Arch Virol. 2015 Oct;160(10):2517-24. doi: 10.1007/s00705-015-2535-7. Epub 2015 Jul 28.
• [374] The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection.PLoS One. 2014 Jun 13;9(6):e99601. doi: 10.1371/journal.pone.0099601. eCollection 2014.
• [375] MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma.Med Oncol. 2012 Jun;29(2):994-9. doi: 10.1007/s12032-011-9917-9. Epub 2011 Mar 31.
• [376] Hepatitis C virus NS5A inhibits mixed lineage kinase 3 to block apoptosis.J Biol Chem. 2013 Aug 23;288(34):24753-63. doi: 10.1074/jbc.M113.491985. Epub 2013 Jul 15.
• [377] Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection.Int J Infect Dis. 2015 Apr;33:15-21. doi: 10.1016/j.ijid.2014.08.021. Epub 2014 Oct 24.
• [378] A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.Gastroenterology. 2009 May;136(5):1796-805.e6. doi: 10.1053/j.gastro.2009.01.061. Epub 2009 Jan 31.
• [379] The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly.PLoS One. 2011;6(8):e23246. doi: 10.1371/journal.pone.0023246. Epub 2011 Aug 17.
• [380] Expression of immunoreactive forms of the hepatitis C NS5A protein in E. coli and their use for diagnostic assays.Arch Virol. 2002 Sep;147(9):1733-45. doi: 10.1007/s00705-002-0836-0.
• [381] Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients.Nephrol Dial Transplant. 2012 Mar;27(3):1176-83. doi: 10.1093/ndt/gfr458. Epub 2011 Sep 5.
• [382] Development of a Method That Delivers Drugs to Enveloped Viruses.Biol Pharm Bull. 2019;42(6):977-981. doi: 10.1248/bpb.b18-01000.
• [383] Association between hepatic steatosis and MTP gene -493G/T polymorphism in the patients with HCV genotype 1 infection.Infect Genet Evol. 2019 Jun;70:101-106. doi: 10.1016/j.meegid.2019.02.019. Epub 2019 Feb 18.
• [384] Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis.Liver Int. 2019 Nov;39(11):2061-2065. doi: 10.1111/liv.14203. Epub 2019 Aug 21.
• [385] CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age.Aging (Albany NY). 2019 Jan 27;11(2):724-740. doi: 10.18632/aging.101774.
• [386] Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.Transplantation. 2016 Feb;100(2):355-64. doi: 10.1097/TP.0000000000001031.
• [387] Functional and topological properties in hepatocellular carcinoma transcriptome.PLoS One. 2012;7(4):e35510. doi: 10.1371/journal.pone.0035510. Epub 2012 Apr 23.
• [388] NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2.J Virol. 2017 Nov 14;91(23):e01264-17. doi: 10.1128/JVI.01264-17. Print 2017 Dec 1.
• [389] Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases.Oncotarget. 2017 May 6;8(42):71528-71535. doi: 10.18632/oncotarget.17655. eCollection 2017 Sep 22.
• [390] A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage.Antiviral Res. 2018 Feb;150:47-59. doi: 10.1016/j.antiviral.2017.12.004. Epub 2017 Dec 7.
• [391] Genetic variations of the NPC1L1 gene associated with hepatitis C virus (HCV) infection and biochemical characteristics of HCV patients in China.Int J Infect Dis. 2016 Dec;53:6-11. doi: 10.1016/j.ijid.2016.10.007. Epub 2016 Oct 18.
• [392] The metabolic regulator small heterodimer partner contributes to the glucose and lipid homeostasis abnormalities induced by hepatitis C virus infection.Metabolism. 2019 Nov;100:153954. doi: 10.1016/j.metabol.2019.153954. Epub 2019 Aug 8.
• [393] Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection.Clin Gastroenterol Hepatol. 2017 Jun;15(6):937-944.e5. doi: 10.1016/j.cgh.2016.12.029. Epub 2017 Jan 5.
• [394] Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users.Arch Virol. 2019 Feb;164(2):349-357. doi: 10.1007/s00705-018-4066-5. Epub 2018 Nov 2.
• [395] The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF- signaling.J Hepatol. 2013 Nov;59(5):942-8. doi: 10.1016/j.jhep.2013.06.025. Epub 2013 Jul 2.
• [396] micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.Gut. 2007 Jul;56(7):974-81. doi: 10.1136/gut.2006.105122. Epub 2007 Feb 13.
• [397] Identification of ionotrophic purinergic receptors in Huh-7 cells and their response towards structural proteins of HCV genotype 3a.Virol J. 2011 Sep 8;8:431. doi: 10.1186/1743-422X-8-431.
• [398] The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.Front Cell Infect Microbiol. 2019 Jun 13;9:207. doi: 10.3389/fcimb.2019.00207. eCollection 2019.
• [399] The SR-BI partner PDZK1 facilitates hepatitis C virus entry.PLoS Pathog. 2010 Oct 7;6(10):e1001130. doi: 10.1371/journal.ppat.1001130.
• [400] CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis.Hepatology. 2010 Apr;51(4):1345-53. doi: 10.1002/hep.23435.
• [401] Hepatitis C Virus Subverts Human Choline Kinase- To Bridge Phosphatidylinositol-4-Kinase III (PI4KIII) and NS5A and Upregulates PI4KIII Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication.J Virol. 2017 Jul 27;91(16):e00355-17. doi: 10.1128/JVI.00355-17. Print 2017 Aug 15.
• [402] Activity-Based Phosphatidylinositol Kinase Probes Detect Changes to Protein-Protein Interactions During Hepatitis C Virus Replication.ACS Infect Dis. 2018 May 11;4(5):752-757. doi: 10.1021/acsinfecdis.8b00047. Epub 2018 Mar 14.
• [403] Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis.Liver Int. 2007 Sep;27(7):960-8. doi: 10.1111/j.1478-3231.2007.01542.x.
• [404] The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.J Lipid Res. 2017 Feb;58(2):420-432. doi: 10.1194/jlr.M073734. Epub 2016 Dec 10.
• [405] The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus.FEBS Lett. 2013 Jan 16;587(2):156-64. doi: 10.1016/j.febslet.2012.11.010. Epub 2012 Nov 26.
• [406] Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma.World J Gastroenterol. 2019 Jan 7;25(1):42-58. doi: 10.3748/wjg.v25.i1.42.
• [407] Human MxB Inhibits the Replication of Hepatitis C Virus.J Virol. 2018 Dec 10;93(1):e01285-18. doi: 10.1128/JVI.01285-18. Print 2019 Jan 1.
• [408] Cyclophilin B facilitates the replication of Orf virus.Virol J. 2017 Jun 15;14(1):114. doi: 10.1186/s12985-017-0781-x.
• [409] Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.J Exp Clin Cancer Res. 2017 Mar 10;36(1):42. doi: 10.1186/s13046-017-0510-8.
• [410] Emerging viral STIs among HIV-positive men who have sex with men: the era of hepatitis C virus and human papillomavirus.Sex Transm Infect. 2017 Aug;93(5):368-373. doi: 10.1136/sextrans-2016-052677. Epub 2016 Oct 27.
• [411] Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C.Cell Mol Immunol. 2017 Dec;14(12):986-996. doi: 10.1038/cmi.2016.10. Epub 2016 Apr 18.
• [412] Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.Clin Exp Immunol. 2013 Nov;174(2):265-73. doi: 10.1111/cei.12174.
• [413] MEAN inhibits hepatitis C virus replication by interfering with a polypyrimidine tract-binding protein.J Cell Mol Med. 2016 Jul;20(7):1255-65. doi: 10.1111/jcmm.12798. Epub 2016 Mar 1.
• [414] Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.PLoS One. 2015 Mar 23;10(3):e0119172. doi: 10.1371/journal.pone.0119172. eCollection 2015.
• [415] Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.PLoS One. 2017 Mar 2;12(3):e0172412. doi: 10.1371/journal.pone.0172412. eCollection 2017.
• [416] Hepatitis C virus promotes virion secretion through cleavage of the Rab7 adaptor protein RILP.Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12484-12489. doi: 10.1073/pnas.1607277113. Epub 2016 Oct 17.
• [417] RACK1 mediates rewiring of intracellular networks induced by hepatitis C virus infection.PLoS Pathog. 2019 Sep 16;15(9):e1008021. doi: 10.1371/journal.ppat.1008021. eCollection 2019 Sep.
• [418] RECK Gene Promoter rs10814325 Polymorphism in Egyptian Patients with Hepatocellular Carcinoma on Top of Chronic Hepatitis C Viral Infection.Asian Pac J Cancer Prev. 2016;17(5):2383-8.
• [419] Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.Gastroenterology. 2012 Nov;143(5):1244-1252.e12. doi: 10.1053/j.gastro.2012.07.097. Epub 2012 Jul 27.
• [420] Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women.BMC Infect Dis. 2018 Jun 4;18(1):254. doi: 10.1186/s12879-018-3153-2.
• [421] Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission.Sex Transm Infect. 2017 Dec;93(8):590-598. doi: 10.1136/sextrans-2016-053029. Epub 2017 Jul 5.
• [422] Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation.J Biol Chem. 2019 Apr 12;294(15):5759-5773. doi: 10.1074/jbc.RA118.004397. Epub 2019 Feb 12.
• [423] Hepatitis C virus Core overcomes all-trans retinoic acid-induced apoptosis in human hepatoma cells by inhibiting p14 expression via DNA methylation.Oncotarget. 2017 Aug 18;8(49):85584-85598. doi: 10.18632/oncotarget.20337. eCollection 2017 Oct 17.
• [424] Syndecan-1 in Liver Diseases.Pathol Oncol Res. 2020 Apr;26(2):813-819. doi: 10.1007/s12253-019-00617-0. Epub 2019 Mar 2.
• [425] Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.J Virol. 2017 Jun 9;91(13):e00280-17. doi: 10.1128/JVI.00280-17. Print 2017 Jul 1.
• [426] Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the IFN-related pathway.J Immunol. 2015 Mar 15;194(6):2757-68. doi: 10.4049/jimmunol.1400583. Epub 2015 Feb 13.
• [427] Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection.J Virol. 2013 Jun;87(11):6377-90. doi: 10.1128/JVI.03557-12. Epub 2013 Mar 27.
• [428] A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15. Epub 2015 Sep 16.
• [429] Immunoreactive core peptides of hepatitis C virus produced in Escherichia coli and in vitro DNA amplification-restricted transcription-translation system.J Virol Methods. 1996 May;59(1-2):91-8. doi: 10.1016/0166-0934(96)02025-3.
• [430] Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180. doi: 10.1016/S2468-1253(18)30002-5. Epub 2018 Jan 19.
• [431] Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?.Hepatol Int. 2019 Mar;13(2):165-172. doi: 10.1007/s12072-019-09933-8. Epub 2019 Feb 13.
• [432] Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. J Clin Virol. 2015 Jul;68:56-60.
• [433] SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.J Antimicrob Chemother. 2015 Apr;70(4):1155-60. doi: 10.1093/jac/dku519. Epub 2015 Jan 11.
• [434] SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients.AIDS. 2014 Jun 1;28(9):1325-32. doi: 10.1097/QAD.0000000000000215.
• [435] Hepatitis C Virus Modulates Solute carrier family 3 member 2 for Viral Propagation.Sci Rep. 2018 Oct 19;8(1):15486. doi: 10.1038/s41598-018-33861-6.
• [436] Monoclonal antibody 2-152a suppresses hepatitis C virus infection through betaine/GABA transporter-1.J Infect Dis. 2011 Oct 15;204(8):1172-80. doi: 10.1093/infdis/jir501.
• [437] Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.Clin Pharmacokinet. 2017 Jul;56(7):781-792. doi: 10.1007/s40262-016-0476-2.
• [438] Hepatitis C Virus Core Protein Modulates Endoglin (CD105) Signaling Pathway for Liver Pathogenesis.J Virol. 2017 Oct 13;91(21):e01235-17. doi: 10.1128/JVI.01235-17. Print 2017 Nov 1.
• [439] The potential regulatory role of miR16 to the interplay between interferon and transforming growth factor beta pathways through IRF3 and SMAD7 in hepatitis C virus infected patients.J Cell Biochem. 2019 Aug;120(8):12694-12701. doi: 10.1002/jcb.28537. Epub 2019 Mar 12.
• [440] Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.Microbiol Immunol. 2016 Jan;60(1):17-25. doi: 10.1111/1348-0421.12345.
• [441] Phosphorylated tyrosine 93 of hepatitis C virus nonstructural protein 5A is essential for interaction with host c-Src and efficient viral replication.J Biol Chem. 2019 May 3;294(18):7388-7402. doi: 10.1074/jbc.RA119.007656. Epub 2019 Mar 12.
• [442] Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation.Biomed Res Int. 2019 Mar 11;2019:3102414. doi: 10.1155/2019/3102414. eCollection 2019.
• [443] HCV and flaviviruses hijack cellular mechanisms for nuclear STAT2 degradation: Up-regulation of PDLIM2 suppresses the innate immune response.PLoS Pathog. 2019 Aug 2;15(8):e1007949. doi: 10.1371/journal.ppat.1007949. eCollection 2019 Aug.
• [444] Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity.J Virol. 2003 Aug;77(15):8299-309. doi: 10.1128/jvi.77.15.8299-8309.2003.
• [445] Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs.EBioMedicine. 2018 Sep;35:106-113. doi: 10.1016/j.ebiom.2018.08.007. Epub 2018 Aug 20.
• [446] Inhibition of TRF2 accelerates telomere attrition and DNA damage in nave CD4 T cells during HCV infection.Cell Death Dis. 2018 Sep 5;9(9):900. doi: 10.1038/s41419-018-0897-y.
• [447] Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.Ann Transplant. 2017 Oct 24;22:638-645. doi: 10.12659/aot.905540.
• [448] Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Ann Hematol. 2017 Sep;96(9):1421-1434. doi: 10.1007/s00277-017-2953-6. Epub 2017 Mar 8.
• [449] Correction: Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway.PLoS Pathog. 2018 Nov 16;14(11):e1007455. doi: 10.1371/journal.ppat.1007455. eCollection 2018 Nov.
• [450] Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.Front Microbiol. 2019 Mar 15;10:475. doi: 10.3389/fmicb.2019.00475. eCollection 2019.
• [451] TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection.Br J Biomed Sci. 2019 Jan;76(1):35-41. doi: 10.1080/09674845.2018.1547179. Epub 2018 Dec 3.
• [452] Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins.J Leukoc Biol. 2007 Sep;82(3):479-87. doi: 10.1189/jlb.0207128. Epub 2007 Jun 26.
• [453] Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression.Liver Int. 2018 Mar;38(3):432-442. doi: 10.1111/liv.13533. Epub 2017 Aug 24.
• [454] TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses.J Hepatol. 2019 Nov;71(5):908-919. doi: 10.1016/j.jhep.2019.06.029. Epub 2019 Jul 4.
• [455] PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.
• [456] Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection.Infect Genet Evol. 2018 Mar;58:17-22. doi: 10.1016/j.meegid.2017.12.002. Epub 2017 Dec 6.
• [457] Hepatitis C Virus Exploits Death Receptor 6-mediated Signaling Pathway to Facilitate Viral Propagation.Sci Rep. 2017 Jul 25;7(1):6445. doi: 10.1038/s41598-017-06740-9.
• [458] Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia.Blood. 1998 Mar 15;91(6):2062-6.
• [459] A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients.J Hepatol. 2011 Apr;54(4):629-39. doi: 10.1016/j.jhep.2010.07.021. Epub 2010 Nov 18.
• [460] Online symptom checker diagnostic and triage accuracy for HIV and hepatitis C.Epidemiol Infect. 2019 Jan;147:e104. doi: 10.1017/S0950268819000268.
• [461] GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation.PLoS Pathog. 2017 Apr 10;13(4):e1006321. doi: 10.1371/journal.ppat.1006321. eCollection 2017 Apr.
• [462] HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells.PLoS Pathog. 2019 Jul 1;15(7):e1007883. doi: 10.1371/journal.ppat.1007883. eCollection 2019 Jul.
• [463] Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.Br J Pharmacol. 2017 Feb;174(3):254-266. doi: 10.1111/bph.13679. Epub 2017 Jan 12.
• [464] Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes.Sci Rep. 2017 Jun 30;7(1):4448. doi: 10.1038/s41598-017-04259-7.
• [465] E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.Carcinogenesis. 2019 Jul 6;40(6):707-714. doi: 10.1093/carcin/bgz072.
• [466] Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus-coinfected Women.Clin Infect Dis. 2016 Aug 15;63(4):512-8. doi: 10.1093/cid/ciw350. Epub 2016 May 25.
• [467] Hepatitis C Virus NS3 Protein Plays a Dual Role in WRN-Mediated Repair of Nonhomologous End Joining.J Virol. 2019 Oct 29;93(22):e01273-19. doi: 10.1128/JVI.01273-19. Print 2019 Nov 15.
• [468] Analysis of Lamin B1, Vimentin and Anti-Ku86 as Prospective Biomarkers of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection.Cell Physiol Biochem. 2019;52(3):595-605. doi: 10.33594/000000042.
• [469] Barriers to Hepatitis C Screening in a Minority Population: A Comparison of Hepatitis C and Human Immunodeficiency Virus Screening Rates at a Community STD Clinic in Miami, Florida.J Community Health. 2017 Oct;42(5):921-925. doi: 10.1007/s10900-017-0335-6.
• [470] Relationship of genetic polymorphisms in CTLA-4 and IL-18 with viral hepatitis: evidence from a meta-analysis.Epidemiol Infect. 2019 Dec 5;147:e313. doi: 10.1017/S0950268819001997.
• [471] The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.J Biol Chem. 2020 Jan 17;295(3):800-807. doi: 10.1074/jbc.AC119.010366. Epub 2019 Dec 12.
• [472] High MELD score does not adversely affect outcome of living donor liver transplantation: Experience in 1000 recipients.Clin Transplant. 2017 Aug;31(8). doi: 10.1111/ctr.13006.
• [473] Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10.
• [474] Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2759-2768.e5. doi: 10.1016/j.cgh.2019.04.033. Epub 2019 Apr 17.
• [475] Association of genetic variants in estrogen receptor with HCV infection susceptibility and viral clearance in a high-risk Chinese population.Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):999-1010. doi: 10.1007/s10096-013-2038-y. Epub 2014 Jan 7.
• [476] Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.Pharmacogenomics. 2011 Dec;12(12):1729-40. doi: 10.2217/pgs.11.99.
• [477] Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.Pharmacogenet Genomics. 2011 May;21(5):289-96. doi: 10.1097/FPC.0b013e32834412e7.
• [478] UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.Medicine (Baltimore). 2017 Mar;96(11):e6306. doi: 10.1097/MD.0000000000006306.
• [479] Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis.Dig Dis Sci. 2020 Jul;65(7):1940-1950. doi: 10.1007/s10620-019-05918-7. Epub 2019 Nov 23.
• [480] The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy.Tissue Antigens. 2005 Sep;66(3):200-8. doi: 10.1111/j.1399-0039.2005.00457.x.
• [481] Degradation of AIMP1/p43 induced by hepatitis C virus E2 leads to upregulation of TGF- signaling and increase in surface expression of gp96.PLoS One. 2014 May 9;9(5):e96302. doi: 10.1371/journal.pone.0096302. eCollection 2014.
• [482] Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.J Gastroenterol Hepatol. 2016 Jul;31(7):1315-22. doi: 10.1111/jgh.13295.
• [483] Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.BMC Gastroenterol. 2017 Apr 17;17(1):54. doi: 10.1186/s12876-017-0613-x.
• [484] Caught before Released: Structural Mapping of the Reaction Trajectory for the Sofosbuvir Activating Enzyme, Human Histidine Triad Nucleotide Binding Protein 1 (hHint1).Biochemistry. 2017 Jul 18;56(28):3559-3570. doi: 10.1021/acs.biochem.7b00148. Epub 2017 Jul 10.
• [485] Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.Pediatr Blood Cancer. 2016 Sep;63(9):1539-45. doi: 10.1002/pbc.26045. Epub 2016 May 10.
• [486] UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis.Biochem Biophys Res Commun. 2008 Feb 15;366(3):643-8. doi: 10.1016/j.bbrc.2007.11.125. Epub 2007 Dec 3.
• [487] Application of a Waveguide-Mode Sensor to Blood Testing for Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Treponema pallidum Infection.Sensors (Basel). 2019 Apr 11;19(7):1729. doi: 10.3390/s19071729.
• [488] Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients.J Med Virol. 2003 Aug;70(4):581-7. doi: 10.1002/jmv.10433.
• [489] Impact of CYP2R1, CYP27A1 and CYP27B1 genetic polymorphisms controlling vitamin D metabolism on susceptibility to hepatitis C virus infection in a high-risk Chinese population.Arch Virol. 2019 Dec;164(12):2909-2918. doi: 10.1007/s00705-019-04378-8. Epub 2019 Sep 13.
• [490] Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians.J Toxicol Environ Health A. 2007 Jan;70(1):58-66. doi: 10.1080/15287390600748880.
• [491] Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24h.Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1211-20. doi: 10.1097/MEG.0b013e32833caf7b.
• [492] Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort.J Viral Hepat. 2011 Apr;18(4):e66-74. doi: 10.1111/j.1365-2893.2010.01392.x. Epub 2010 Nov 12.
• [493] Hepatitis C virus alters metabolism of biogenic polyamines by affecting expression of key enzymes of their metabolism.Biochem Biophys Res Commun. 2017 Feb 5;483(2):904-909. doi: 10.1016/j.bbrc.2017.01.032. Epub 2017 Jan 9.
• [494] Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis.Ann Surg Oncol. 2014 Jun;21 Suppl 3:S443-50. doi: 10.1245/s10434-014-3581-1. Epub 2014 Mar 7.
• [495] Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection.Clin Vaccine Immunol. 2007 Sep;14(9):1127-37. doi: 10.1128/CVI.00141-07. Epub 2007 Jul 18.
• [496] AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
• [497] Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses.J Gen Virol. 2018 Aug;99(8):1086-1096. doi: 10.1099/jgv.0.001099. Epub 2018 Jun 20.
• [498] Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion.J Gen Virol. 2010 Feb;91(Pt 2):373-81. doi: 10.1099/vir.0.015305-0. Epub 2009 Oct 21.
• [499] Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression.Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10388-93. doi: 10.1073/pnas.1525022113. Epub 2016 Aug 31.
• [500] LC3B is not recruited along with the autophagy elongation complex (ATG5-12/16L1) at HCV replication site and is dispensable for viral replication.PLoS One. 2018 Oct 4;13(10):e0205189. doi: 10.1371/journal.pone.0205189. eCollection 2018.
• [501] Augmentation of hepatitis C virus-specific immunity and sustained virologic response.J Viral Hepat. 2017 Sep;24(9):742-749. doi: 10.1111/jvh.12702. Epub 2017 May 4.
• [502] Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.J Clin Microbiol. 2006 Mar;44(3):729-37. doi: 10.1128/JCM.44.3.729-737.2006.
• [503] Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C.Mediators Inflamm. 2004 Dec;13(5-6):357-9. doi: 10.1080/09629350400003159.
• [504] Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis?.Med Hypotheses. 2013 Feb;80(2):131-3. doi: 10.1016/j.mehy.2012.11.009. Epub 2012 Dec 5.
• [505] KAI1, a prostate metastasis suppressor: prediction of solvated structure and interactions with binding partners; integrins, cadherins, and cell-surface receptor proteins.Mol Carcinog. 2001 Nov;32(3):139-53. doi: 10.1002/mc.1073.
• [506] Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma.Mol Med Rep. 2015 Jun;11(6):4053-62. doi: 10.3892/mmr.2015.3256. Epub 2015 Jan 26.
• [507] The hepatitis C virus (HCV) protein, p7, suppresses inflammatory responses to tumor necrosis factor (TNF)- via signal transducer and activator of transcription (STAT)3 and extracellular signal-regulated kinase (ERK)-mediated induction of suppressor of cytokine signaling (SOCS)3.FASEB J. 2019 Aug;33(8):8732-8744. doi: 10.1096/fj.201800629RR. Epub 2019 Jun 4.
• [508] Low oxygen tension enhances hepatitis C virus replication.J Virol. 2013 Mar;87(5):2935-48. doi: 10.1128/JVI.02534-12. Epub 2012 Dec 26.
• [509] Towards a better resolution of hepatitis C virus variants: CLIP sequencing of an HCV core fragment and automated assignment of genotypes and subtypes.J Virol Methods. 2008 Mar;148(1-2):25-33. doi: 10.1016/j.jviromet.2007.10.012. Epub 2007 Nov 28.
• [510] The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma.Nucleic Acids Res. 2005 Mar 30;33(6):1859-73. doi: 10.1093/nar/gki332. Print 2005.
• [511] Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal.Int J Drug Policy. 2020 Jan;75:102613. doi: 10.1016/j.drugpo.2019.102613. Epub 2019 Nov 28.
• [512] Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51.Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):83-92. doi: 10.1177/039463200401700112.
• [513] DCAF1 is involved in HCV replication through regulation of miR-122.Arch Virol. 2018 Apr;163(4):977-985. doi: 10.1007/s00705-017-3691-8. Epub 2018 Jan 11.
• [514] Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus.Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4641-5. doi: 10.1073/pnas.88.11.4641.
• [515] Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5' untranslated region of hepatitis C virus RNA.Virology. 2017 Jul;507:231-241. doi: 10.1016/j.virol.2017.04.014. Epub 2017 Apr 26.
• [516] Laboratory of genetics and physiology 2 (LGP2) plays an essential role in hepatitis C virus infection-induced interferon responses.Hepatology. 2017 May;65(5):1478-1491. doi: 10.1002/hep.29050. Epub 2017 Mar 30.
• [517] Identification of Potential Gene Network Associated with HCV-Related Hepatocellular Carcinoma Using Microarray Analysis.Pathol Oncol Res. 2018 Jul;24(3):507-514. doi: 10.1007/s12253-017-0273-8. Epub 2017 Jul 1.
• [518] The Initiation Factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G Are Not Involved in Translation Driven by Hepatitis C Virus IRES in Human Cells.Front Microbiol. 2018 Feb 13;9:207. doi: 10.3389/fmicb.2018.00207. eCollection 2018.
• [519] Four translation initiation pathways employed by the leaderless mRNA in eukaryotes.Sci Rep. 2016 Nov 28;6:37905. doi: 10.1038/srep37905.
• [520] Glecaprevir/Pibrentasvir: First Global Approval.Drugs. 2017 Oct;77(16):1797-1804. doi: 10.1007/s40265-017-0817-y.
• [521] Age-specific prevalence, transmission and phylogeny of TT virus in the Czech Republic.BMC Infect Dis. 2004 Dec 3;4(1):56. doi: 10.1186/1471-2334-4-56.
• [522] Single nucleotide polymorphisms of toll-like receptor 7 in hepatitis C virus infection patients from a high-risk chinese population.Inflammation. 2015 Feb;38(1):142-51. doi: 10.1007/s10753-014-0016-x.
• [523] A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C.J Viral Hepat. 2002 Sep;9(5):377-84. doi: 10.1046/j.1365-2893.2002.00365.x.
• [524] Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus.J Virol. 2014 Apr;88(8):4195-203. doi: 10.1128/JVI.03327-13. Epub 2014 Jan 29.
• [525] Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population.Gene. 2018 Dec 30;679:405-411. doi: 10.1016/j.gene.2018.09.021. Epub 2018 Sep 12.
• [526] Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.
• [527] Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.J Med Virol. 2017 Jul;89(7):1224-1234. doi: 10.1002/jmv.24739. Epub 2017 Mar 28.
• [528] Zika Virus Persistently Infects and Is Basolaterally Released from Primary Human Brain Microvascular Endothelial Cells.mBio. 2017 Jul 11;8(4):e00952-17. doi: 10.1128/mBio.00952-17.
• [529] NS3 from Hepatitis C Virus Strain JFH-1 Is an Unusually Robust Helicase That Is Primed To Bind and Unwind Viral RNA.J Virol. 2017 Dec 14;92(1):e01253-17. doi: 10.1128/JVI.01253-17. Print 2018 Jan 1.
• [530] Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.Nephrology (Carlton). 2018 Apr;23(4):323-330. doi: 10.1111/nep.13010.
• [531] Association of polymorphisms in HLA antigen presentation-related genes with the outcomes of HCV infection.PLoS One. 2015 Apr 13;10(4):e0123513. doi: 10.1371/journal.pone.0123513. eCollection 2015.
• [532] Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.Onco Targets Ther. 2018 Mar 2;11:1173-1182. doi: 10.2147/OTT.S149254. eCollection 2018.
• [533] Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.J Virol. 1999 Sep;73(9):7241-7. doi: 10.1128/JVI.73.9.7241-7247.1999.
• [534] hnRNP L and NF90 interact with hepatitis C virus 5'-terminal untranslated RNA and promote efficient replication.J Virol. 2014 Jul;88(13):7199-209. doi: 10.1128/JVI.00225-14. Epub 2014 Apr 9.
• [535] Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.Clin Infect Dis. 2013 Dec;57(11):1618-25. doi: 10.1093/cid/cit550. Epub 2013 Sep 30.
• [536] NF90-NF45 is a selective RNA chaperone that rearranges viral and cellular riboswitches: biochemical analysis of a virus host factor activity.Nucleic Acids Res. 2017 Dec 1;45(21):12441-12454. doi: 10.1093/nar/gkx931.
• [537] Modulation of HCV replication and translation by ErbB3 binding protein1 isoforms.Virology. 2017 Jan;500:35-49. doi: 10.1016/j.virol.2016.10.006. Epub 2016 Oct 19.
• [538] Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells.Oncotarget. 2017 Sep 30;8(49):86681-86692. doi: 10.18632/oncotarget.21407. eCollection 2017 Oct 17.
• [539] Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.Antiviral Res. 2012 Apr;94(1):54-6. doi: 10.1016/j.antiviral.2012.02.007. Epub 2012 Feb 22.
• [540] Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.Hepatology. 2012 Oct;56(4):1361-70. doi: 10.1002/hep.25810. Epub 2012 Aug 27.
• [541] Association Between Impaired V7.2+CD161++CD8+ (MAIT) and V7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients.Front Microbiol. 2019 Aug 28;10:1972. doi: 10.3389/fmicb.2019.01972. eCollection 2019.
• [542] Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C.Liver Int. 2013 Apr;33(4):569-79. doi: 10.1111/liv.12050. Epub 2012 Dec 13.
• [543] Hepatic compartmentalization of exhausted and regulatory cells in HIV/HCV-coinfected patients.J Viral Hepat. 2015 Mar;22(3):281-8. doi: 10.1111/jvh.12291. Epub 2014 Sep 1.
• [544] Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection.Cell Discov. 2018 Apr 10;4:16. doi: 10.1038/s41421-018-0015-4. eCollection 2018.
• [545] Estimated impact of hepatitis C-positive lung donor utilization on US donor lung supply.Am J Transplant. 2020 Jan;20(1):289-297. doi: 10.1111/ajt.15558. Epub 2019 Sep 5.
• [546] S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells.World J Gastroenterol. 2016 Apr 14;22(14):3746-57. doi: 10.3748/wjg.v22.i14.3746.
• [547] Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV.Life Sci. 2019 Dec 1;238:116958. doi: 10.1016/j.lfs.2019.116958. Epub 2019 Oct 16.
• [548] Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population.Epidemiol Infect. 2018 Feb;146(3):379-385. doi: 10.1017/S0950268817002928. Epub 2017 Dec 22.
• [549] TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice.Gastroenterology. 2016 Mar;150(3):707-19. doi: 10.1053/j.gastro.2015.11.002. Epub 2015 Nov 12.
• [550] NKp30 isoforms in patients with chronic hepatitis C virus infection.Immunology. 2015 Oct;146(2):234-42. doi: 10.1111/imm.12495. Epub 2015 Jul 8.
• [551] Polymorphisms of base-excision repair genes and the hepatocarcinogenesis.Gene. 2018 Oct 30;675:62-68. doi: 10.1016/j.gene.2018.06.056. Epub 2018 Jun 20.
• [552] Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.J Viral Hepat. 2019 Jan;26(1):93-100. doi: 10.1111/jvh.13016. Epub 2018 Nov 14.
• [553] Hepatitis C Virus Replication Depends on Endosomal Cholesterol Homeostasis.J Virol. 2017 Dec 14;92(1):e01196-17. doi: 10.1128/JVI.01196-17. Print 2018 Jan 1.
• [554] Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.Clin Kidney J. 2018 Jun;11(3):429-433. doi: 10.1093/ckj/sfx112. Epub 2017 Oct 30.
• [555] Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.RNA. 2004 Aug;10(8):1277-90. doi: 10.1261/rna.7100904. Epub 2004 Jul 9.
• [556] 2',5'-Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro.Biochem Biophys Res Commun. 2010 Feb 12;392(3):397-402. doi: 10.1016/j.bbrc.2010.01.034. Epub 2010 Jan 13.
• [557] Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.Transpl Infect Dis. 2020 Feb;22(1):e13204. doi: 10.1111/tid.13204. Epub 2019 Nov 26.
• [558] Clinical detection of Hepatitis C viral infection by yeast-secreted HCV-core:Gold-binding-peptide.Biosens Bioelectron. 2018 Nov 15;119:230-236. doi: 10.1016/j.bios.2018.07.026. Epub 2018 Aug 22.
• [559] Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.J Hepatol. 2012 Jul;57(1):17-23. doi: 10.1016/j.jhep.2012.02.018. Epub 2012 Mar 10.
• [560] Autophagy protects cells from HCV-induced defects in lipid metabolism.Gastroenterology. 2012 Mar;142(3):644-653.e3. doi: 10.1053/j.gastro.2011.11.033. Epub 2011 Dec 7.
• [561] Selective inhibitor of Wnt/-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model.Sci Rep. 2017 Mar 23;7(1):325. doi: 10.1038/s41598-017-00282-w.
• [562] High risk injecting behaviour among people who inject pharmaceutical opioids in Australia.Int J Drug Policy. 2017 Apr;42:1-6. doi: 10.1016/j.drugpo.2016.12.004. Epub 2017 Jan 16.
• [563] Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.Bioorg Med Chem. 2018 May 15;26(9):2621-2631. doi: 10.1016/j.bmc.2018.04.029. Epub 2018 Apr 16.
• [564] Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.PLoS One. 2018 Dec 4;13(12):e0208554. doi: 10.1371/journal.pone.0208554. eCollection 2018.
• [565] Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.Clin Infect Dis. 2019 Aug 1;69(4):571-576. doi: 10.1093/cid/ciy965.
• [566] Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease.Transplantation. 2013 Jan 15;95(1):203-8. doi: 10.1097/TP.0b013e318277e2f6.
• [567] SUMO1 depletion prevents lipid droplet accumulation and HCV replication.Arch Virol. 2016 Jan;161(1):141-8. doi: 10.1007/s00705-015-2628-3. Epub 2015 Oct 8.
• [568] Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis.Hepatology. 2002 Nov;36(5):1227-35. doi: 10.1053/jhep.2002.36157.
• [569] The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection.J Virol. 2009 Aug;83(16):8012-20. doi: 10.1128/JVI.00038-09. Epub 2009 Jun 10.
• [570] miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-B Signaling.Yonsei Med J. 2018 Jun;59(4):511-518. doi: 10.3349/ymj.2018.59.4.511.
• [571] Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.Hepatology. 2019 Mar;69(3):1032-1045. doi: 10.1002/hep.30303. Epub 2019 Feb 10.
• [572] HCV adaptation to HIV coinfection.Infect Genet Evol. 2018 Nov;65:216-225. doi: 10.1016/j.meegid.2018.07.039. Epub 2018 Jul 31.
• [573] Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3.Cancer Sci. 2017 May;108(5):910-917. doi: 10.1111/cas.13204. Epub 2017 Apr 24.
• [574] High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic.Br J Dermatol. 2008 Sep;159(3):585-90. doi: 10.1111/j.1365-2133.2008.08693.x. Epub 2008 Jun 28.
• [575] Distinct Roles for Intracellular and Extracellular Lipids in Hepatitis C Virus Infection.PLoS One. 2016 Jun 9;11(6):e0156996. doi: 10.1371/journal.pone.0156996. eCollection 2016.
• [576] Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).J Clin Microbiol. 2004 Feb;42(2):563-9. doi: 10.1128/JCM.42.2.563-569.2004.
• [577] Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.J Biol Chem. 2008 Jan 11;283(2):849-54. doi: 10.1074/jbc.M706160200. Epub 2007 Nov 14.
• [578] Assessment of the Prevalence of Non-Organ-Specific Autoantibodies in Egyptian Patients with HCV.Immunol Invest. 2020 Aug;49(6):676-686. doi: 10.1080/08820139.2019.1699108. Epub 2019 Dec 10.
• [579] Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.Biochem Biophys Res Commun. 2008 Jul 18;372(1):157-61. doi: 10.1016/j.bbrc.2008.05.018. Epub 2008 May 12.
• [580] Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown.J Infect Dis. 2004 Jan 1;189(1):7-14. doi: 10.1086/380202. Epub 2003 Dec 31.
• [581] Relevance of Rab Proteins for the Life Cycle of Hepatitis C Virus.Front Cell Dev Biol. 2018 Dec 4;6:166. doi: 10.3389/fcell.2018.00166. eCollection 2018.
• [582] Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada.J Infect Dis. 1995 Apr;171(4):1034-8. doi: 10.1093/infdis/171.4.1034.
• [583] MicroRNA-122 dependent binding of Ago2 protein to hepatitis C virus RNA is associated with enhanced RNA stability and translation stimulation.PLoS One. 2013;8(2):e56272. doi: 10.1371/journal.pone.0056272. Epub 2013 Feb 6.
• [584] miR-122 and Ago interactions with the HCV genome alter the structure of the viral 5' terminus.Nucleic Acids Res. 2019 Jun 4;47(10):5307-5324. doi: 10.1093/nar/gkz194.
• [585] Advanced Hepatitis C Virus Replication PDE Models within a Realistic Intracellular Geometric Environment.Int J Environ Res Public Health. 2019 Feb 12;16(3):513. doi: 10.3390/ijerph16030513.
• [586] Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. doi: 10.1128/AAC.05854-11. Epub 2012 Jan 30.
• [587] AP1S3 is required for hepatitis C virus infection by stabilizing E2 protein.Antiviral Res. 2016 Jul;131:26-34. doi: 10.1016/j.antiviral.2016.04.006. Epub 2016 Apr 11.
• [588] The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma.J Cell Biochem. 2019 Mar;120(3):4140-4146. doi: 10.1002/jcb.27699. Epub 2018 Sep 27.
• [589] Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.Antiviral Res. 2018 Feb;150:79-92. doi: 10.1016/j.antiviral.2017.10.012. Epub 2017 Oct 14.
• [590] Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis.Virology. 2018 Nov;524:1-9. doi: 10.1016/j.virol.2018.08.004. Epub 2018 Aug 18.
• [591] Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis.J Hepatol. 2008 Nov;49(5):787-98. doi: 10.1016/j.jhep.2008.06.029. Epub 2008 Sep 7.
• [592] Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27.
• [593] TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection.J Virol. 2017 Jan 3;91(2):e01583-16. doi: 10.1128/JVI.01583-16. Print 2017 Jan 15.
• [594] Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma.J Cell Physiol. 2020 Jan;235(1):611-618. doi: 10.1002/jcp.28999. Epub 2019 Jul 8.
• [595] Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.Int J Cancer. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.
• [596] Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections.Viruses. 2016 Feb 3;8(2):38. doi: 10.3390/v8020038.
• [597] Induction of selective autophagy in cells replicating hepatitis C virus genome.J Gen Virol. 2018 Dec;99(12):1643-1657. doi: 10.1099/jgv.0.001161. Epub 2018 Oct 12.
• [598] Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.J Hepatol. 2009 Sep;51(3):520-7. doi: 10.1016/j.jhep.2009.06.005. Epub 2009 Jun 23.
• [599] A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.Hepatology. 2011 Dec;54(6):2198-207. doi: 10.1002/hep.24608.
• [600] A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.Liver Int. 2014 Apr;34(4):558-66. doi: 10.1111/liv.12330. Epub 2013 Oct 16.
• [601] Synthetic Antibody Binding to a Preorganized RNA Domain of Hepatitis C Virus Internal Ribosome Entry Site Inhibits Translation.ACS Chem Biol. 2020 Jan 17;15(1):205-216. doi: 10.1021/acschembio.9b00785. Epub 2019 Dec 10.
• [602] Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.Rev Esp Enferm Dig. 2017 Jan;109(1):17-25. doi: 10.17235/reed.2016.4235/2016.
• [603] High prevalence of a variety of autoantibodies in a population of hepatitis C virus-infected individuals.APMIS. 2018 Jun;126(6):515-522. doi: 10.1111/apm.12850.
• [604] Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.Genes Immun. 2015 Jul-Aug;16(5):297-300. doi: 10.1038/gene.2015.14. Epub 2015 Apr 30.
• [605] Inflammasome Genes' Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment.Mediators Inflamm. 2019 Jan 9;2019:3273645. doi: 10.1155/2019/3273645. eCollection 2019.
• [606] Increases in endothelial caveolin-1 and cavins correlate with cirrhosis progression.Micron. 2015 Sep;76:52-61. doi: 10.1016/j.micron.2015.03.009. Epub 2015 Mar 31.
• [607] Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C.J Hepatol. 2010 Feb;52(2):153-9. doi: 10.1016/j.jhep.2009.11.001. Epub 2009 Nov 27.
• [608] Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes.Gastroenterology. 2008 Dec;135(6):2119-27. doi: 10.1053/j.gastro.2008.07.082. Epub 2008 Aug 7.
• [609] Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.J Immunol. 2004 Aug 1;173(3):2159-66. doi: 10.4049/jimmunol.173.3.2159.
• [610] DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?.Int J Mol Sci. 2019 Jul 30;20(15):3715. doi: 10.3390/ijms20153715.
• [611] Discovery of cellular proteins required for the early steps of HCV infection using integrative genomics.PLoS One. 2013 Apr 12;8(4):e60333. doi: 10.1371/journal.pone.0060333. Print 2013.
• [612] CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2.PLoS One. 2009 Dec 3;4(12):e8142. doi: 10.1371/journal.pone.0008142.
• [613] The identification of three sizes of core proteins during the establishment of persistent hepatitis C virus infection in vitro.Virol Sin. 2013 Jun;28(3):129-35. doi: 10.1007/s12250-013-3296-7. Epub 2013 Mar 25.
• [614] Hepatitis C Virus core+1/ARF Protein Modulates the Cyclin D1/pRb Pathway and Promotes Carcinogenesis.J Virol. 2018 Apr 13;92(9):e02036-17. doi: 10.1128/JVI.02036-17. Print 2018 May 1.
• [615] Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.PLoS One. 2013 May 7;8(5):e62674. doi: 10.1371/journal.pone.0062674. Print 2013.
• [616] YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.J Gastroenterol Hepatol. 2013 Jan;28(1):153-60. doi: 10.1111/j.1440-1746.2012.07270.x.
• [617] Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP).J Biol Chem. 2011 Jul 29;286(30):26603-15. doi: 10.1074/jbc.M111.225672. Epub 2011 May 31.
• [618] Altered m(6)A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection.Mol Cell. 2020 Feb 6;77(3):542-555.e8. doi: 10.1016/j.molcel.2019.11.007. Epub 2019 Dec 3.
• [619] RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):8197-8202. doi: 10.1073/pnas.1802326115. Epub 2018 Jul 23.
• [620] In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.
• [621] CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection.Arch Virol. 2014 Nov;159(11):2949-55. doi: 10.1007/s00705-014-2150-z. Epub 2014 Jun 26.
• [622] Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region.Immunol Res. 2018 Feb;66(1):67-73. doi: 10.1007/s12026-017-8962-7.
• [623] Metabolic alterations and hepatitis C: From bench to bedside.World J Gastroenterol. 2016 Jan 28;22(4):1461-76. doi: 10.3748/wjg.v22.i4.1461.
• [624] Eukaryotic translation initiation factor 4AII contributes to microRNA-122 regulation of hepatitis C virus replication.Nucleic Acids Res. 2018 Jul 6;46(12):6330-6343. doi: 10.1093/nar/gky262.
• [625] Selective transmission of hepatitis C virus genotypes and quasispecies in humans and experimentally infected chimpanzees.J Gen Virol. 2006 Jan;87(Pt 1):83-91. doi: 10.1099/vir.0.81268-0.
• [626] Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver.J Interferon Cytokine Res. 2007 Dec;27(12):985-90. doi: 10.1089/jir.2007.0039.
• [627] Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance.J Virol. 2019 Apr 3;93(8):e02302-18. doi: 10.1128/JVI.02302-18. Print 2019 Apr 15.
• [628] Critical role of CREBH-mediated induction of transforming growth factor 2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells.Hepatology. 2017 Nov;66(5):1430-1443. doi: 10.1002/hep.29319. Epub 2017 Sep 29.
• [629] Cysteine-rich secretory protein 3 inhibits hepatitis C virus at the initial phase of infection.Biochem Biophys Res Commun. 2014 Jul 25;450(2):1076-82. doi: 10.1016/j.bbrc.2014.06.106. Epub 2014 Jun 27.
• [630] Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.Arthritis Rheum. 2004 Jul;50(7):2305-8. doi: 10.1002/art.20355.
• [631] Standardized hepatitis C virus RNA panels for nucleic acid testing assays.J Clin Virol. 2001 Jan;20(1-2):35-40. doi: 10.1016/s1386-6532(00)00153-0.
• [632] Association of a variant in the regulatory region of NADPH oxidase 4 gene and metabolic syndrome in patients with chronic hepatitis C.Eur J Med Res. 2015 Mar 28;20(1):45. doi: 10.1186/s40001-015-0136-2.
• [633] Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition.J Exp Med. 1999 Jul 19;190(2):169-76. doi: 10.1084/jem.190.2.169.
• [634] A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Sci Rep. 2017 Jul 19;7(1):5816. doi: 10.1038/s41598-017-04449-3.
• [635] Hepatitis C virus infection in Irish drug users and prisoners - a scoping review.BMC Infect Dis. 2019 Aug 8;19(1):702. doi: 10.1186/s12879-019-4218-6.
• [636] Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.PLoS One. 2014 Jun 5;9(6):e98877. doi: 10.1371/journal.pone.0098877. eCollection 2014.
• [637] RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP.Sci Rep. 2017 Jan 27;7:41452. doi: 10.1038/srep41452.
• [638] Endoscopic Therapy is Effective for Recurrent Anastomotic Biliary Strictures after Orthotopic Liver Transplantation.Ann Hepatol. 2017 November-December,;16(6):924-931. doi: 10.5604/01.3001.0010.5284.
• [639] Correlation between the DEPDC5 rs1012068 polymorphism and the risk of HBV-related hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):446-450. doi: 10.1016/j.clinre.2018.12.005. Epub 2019 Jan 23.
• [640] Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.World J Gastroenterol. 2013 Mar 14;19(10):1602-10. doi: 10.3748/wjg.v19.i10.1602.
• [641] Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via Np63-miR-181a-Sirt1 pathway.J Leukoc Biol. 2016 Nov;100(5):1201-1211. doi: 10.1189/jlb.5A0316-119RR. Epub 2016 Jun 27.
• [642] Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions.Nucleic Acids Res. 2019 Mar 18;47(5):2455-2471. doi: 10.1093/nar/gkz052.
• [643] Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles.J Biol Chem. 2011 Oct 28;286(43):37264-73. doi: 10.1074/jbc.M111.259085. Epub 2011 Aug 30.
• [644] Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis.Ann Intern Med. 1992 Jan 1;116(1):21-5. doi: 10.7326/0003-4819-116-1-21.
• [645] Human eIF3: from 'blobology' to biological insight.Philos Trans R Soc Lond B Biol Sci. 2017 Mar 19;372(1716):20160176. doi: 10.1098/rstb.2016.0176.
• [646] New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.Eur J Cancer. 2017 Sep;83:56-70. doi: 10.1016/j.ejca.2017.06.003. Epub 2017 Jul 14.
• [647] Genetic alteration of the hepatitis C virus hypervariable region obtained from an asymptomatic carrier.Int J Cancer. 1994 Jan 15;56(2):204-7. doi: 10.1002/ijc.2910560210.
• [648] Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.Clin Exp Immunol. 1999 Nov;118(2):290-7. doi: 10.1046/j.1365-2249.1999.01027.x.
• [649] Hepatitis C virus NS3 protein interacts with ELKS-{delta} and ELKS-{alpha}, members of a novel protein family involved in intracellular transport and secretory pathways.J Gen Virol. 2005 Aug;86(Pt 8):2197-2208. doi: 10.1099/vir.0.80862-0.
• [650] The Host Factor Erlin-1 is Required for Efficient Hepatitis C Virus Infection.Cells. 2019 Dec 2;8(12):1555. doi: 10.3390/cells8121555.
• [651] Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.J Hepatol. 2019 Jul;71(1):52-61. doi: 10.1016/j.jhep.2019.03.006. Epub 2019 Mar 15.
• [652] HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Infect Genet Evol. 2016 Jan;37:252-8. doi: 10.1016/j.meegid.2015.11.028. Epub 2015 Nov 26.
• [653] Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china.J Virol. 2004 Dec;78(24):13591-9. doi: 10.1128/JVI.78.24.13591-13599.2004.
• [654] Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.J Biol Chem. 2015 Sep 18;290(38):23173-87. doi: 10.1074/jbc.M115.662999. Epub 2015 Jul 29.
• [655] Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection.Virology. 2019 Apr;530:99-106. doi: 10.1016/j.virol.2019.02.002. Epub 2019 Feb 12.
• [656] Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.Blood. 2011 May 19;117(20):5425-37. doi: 10.1182/blood-2010-10-312942. Epub 2011 Mar 18.
• [657] Prevalence of hepatitis C virus infection in patients with COPD.Epidemiol Infect. 2010 Feb;138(2):167-73. doi: 10.1017/S0950268809990276. Epub 2009 Jun 29.
• [658] A single-amino-acid mutation in hepatitis C virus NS5A disrupts physical and functional interaction with the transcription factor HNF-1.J Gen Virol. 2015 Aug;96(8):2200-2205. doi: 10.1099/vir.0.000179. Epub 2015 May 8.
• [659] HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats.Ann Hepatol. 2018 May-June;17(3):511-518. doi: 10.5604/01.3001.0011.7396. Epub 2018 Apr 9.
• [660] HIV and HCV Co-Culture Promotes Profibrogenic Gene Expression through an Epimorphin-Mediated ERK Signaling Pathway in Hepatic Stellate Cells.PLoS One. 2016 Jun 30;11(6):e0158386. doi: 10.1371/journal.pone.0158386. eCollection 2016.
• [661] Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells.Viruses. 2019 Apr 24;11(4):378. doi: 10.3390/v11040378.
• [662] Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-1 contributes to its anti-HCV activity in human hepatoma cells.Antiviral Res. 2017 Apr;140:83-94. doi: 10.1016/j.antiviral.2017.01.016. Epub 2017 Jan 26.
• [663] Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population.Viral Immunol. 2014 Oct;27(8):404-11. doi: 10.1089/vim.2014.0044. Epub 2014 Sep 8.
• [664] Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein.J Virol. 2019 Mar 5;93(6):e01459-18. doi: 10.1128/JVI.01459-18. Print 2019 Mar 15.
• [665] Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation.Arch Virol. 2018 Jun;163(6):1429-1438. doi: 10.1007/s00705-018-3748-3. Epub 2018 Feb 7.
• [666] Nrf2 activates augmenter of liver regeneration (ALR) via antioxidant response element and links oxidative stress to liver regeneration.Mol Med. 2013 Aug 28;19(1):237-44. doi: 10.2119/molmed.2013.00027.
• [667] Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C.Hepatology. 2005 Oct;42(4):846-53. doi: 10.1002/hep.20860.
• [668] Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells.Virus Res. 2009 Oct;145(1):141-4. doi: 10.1016/j.virusres.2009.06.001. Epub 2009 Jun 18.
• [669] Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication.Acta Pharm Sin B. 2019 Jul;9(4):769-781. doi: 10.1016/j.apsb.2019.01.013. Epub 2019 Jan 29.
• [670] GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.J Hepatol. 2005 Sep;43(3):388-93. doi: 10.1016/j.jhep.2005.03.020.
• [671] Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries.Dis Markers. 2019 Sep 17;2019:3862024. doi: 10.1155/2019/3862024. eCollection 2019.
• [672] Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo.J Gen Virol. 2017 Aug;98(8):2069-2078. doi: 10.1099/jgv.0.000869. Epub 2017 Jul 31.
• [673] A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers.J Immunol Methods. 2019 Sep;472:65-74. doi: 10.1016/j.jim.2019.06.016. Epub 2019 Jun 19.
• [674] Cleavage of La protein by granzyme H induces cytoplasmic translocation and interferes with La-mediated HCV-IRES translational activity.Cell Death Differ. 2009 Feb;16(2):340-8. doi: 10.1038/cdd.2008.165. Epub 2008 Nov 28.
• [675] Molecular analysis of V(H)I+ B lymphocytes in hepatitis C patients.Dig Liver Dis. 2003 Nov;35(11):788-94. doi: 10.1016/s1590-8658(03)00452-3.
• [676] The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.Hepatology. 2009 Mar;49(3):775-80. doi: 10.1002/hep.22707.
• [677] Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.Int J Drug Policy. 2019 Dec;74:236-245. doi: 10.1016/j.drugpo.2019.10.012. Epub 2019 Nov 6.
• [678] Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.J Viral Hepat. 2019 Aug;26(8):942-950. doi: 10.1111/jvh.13108. Epub 2019 Apr 29.
• [679] Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus.Autoimmunity. 2011 Nov;44(7):532-42. doi: 10.3109/08916934.2011.592881. Epub 2011 Aug 24.
• [680] Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.Sci Rep. 2017 Sep 19;7(1):11912. doi: 10.1038/s41598-017-10363-5.
• [681] Cloning and identification of NS5ATP2 gene and its spliced variant transactivated by hepatitis C virus non-structural protein 5A.World J Gastroenterol. 2004 Jun 15;10(12):1735-9. doi: 10.3748/wjg.v10.i12.1735.
• [682] In vitro-targeted gene identification in patients with hepatitis C using a genome-wide microarray technology.Hepatology. 2009 Feb;49(2):378-86. doi: 10.1002/hep.22677.
• [683] Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population.Int J Mol Sci. 2014 Jun 3;15(6):9826-43. doi: 10.3390/ijms15069826.
• [684] The relationship between human leukocyte antigen-DP/DQ gene polymorphisms and the outcomes of HCV infection in a Chinese population.Virol J. 2017 Dec 6;14(1):235. doi: 10.1186/s12985-017-0901-7.
• [685] Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids.Hepatology. 1996 Dec;24(6):1342-5. doi: 10.1053/jhep.1996.v24.pm0008938158.
• [686] Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus.Genes Immun. 2013 Jul-Aug;14(5):330-5. doi: 10.1038/gene.2013.25. Epub 2013 May 2.
• [687] TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.BMC Cancer. 2012 Mar 8;12:85. doi: 10.1186/1471-2407-12-85.
• [688] Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?.Front Immunol. 2017 Jul 18;8:832. doi: 10.3389/fimmu.2017.00832. eCollection 2017.
• [689] Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.Gastroenterology. 2018 Nov;155(5):1366-1371.e3. doi: 10.1053/j.gastro.2018.07.019. Epub 2018 Jul 19.
• [690] The potential of signal peptide peptidase as a therapeutic target for hepatitis C.Expert Opin Ther Targets. 2017 Sep;21(9):827-836. doi: 10.1080/14728222.2017.1369959. Epub 2017 Aug 22.
• [691] RNA-binding protein hnRNP D modulates internal ribosome entry site-dependent translation of hepatitis C virus RNA.J Virol. 2008 Dec;82(24):12082-93. doi: 10.1128/JVI.01405-08. Epub 2008 Oct 8.
• [692] A human proteome microarray identifies that the heterogeneous nuclear ribonucleoprotein K (hnRNP K) recognizes the 5' terminal sequence of the hepatitis C virus RNA.Mol Cell Proteomics. 2014 Jan;13(1):84-92. doi: 10.1074/mcp.M113.031682. Epub 2013 Oct 10.
• [693] Diagnosis and monitoring of HCV infection using the cobas() HCV test for use on the cobas() 6800/8800 systems.J Clin Virol. 2018 May;102:63-69. doi: 10.1016/j.jcv.2018.02.017. Epub 2018 Feb 24.
• [694] The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads.Clin Microbiol Infect. 2014 May;20(5):O325-32. doi: 10.1111/1469-0691.12403. Epub 2013 Nov 6.
• [695] T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature.PLoS One. 2013 Oct 10;8(10):e77008. doi: 10.1371/journal.pone.0077008. eCollection 2013.
• [696] Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.AIDS. 2017 Jun 1;31(9):1223-1234. doi: 10.1097/QAD.0000000000001455.
• [697] A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.Hepatology. 2019 Mar;69(3):1004-1019. doi: 10.1002/hep.30266. Epub 2019 Feb 13.
• [698] Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.J Interferon Cytokine Res. 2019 Mar;39(3):133-146. doi: 10.1089/jir.2018.0103.
• [699] Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.J Virol. 2012 Sep;86(18):10221-5. doi: 10.1128/JVI.00882-12. Epub 2012 Jul 11.
• [700] Detection of interferon-alpha expression by PCR in patients with chronic hepatitis C and hepatitis non-A, non-B.J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):373-80. doi: 10.1111/j.1440-1746.1994.tb01258.x.
• [701] HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN2a and Ribavirin: a randomized controlled trial.J Viral Hepat. 2014 Jul;21(7):458-65. doi: 10.1111/jvh.12163. Epub 2013 Aug 27.
• [702] Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C.J Interferon Cytokine Res. 2007 Mar;27(3):239-46. doi: 10.1089/jir.2006.0062.
• [703] Zinc is a potent and specific inhibitor of IFN-3 signalling.Nat Commun. 2017 May 17;8:15245. doi: 10.1038/ncomms15245.
• [704] Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.Gut. 2018 Feb;67(2):372-379. doi: 10.1136/gutjnl-2016-312208. Epub 2016 Oct 26.
• [705] Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.Hepatology. 2020 Feb;71(2):456-462. doi: 10.1002/hep.30840. Epub 2019 Aug 13.
• [706] The CD81 partner EWI-2wint inhibits hepatitis C virus entry.PLoS One. 2008 Apr 2;3(4):e1866. doi: 10.1371/journal.pone.0001866.
• [707] Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.Clin Exp Immunol. 2002 Aug;129(2):332-8. doi: 10.1046/j.1365-2249.2002.01911.x.
• [708] Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England.Int J Drug Policy. 2020 Jan;75:102608. doi: 10.1016/j.drugpo.2019.102608. Epub 2019 Nov 20.
• [709] Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.J Viral Hepat. 2017 Apr;24(4):287-294. doi: 10.1111/jvh.12645. Epub 2016 Nov 23.
• [710] Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection.Oncol Rep. 2007 Sep;18(3):545-52.
• [711] History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist.Transplantation. 2018 May;102(5):794-802. doi: 10.1097/TP.0000000000002045.
• [712] A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.Hepatology. 2015 Nov;62(5):1375-87. doi: 10.1002/hep.28105. Epub 2015 Sep 28.
• [713] Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.Yonsei Med J. 2018 Dec;59(10):1181-1189. doi: 10.3349/ymj.2018.59.10.1181.
• [714] Removal of the C6 Vaccinia Virus Interferon- Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.Viruses. 2018 Aug 8;10(8):414. doi: 10.3390/v10080414.
• [715] Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M.Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3462-E3471. doi: 10.1073/pnas.1616683114. Epub 2017 Apr 7.
• [716] Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5.J Virol. 2018 Aug 16;92(17):e00507-18. doi: 10.1128/JVI.00507-18. Print 2018 Sep 1.
• [717] Antibody response to E2 glycoprotein induced in mice by immunization with plasmid DNA containing sequence derived from a Chinese genotype III/2a isolate of hepatitis C virus.Chin Med J (Engl). 1999 Feb;112(2):166-8.
• [718] All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-nave patients with genotype 1 HCV infection.Hepatology. 2014 Jul;60(1):56-64. doi: 10.1002/hep.27053. Epub 2014 May 28.
• [719] Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci in a Chinese population.PLoS One. 2013 Oct 28;8(10):e77315. doi: 10.1371/journal.pone.0077315. eCollection 2013.
• [720] Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.Liver Int. 2010 Apr;30(4):567-73. doi: 10.1111/j.1478-3231.2010.02212.x.
• [721] Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015.
• [722] Protective KIR-HLA interactions for HCV infection in intravenous drug users.Mol Immunol. 2009 Aug;46(13):2723-7. doi: 10.1016/j.molimm.2009.05.014. Epub 2009 Jun 24.
• [723] Decreased interferon- production by NK cells from KIR haplotype B carriers in hepatitis C virus infection.Liver Int. 2019 Jul;39(7):1237-1245. doi: 10.1111/liv.14172. Epub 2019 Jun 26.
• [724] Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection.J Hepatol. 2001 Dec;35(6):765-73. doi: 10.1016/s0168-8278(01)00216-1.
• [725] Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.Genes Chromosomes Cancer. 2009 Dec;48(12):1057-68. doi: 10.1002/gcc.20708.
• [726] Functional characterization of nuclear localization and export signals in hepatitis C virus proteins and their role in the membranous web.PLoS One. 2014 Dec 8;9(12):e114629. doi: 10.1371/journal.pone.0114629. eCollection 2014.
• [727] Activation-induced cytidine deaminase is dispensable for virus-mediated liver and skin tumor development in mouse models.Int Immunol. 2014 Jul;26(7):397-406. doi: 10.1093/intimm/dxu040. Epub 2014 Feb 25.
• [728] Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.Eur J Gastroenterol Hepatol. 2019 May;31(5):633-641. doi: 10.1097/MEG.0000000000001385.
• [729] Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection.Sci Rep. 2019 Jun 21;9(1):9054. doi: 10.1038/s41598-019-45389-4.
• [730] Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) and Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein (WFA?M2BP) in Patients with Chronic Liver Disease.Med Sci Monit. 2019 Sep 24;25:7169-7174. doi: 10.12659/MSM.916533.
• [731] Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator.J Virol. 1997 Nov;71(11):8856-9. doi: 10.1128/JVI.71.11.8856-8859.1997.
• [732] CD14(+) monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C.Hepatology. 2017 Jan;65(1):18-31. doi: 10.1002/hep.28847. Epub 2016 Nov 5.
• [733] Screening of hepatitis C virus genotypes in urticaria patients in Saudi Arabia.Genet Test Mol Biomarkers. 2012 Aug;16(8):964-7. doi: 10.1089/gtmb.2012.0014. Epub 2012 Jul 12.
• [734] Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20.
• [735] Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.Gut. 2017 Dec;66(12):2160-2169. doi: 10.1136/gutjnl-2016-311508. Epub 2016 Aug 31.
• [736] Genetic variations in humans associated with differences in the course of hepatitis C.Biochem Biophys Res Commun. 2004 Apr 30;317(2):335-41. doi: 10.1016/j.bbrc.2004.03.056.
• [737] Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis.Lab Invest. 2012 Dec;92(12):1712-25. doi: 10.1038/labinvest.2012.121. Epub 2012 Sep 24.
• [738] Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response.Hepatology. 2008 Oct;48(4):1054-61. doi: 10.1002/hep.22464.
• [739] Alcohol-induced autophagy via upregulation of PIASy promotes HCV replication in human hepatoma cells.Cell Death Dis. 2018 Sep 5;9(9):898. doi: 10.1038/s41419-018-0845-x.
• [740] Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.Lancet Gastroenterol Hepatol. 2019 Apr;4(4):269-277. doi: 10.1016/S2468-1253(18)30414-X. Epub 2019 Jan 17.
• [741] Evaluation of Three Rapid Screening Tests for Detection of Hepatitis C Antibodies on Mass Scale.Crit Rev Eukaryot Gene Expr. 2019;29(1):25-28. doi: 10.1615/CritRevEukaryotGeneExpr.2018025062.
• [742] Identification of special key genes for alcohol-related hepatocellular carcinoma through bioinformatic analysis.PeerJ. 2019 Feb 6;7:e6375. doi: 10.7717/peerj.6375. eCollection 2019.
• [743] Dynamic Interaction of Stress Granules, DDX3X, and IKK- Mediates Multiple Functions in Hepatitis C Virus Infection.J Virol. 2015 May;89(10):5462-77. doi: 10.1128/JVI.03197-14. Epub 2015 Mar 4.
• [744] Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.J Biol Chem. 2016 Jan 22;291(4):1974-1990. doi: 10.1074/jbc.M115.674861. Epub 2015 Dec 1.
• [745] Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis.BMC Med Genet. 2019 Aug 16;20(1):142. doi: 10.1186/s12881-019-0871-2.
• [746] Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.Pathology. 2011 Feb;43(2):156-60. doi: 10.1097/PAT.0b013e32834317ed.
• [747] The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model.Drug Deliv. 2016 Oct;23(8):2852-2859. doi: 10.3109/10717544.2015.1108375. Epub 2015 Nov 11.
• [748] Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia.Blood. 2000 Nov 15;96(10):3578-84.
• [749] Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.Am J Pathol. 2003 Sep;163(3):1101-7. doi: 10.1016/S0002-9440(10)63469-4.
• [750] Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas.Acta Naturae. 2017 Jul-Sep;9(3):108-114.
• [751] Role of phosphatidylinositol 4-phosphate (PI4P) and its binding protein GOLPH3 in hepatitis C virus secretion.J Biol Chem. 2012 Aug 10;287(33):27637-47. doi: 10.1074/jbc.M112.346569. Epub 2012 Jun 28.
• [752] Hepatitis C Virus NS5A Targets Nucleosome Assembly Protein NAP1L1 To Control the Innate Cellular Response.J Virol. 2017 Aug 24;91(18):e00880-17. doi: 10.1128/JVI.00880-17. Print 2017 Sep 15.
• [753] Etiological role of hepatitis E virus in sporadic fulminant hepatitis.J Med Virol. 1994 Feb;42(2):133-7. doi: 10.1002/jmv.1890420207.
• [754] The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry.Nat Microbiol. 2018 Dec;3(12):1369-1376. doi: 10.1038/s41564-018-0273-9. Epub 2018 Nov 26.
• [755] Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1.J Gastroenterol Hepatol. 2010 Mar;25(3):627-34. doi: 10.1111/j.1440-1746.2009.06128.x. Epub 2010 Jan 14.
• [756] Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma.Oncol Rep. 2012 Aug;28(2):728-34. doi: 10.3892/or.2012.1821. Epub 2012 May 18.
• [757] Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.J Virol. 2018 Oct 12;92(21):e01123-18. doi: 10.1128/JVI.01123-18. Print 2018 Nov 1.
• [758] Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.J Virol. 2005 Jun;79(12):7648-57. doi: 10.1128/JVI.79.12.7648-7657.2005.
• [759] Genetic variation in toll-like receptors and retinoic acid-inducible gene I and outcome of hepatitis C virus infection: a candidate gene association study.J Viral Hepat. 2014 Aug;21(8):578-84. doi: 10.1111/jvh.12188. Epub 2013 Nov 13.
• [760] Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for nave hepatitis C patients with a real-world cohort and database.Medicine (Baltimore). 2017 Jun;96(22):e6984. doi: 10.1097/MD.0000000000006984.
• [761] AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.J Virol. 2015 Apr;89(8):4387-404. doi: 10.1128/JVI.02705-14. Epub 2015 Feb 4.
• [762] A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma.BMC Med Genomics. 2019 Oct 28;12(1):147. doi: 10.1186/s12920-019-0580-x.
• [763] Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.Gut. 2020 Feb;69(2):380-392. doi: 10.1136/gutjnl-2018-317423. Epub 2019 May 10.
• [764] Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients.Clin Gastroenterol Hepatol. 2019 Jul;17(8):1634-1636. doi: 10.1016/j.cgh.2018.09.036. Epub 2018 Sep 27.
• [765] Association between Cys282Tyr missense mutation and haptoglobin phenotype polymorphism in patients with chronic hepatitis C.Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1077-81. doi: 10.1097/00042737-200109000-00014.
• [766] Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation.PLoS One. 2013 Sep 17;8(9):e75648. doi: 10.1371/journal.pone.0075648. eCollection 2013.
• [767] PACSIN2 Interacts with Nonstructural Protein 5A and Regulates Hepatitis C Virus Assembly.J Virol. 2020 Feb 14;94(5):e01531-19. doi: 10.1128/JVI.01531-19. Print 2020 Feb 14.
• [768] Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway.Int J Infect Dis. 2013 Jul;17(7):e539-45. doi: 10.1016/j.ijid.2013.01.027. Epub 2013 Mar 16.
• [769] NS5ATP9, a gene up-regulated by HCV NS5A protein.Cancer Lett. 2008 Feb 8;259(2):192-7. doi: 10.1016/j.canlet.2007.10.029.
• [770] Induction of Huh? cell apoptosis by HCV core proteins via CK1p53Bid signaling pathway.Mol Med Rep. 2018 Jun;17(6):7559-7566. doi: 10.3892/mmr.2018.8844. Epub 2018 Apr 5.
• [771] Anti-HCV immunoblot indeterminate results in blood donors: non-specific reactivity or past exposure to HCV?.Vox Sang. 2017 Aug;112(6):542-548. doi: 10.1111/vox.12547.
• [772] The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate.J Heart Lung Transplant. 2019 Nov;38(11):1178-1188. doi: 10.1016/j.healun.2019.08.010. Epub 2019 Aug 14.
• [773] Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease.Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G364-74. doi: 10.1152/ajpgi.00077.2013. Epub 2013 Jun 27.
• [774] Protein Inhibitor of Activated STAT2 Restricts HCV Replication by Modulating Viral Proteins Degradation.Viruses. 2017 Sep 30;9(10):285. doi: 10.3390/v9100285.
• [775] Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis.J Hepatol. 2005 Oct;43(4):687-95. doi: 10.1016/j.jhep.2005.03.024.
• [776] A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.Biochem Biophys Res Commun. 2013 Oct 11;440(1):150-6. doi: 10.1016/j.bbrc.2013.09.048. Epub 2013 Sep 18.
• [777] Early events in the generation of autophagosomes are required for the formation of membrane structures involved in hepatitis C virus genome replication.J Gen Virol. 2016 Mar;97(3):680-693. doi: 10.1099/jgv.0.000387. Epub 2016 Jan 4.
• [778] Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.PLoS Pathog. 2013 Mar;9(3):e1003285. doi: 10.1371/journal.ppat.1003285. Epub 2013 Mar 28.
• [779] Nir2 Is an Effector of VAPs Necessary for Efficient Hepatitis C Virus Replication and Phosphatidylinositol 4-Phosphate Enrichment at the Viral Replication Organelle.J Virol. 2019 Oct 29;93(22):e00742-19. doi: 10.1128/JVI.00742-19. Print 2019 Nov 15.
• [780] Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1.Virology. 2003 Feb 1;306(1):51-9. doi: 10.1016/s0042-6822(02)00029-6.
• [781] Phosphatidylserine-Specific Phospholipase A1 is the Critical Bridge for Hepatitis C Virus Assembly.Virol Sin. 2019 Oct;34(5):521-537. doi: 10.1007/s12250-019-00123-2. Epub 2019 Jun 3.
• [782] Perilipin-2 is critical for efficient lipoprotein and hepatitis C virus particle production.J Cell Sci. 2019 Jan 9;132(1):jcs217042. doi: 10.1242/jcs.217042.
• [783] miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models.J Med Virol. 2017 Apr;89(4):653-659. doi: 10.1002/jmv.24677. Epub 2016 Sep 20.
• [784] Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver.Lipids Health Dis. 2019 Apr 6;18(1):87. doi: 10.1186/s12944-019-1022-7.
• [785] Interferon--Enhanced CD100/Plexin-B1/B2 Interactions Promote Natural Killer Cell Functions in Patients with Chronic Hepatitis C Virus Infection.Front Immunol. 2017 Nov 3;8:1435. doi: 10.3389/fimmu.2017.01435. eCollection 2017.
• [786] Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance.Front Mol Biosci. 2017 Nov 22;4:74. doi: 10.3389/fmolb.2017.00074. eCollection 2017.
• [787] Development of novel triplex single-step real-time PCR assay for detection of Hepatitis Virus B and C simultaneously.Virology. 2016 May;492:101-7. doi: 10.1016/j.virol.2016.01.029. Epub 2016 Feb 22.
• [788] Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?.Int J Antimicrob Agents. 2017 Mar;49(3):379-382. doi: 10.1016/j.ijantimicag.2016.12.004. Epub 2017 Feb 6.
• [789] Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.Mol Cell. 2005 Jul 1;19(1):111-22. doi: 10.1016/j.molcel.2005.05.014.
• [790] No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection.J Gastroenterol Hepatol. 2011 Feb;26(2):319-27. doi: 10.1111/j.1440-1746.2010.06368.x.
• [791] Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation.J Exp Clin Cancer Res. 2015 Nov 14;34:140. doi: 10.1186/s13046-015-0255-1.
• [792] Repressing PU.1 by miR-29a?in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models.Hum Immunol. 2015 Sep;76(9):687-94. doi: 10.1016/j.humimm.2015.09.021. Epub 2015 Sep 30.
• [793] Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection.J Innate Immun. 2010;2(6):607-17. doi: 10.1159/000317690. Epub 2010 Aug 17.
• [794] A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms.G Ital Dermatol Venereol. 2019 Aug;154(4):488-491. doi: 10.23736/S0392-0488.17.05151-3.
• [795] N-terminal HCV core protein fragment decreases 20S proteasome activity in the presence of PA28.Biochem Biophys Res Commun. 2019 Feb 5;509(2):590-595. doi: 10.1016/j.bbrc.2018.12.167. Epub 2018 Dec 31.
• [796] Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells.PLoS One. 2012;7(8):e44147. doi: 10.1371/journal.pone.0044147. Epub 2012 Aug 28.
• [797] Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus Infection.Sci Rep. 2017 Jul 19;7(1):5876. doi: 10.1038/s41598-017-06254-4.
• [798] Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets.PLoS Pathog. 2013;9(8):e1003513. doi: 10.1371/journal.ppat.1003513. Epub 2013 Aug 1.
• [799] Role for TBC1D20 and Rab1 in hepatitis C virus replication via interaction with lipid droplet-bound nonstructural protein 5A.J Virol. 2012 Jun;86(12):6491-502. doi: 10.1128/JVI.00496-12. Epub 2012 Apr 4.
• [800] Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b.Cell Rep. 2017 Oct 10;21(2):431-441. doi: 10.1016/j.celrep.2017.09.053.
• [801] Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication.Proc Natl Acad Sci U S A. 2009 May 5;106(18):7577-82. doi: 10.1073/pnas.0902693106. Epub 2009 Apr 17.
• [802] Hepatitis C Virus-Induced Rab32 Aggregation and Its Implications for Virion Assembly.J Virol. 2017 Jan 18;91(3):e01662-16. doi: 10.1128/JVI.01662-16. Print 2017 Feb 1.
• [803] Hepatitis C virus Core protein overcomes all-trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-2 expression via DNA methylation.Cancer Lett. 2013 Jul 28;335(2):372-9. doi: 10.1016/j.canlet.2013.02.057. Epub 2013 Mar 6.
• [804] Rab5 Enhances Classical Swine Fever Virus Proliferation and Interacts with Viral NS4B Protein to Facilitate Formation of NS4B Related Complex.Front Microbiol. 2017 Aug 8;8:1468. doi: 10.3389/fmicb.2017.01468. eCollection 2017.
• [805] Nonstructural Protein 5A Impairs DNA Damage Repair: Implications for Hepatitis C Virus-Mediated Hepatocarcinogenesis.J Virol. 2018 May 14;92(11):e00178-18. doi: 10.1128/JVI.00178-18. Print 2018 Jun 1.
• [806] Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation.Hepatology. 2020 May;71(5):1775-1786. doi: 10.1002/hep.30939. Epub 2020 Jan 28.
• [807] Human Endogenous Retrovirus-K HML-2 integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model.Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10434-10439. doi: 10.1073/pnas.1811940115. Epub 2018 Sep 24.
• [808] RNA binding protein 24 regulates the translation and replication of hepatitis C virus.Protein Cell. 2018 Nov;9(11):930-944. doi: 10.1007/s13238-018-0507-x. Epub 2018 Jan 30.
• [809] Hepatitis C virus core protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infections by ELISA.J Med Virol. 1999 Feb;57(2):104-10.
• [810] Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization.Hepatology. 2003 Sep;38(3):577-88. doi: 10.1053/jhep.2003.50376.
• [811] Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.Hepatology. 2014 Nov;60(5):1519-30. doi: 10.1002/hep.27277. Epub 2014 Oct 2.
• [812] Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region.J Clin Invest. 1992 Jun;89(6):2040-5. doi: 10.1172/JCI115815.
• [813] TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis.Nat Commun. 2016 May 4;7:11379. doi: 10.1038/ncomms11379.
• [814] A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.
• [815] In vitro selection of the 3'-untranslated regions of the human liver mRNA that bind to the HCV nonstructural protein 5B.Virology. 2014 Feb;450-451:13-23. doi: 10.1016/j.virol.2013.11.036. Epub 2013 Dec 18.
• [816] Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication.PLoS Pathog. 2012 Jun;8(6):e1002766. doi: 10.1371/journal.ppat.1002766. Epub 2012 Jun 28.
• [817] A naturally occurring antiviral ribonucleotide encoded by the human genome.Nature. 2018 Jun;558(7711):610-614. doi: 10.1038/s41586-018-0238-4. Epub 2018 Jun 20.
• [818] Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.Clin Exp Rheumatol. 2018 Mar-Apr;36 Suppl 111(2):107-114. Epub 2018 Feb 13.
• [819] Understanding the biological context of NS5A-host interactions in HCV infection: a network-based approach.J Proteome Res. 2013 Jun 7;12(6):2537-51. doi: 10.1021/pr3011217. Epub 2013 May 17.
• [820] Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication.Hepatology. 2011 Nov;54(5):1580-90. doi: 10.1002/hep.24576.
• [821] Treatment of hepatitis C virus core-positive hepatocytes with the transfer of recombinant caspase-3 using the 2',5'-oligoadenylate synthetase gene promoter.Acta Biochim Biophys Sin (Shanghai). 2009 Jul;41(7):554-60. doi: 10.1093/abbs/gmp044.
• [822] SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations.J Hepatol. 2019 Apr;70(4):603-614. doi: 10.1016/j.jhep.2018.11.012. Epub 2018 Nov 23.
• [823] Sec24C-Dependent Transport of Claudin-1 Regulates Hepatitis C Virus Entry.J Virol. 2017 Aug 24;91(18):e00629-17. doi: 10.1128/JVI.00629-17. Print 2017 Sep 15.
• [824] microRNAs: Key players in virus-associated hepatocellular carcinoma.J Cell Physiol. 2019 Aug;234(8):12188-12225. doi: 10.1002/jcp.27956. Epub 2018 Dec 7.
• [825] Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease.Dig Liver Dis. 2009 Mar;41(3):212-6. doi: 10.1016/j.dld.2008.06.001. Epub 2008 Jul 25.
• [826] Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis.Virol J. 2014 Jun 20;11:117. doi: 10.1186/1743-422X-11-117.
• [827] Structure-function analysis of the equine hepacivirus 5' untranslated region highlights the conservation of translational mechanisms across the hepaciviruses.J Gen Virol. 2019 Nov;100(11):1501-1514. doi: 10.1099/jgv.0.001316.
• [828] Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity.Gene. 1998 Feb 27;208(2):331-6. doi: 10.1016/s0378-1119(98)00030-4.
• [829] Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.PLoS One. 2016 Jun 16;11(6):e0157771. doi: 10.1371/journal.pone.0157771. eCollection 2016.
• [830] Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis.Nephrol Dial Transplant. 2009 Sep;24(9):2745-51. doi: 10.1093/ndt/gfp167. Epub 2009 Apr 17.
• [831] Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019.
• [832] Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.J Gastroenterol Hepatol. 2017 Apr;32(4):749-755. doi: 10.1111/jgh.13620.
• [833] Invivo treatment of HCV core-positive HepG2 cells with the transfer of recombinant caspase-3 using a 2'-5' OAS promoter.Mol Med Rep. 2012 Mar;5(3):631-6. doi: 10.3892/mmr.2011.703. Epub 2011 Dec 9.
• [834] Pivotal role for the ESCRT-II complex subunit EAP30/SNF8 in IRF3-dependent innate antiviral defense.PLoS Pathog. 2017 Oct 30;13(10):e1006713. doi: 10.1371/journal.ppat.1006713. eCollection 2017 Oct.
• [835] Hepatitis C virus nonstructural protein NS3 binds to Sm-D1, a small nuclear ribonucleoprotein associated with autoimmune disease.Microbiol Immunol. 2003;47(8):601-11. doi: 10.1111/j.1348-0421.2003.tb03423.x.
• [836] Hepatitis C virus recombinants are rare even among intravenous drug users.J Med Virol. 2010 Feb;82(2):232-8. doi: 10.1002/jmv.21631.
• [837] Aberrant methylation of promoter region of SPINT2/HAI-2 gene: an epigenetic mechanism in hepatitis C virus-induced hepatocarcinogenesis.Genet Test Mol Biomarkers. 2015 Jul;19(7):399-404. doi: 10.1089/gtmb.2015.0025. Epub 2015 Jun 1.
• [838] Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany.J Hepatol. 1996 Sep;25(3):385-9. doi: 10.1016/s0168-8278(96)80126-7.
• [839] SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation.PLoS One. 2019 Jul 25;14(7):e0219989. doi: 10.1371/journal.pone.0219989. eCollection 2019.
• [840] Anti-SSB/La antibody is negatively associated with HLA-DR2 in chronic hepatitis C infection.Clin Rheumatol. 2008 Mar;27(3):365-8. doi: 10.1007/s10067-007-0783-y. Epub 2007 Nov 9.
• [841] Hepatitis C virus core protein reduces CD8(+) T-cell proliferation, perforin production and degranulation but increases STAT5 activation.Immunology. 2018 May;154(1):156-165. doi: 10.1111/imm.12882. Epub 2018 Jan 25.
• [842] Staufen1 promotes HCV replication by inhibiting protein kinase R and transporting viral RNA to the site of translation and replication in the cells.Nucleic Acids Res. 2016 Jun 20;44(11):5271-87. doi: 10.1093/nar/gkw312. Epub 2016 Apr 22.
• [843] Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.J Hepatol. 2013 Jul;59(1):52-8. doi: 10.1016/j.jhep.2013.03.019. Epub 2013 Mar 28.
• [844] Identification of syntaxin 4 as an essential factor for the hepatitis C virus life cycle.Eur J Cell Biol. 2017 Sep;96(6):542-552. doi: 10.1016/j.ejcb.2017.06.002. Epub 2017 Jun 10.
• [845] HCV-induced autophagosomes are generated via homotypic fusion of phagophores that mediate HCV RNA replication.PLoS Pathog. 2017 Sep 19;13(9):e1006609. doi: 10.1371/journal.ppat.1006609. eCollection 2017 Sep.
• [846] Surfeit 4 Contributes to the Replication of Hepatitis C Virus Using Double-Membrane Vesicles.J Virol. 2020 Jan 6;94(2):e00858-19. doi: 10.1128/JVI.00858-19. Print 2020 Jan 6.
• [847] Histone-modifying genes as biomarkers in hepatocellular carcinoma.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2496-507. eCollection 2014.
• [848] Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection.Open Forum Infect Dis. 2019 Jul 1;6(7):ofz318. doi: 10.1093/ofid/ofz318.
• [849] Reducing Agent-Assisted Excessive Galvanic Replacement Mediated Seed-Mediated Synthesis of Porous Gold Nanoplates and Highly Efficient Gene-Thermo Cancer Therapy.ACS Appl Mater Interfaces. 2017 Oct 11;9(40):35268-35278. doi: 10.1021/acsami.7b13028. Epub 2017 Oct 2.
• [850] HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis.Oncogene. 2002 Jul 18;21(31):4801-11. doi: 10.1038/sj.onc.1205589.
• [851] Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.Int J Mol Med. 2006 Jun;17(6):989-95.
• [852] The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome.AIDS. 2010 Oct 23;24(16):2499-506. doi: 10.1097/QAD.0b013e32833e922c.
• [853] TIPE2 as a potential therapeutic target in chronic viral hepatitis.Expert Opin Ther Targets. 2019 Jun;23(6):485-493. doi: 10.1080/14728222.2019.1608948. Epub 2019 Apr 22.
• [854] TNRC6 proteins modulate hepatitis C virus replication by spatially regulating the binding of miR-122/Ago2 complexes to viral RNA.Nucleic Acids Res. 2019 Jul 9;47(12):6411-6424. doi: 10.1093/nar/gkz278.
• [855] Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study.Clin Biochem. 2019 Jan;63:10-17. doi: 10.1016/j.clinbiochem.2018.12.001. Epub 2018 Dec 3.
• [856] Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.Hum Genet. 2012 Dec;131(12):1911-20. doi: 10.1007/s00439-012-1220-0. Epub 2012 Aug 17.
• [857] TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.Nature. 2019 Jul;571(7764):265-269. doi: 10.1038/s41586-019-1326-9. Epub 2019 Jun 17.
• [858] Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.J Infect Dis. 2013 Sep;208(6):1000-7. doi: 10.1093/infdis/jit274. Epub 2013 Jun 24.
• [859] 1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2.J Biol Chem. 2003 Aug 15;278(33):30711-8. doi: 10.1074/jbc.M209623200. Epub 2003 Jun 7.
• [860] Interferon alpha (IFN)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A.Cell Mol Immunol. 2016 Jan;13(1):94-102. doi: 10.1038/cmi.2014.131. Epub 2015 Feb 16.
• [861] Nonstructural 3 Protein of Hepatitis C Virus Modulates the Tribbles Homolog 3/Akt Signaling Pathway for Persistent Viral Infection.J Virol. 2016 Jul 27;90(16):7231-7247. doi: 10.1128/JVI.00326-16. Print 2016 Aug 15.
• [862] TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein.Sci Rep. 2016 Aug 31;6:32336. doi: 10.1038/srep32336.
• [863] TRIM56 is an essential component of the TLR3 antiviral signaling pathway.J Biol Chem. 2012 Oct 19;287(43):36404-13. doi: 10.1074/jbc.M112.397075. Epub 2012 Sep 4.
• [864] Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2.
• [865] Strong correlation between ASPM gene expression and HCV cirrhosis progression identified by co-expression analysis.Dig Liver Dis. 2017 Jan;49(1):70-76. doi: 10.1016/j.dld.2016.10.017. Epub 2016 Nov 4.
• [866] A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.J Hepatol. 2014 Nov;61(5):1073-9. doi: 10.1016/j.jhep.2014.06.006. Epub 2014 Jun 16.
• [867] The long-term outcomes of hepatitis C virus core antigen-positive Japanese renal allograft recipients.Clin Exp Nephrol. 2017 Dec;21(6):1113-1123. doi: 10.1007/s10157-017-1394-9. Epub 2017 Mar 29.